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ABSTRACT 
 
 Sindbis virus (SINV), the prototypic alphavirus, is neurotropic in mice, providing 
a valuable model for studying nonfatal alphavirus encephalomyelitis. Infectious virus is 
cleared from the brain within a week after infection, but viral RNA is cleared slowly and 
persists for the life of the animal. To better understand the immunopathogenesis and 
control of SINV infection, C57BL/6 mice were infected with the nonfatal TE strain of 
SINV, and clinical disease, virus clearance, and the immune response were examined. 
During the height of active infection, mice developed clinical signs of encephalomyelitis 
and exhibited neurological deficits. Following recovery from clinical disease, 
hippocampus-dependent memory deficits persisted, concurrent with the presence of viral 
RNA. Treatment with 6-diazo-5-oxo-l-norleucine (DON), a glutamine antagonist that 
inhibits both lymphocyte proliferation and glutamate excitotoxicity, partially prevented 
development of clinical disease and neurological sequelae. Mice treated with DON 
exhibited decreased CNS inflammation and pathology but delayed virus clearance, 
indicating that the immune response mediates both processes. Previous studies have 
shown that clearance of SINV is cooperatively facilitated by anti-SINV antibody and the 
cytokine interferon gamma (IFN-γ). To further examine the role IFN-γ plays in SINV 
clearance and control, neuronal cell cultures and mice deficient in IFN-γ (Ifng-/-) or IFN-γ 
receptor (Ifngr1-/-) were infected with SINV TE. IFN-γ facilitated clearance of both 
infectious virus and viral RNA in vitro, but mice with impaired IFN-γ signaling displayed 
accelerated viral RNA clearance from the CNS despite delayed clearance of infectious 
virus, suggesting IFN-γ-induced immunomodulation. IFN-γ promoted local production of 
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anti-SINV antibody but inhibited infiltration of granzyme B-producing CD8+ T cells. 
Memory T cells, which persist in the brain following clearance of infectious virus, were 
also affected by IFN-γ signaling, with Ifng-/- and Ifngr1-/- mice possessing fewer CD8+ 
tissue resident memory T cells. Therefore, IFN-γ plays a multi-faceted role in SINV 
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ALPHAVIRUSES WORLDWIDE 
 
 Arboviruses, particularly members of the Togaviridae and Flaviviridae families, 
represent an emerging threat of disabling disease worldwide. Alphaviruses, members of 
Togaviridae, are generally divided into two major groups based on geographical location 
and typical disease manifestation1. Old World alphaviruses, which include Sindbis virus 
(SINV), Chikungunya virus (CHIKV), Ross River virus, and Semliki Forest virus (SFV), 
are normally found in Europe, Africa, Asia, and Australia. When humans are infected, 
clinical disease typically manifests as fever, rash, and arthritis2. In contrast, the New 
World alphaviruses, which include eastern equine encephalitis virus (EEEV), western 
equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV), 
are generally found in North and South America. When humans are naturally infected, 
they tend to develop encephalitis and meningitis. Occasionally other disease 
manifestations are seen with alphavirus infection, such as encephalomyelitis induced by 
CHIKV or SFV3,4. Despite alphaviruses being considered to cause acute infections, large 
percentages of people report development of debilitating long-term maladies, such as 
myalgia and arthralgia, that last months to years following recovery from the initial 
clinical illness5-7. 
 Mosquitoes transmit alphaviruses, and like other arboviruses such as flaviviruses 
and bunyaviruses, they represent a remerging threat to populations worldwide as vectors 
expand into new territories. New World alphaviruses are typically maintained in a 
sylvatic cycle, with passerine or aquatic birds and small mammals serving as reservoir 
hosts8. However, promiscuity by permissive mosquitos species, which include Aedes and 
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Culex spp, occasionally results in infection of other species, particularly humans and 
horses. These large mammals are typically dead-end hosts, though VEEV is capable of 
replicating at high enough titers in the blood to permit continued transmission2. 
 Human cases of EEE, WEE, and VEE are only sporadically reported in the United 
States each year, though outbreaks of EEE and VEE over the last few decades have 
increased and are being diagnosed in previously unreported locations. An outbreak of 
VEE in the mid-1990’s in Venezuela and Columbia affected an estimated 75,000 to 
100,000 people9. The number of human cases of EEE in the northeastern United States 
has markedly increased in the last decade, with states such as Vermont and Maine 
reporting locally-acquired human cases for the first time10,11. Mortality associated with 
New World alphavirus infection varies by species. While most people infected with 
WEEV remain asymptomatic, EEE carries a substantial death rate, ranging from 30 to 
70% depending on the source8,12,13. People who survive the clinical illness, especially 
those infected as infants or children, tend to develop lifelong neurological deficits14-18. 
 Currently, no treatments beyond symptomatic care are available for people who 
contract EEE, WEE, or VEE19. A licensed combination vaccine for EEEV, WEEV, and 
VEEV is available for horses, but no effective vaccine is approved for non-military use in 
humans20. Because of the reemerging public health concern and propensity for these 
viruses to cause lasting physical debilitations, it is increasingly important to understand 
the pathogenesis of alphavirus encephalomyelitis so that better preventatives and 
treatments may be developed. 
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SINDBIS VIRUS 
 
 Sindbis virus (SINV) is the prototypic member of the alphaviruses. Like other 
members of the genus, it is enveloped with a positive-sense, single-stranded RNA 
genome21,22. The 70nm virion consists of capsid proteins surrounding a single RNA 
genome, and two transmembrane glycoproteins, E1 and E2, facilitate entry into cells by 
endocytosis via a currently unknown receptor(s). The 11.7kb genome contains a 
5’methylguanylate cap and 3’polyadenylated tail and encodes both structural and 
nonstructural proteins. The four nonstructural proteins (nsp1, nsp2, nsp3, and nsp4) are 
encoded at the 5’ end, and the five structural proteins, which include the capsid and E1 
and E2 glycoproteins, are encoded at the 3’ end. Like other positive-sense RNA viruses, 
the genomic RNA of SINV is infectious, meaning when in a permissive cell, it can 
automatically replicate and produce infectious virus particles. 
 Upon entry into a permissive cell, the viral envelope fuses with the cell 
membrane, and the virion core disassembles, revealing the genomic RNA that serves as 
messenger RNA from which the nonstructural proteins are translated22,23. Virus 
replication occurs within cytopathic vacuoles that form in the cytoplasm on the surface of 
lysosomes and endosomes. The nonstructural proteins are translated as a polyprotein and, 
following multiple cleavage events, facilitate replication of a complementary, negative 
sense, full-length RNA genome (Fig1-1). Additional full-length, positive-sense, single-
stranded RNA genomes are then transcribed from this negative-sense genome for 
incorporation into new virus particles. The negative-sense genome also encodes a 
promoter from which a subgenomic RNA is transcribed. Translation of the subgenomic 
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RNA results in production of a structural polyprotein that includes capsid, E3, E2, 6K, 
and E1. Following post-translational processing of the polyprotein, the capsid proteins 
assemble around a single positive-sense RNA genome. The capsid then buds from the 
plasma membrane, acquiring the envelope proteins that were processed in the 
endoplasmic reticulum. The two glycoproteins form heterodimeric trimers, creating a 
Class II fusion system, with E2 serving as the ligand for receptor binding and E1 
containing the fusion peptide. E2 also contains most of the known epitopes for 
neutralizing antibodies24,25.  
 SINV was first isolated in 1952 from Culex univittatus mosquitoes in Egypt and 
was named after the village in which it was first identified26. It is categorized as an Old 
World alphavirus, and upon natural infection by mosquitos, humans develop a flu-like 
illness with rash and arthralgia. However, upon infection of mice with laboratory-adapted 
strains of SINV, the virus is neurotropic and causes encephalomyelitis27. This provides a 
valuable model of disease typically produced by the New World alphaviruses, allowing 
for the study of pathogenesis of virus infection and the resulting host immune response. 
 
 
SINDBIS VIRUS INFECTION IN THE CENTRAL NERVOUS SYSTEM 
 
Several host and virus strain factors can affect virulence during SINV infection; 
one of these is maturity of neurons and mice. Susceptibility to alphavirus infection is age-
dependent, with maturation associated with decreased virus replication and less severe 
clinical disease. While neonatal mice infected with SINV die within three to four days 
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following infection, mice infected at weanling age with the same strain are able to clear 
the virus and recover from clinical disease28. These disparate outcomes are not due to 
changes in the immune response, but instead are due to increased resistance of neurons to 
infection as the cells mature29-31. Differentiation of neurons in vitro is associated with 
increased expression of antiviral genes and with decreased replication of infectious virus 
and production of viral proteins and RNA during infection32. 
Several strains of SINV have been adapted in the laboratory and produce clinical 
disease of varying severity in mice. The cell culture-adapted HRSP strain is the least 
virulent, reaching lower peak virus titers in vivo than other strains and capable of being 
fully cleared when injected into mice33. On the other end of the spectrum, neuroadapted 
Sindbis virus (NSV) causes 100% mortality in susceptible strains of mice. Neuroadapted 
Sindbis virus was created through intracranially inoculating mice with the original SINV 
isolate from mosquitoes, AR339, and serially passaging it through the brains of 
alternating neonatal and weanling mice six times34. Infection of susceptible weanling 
mice with NSV causes encephalomyelitis with ascending paralysis and results in 100% 
mortality by ten days post infection (DPI)35. Amino acid changes in the E1 (V72A and 
G313D) and E2 (G55H and L209G) proteins of NSV are determinants of its increased 
virulence36. Of intermediate virulence is the TE strain of SINV, which is a recombinant 
virus strain containing the E2 gene of NSV and the E1 gene of AR33936,37. While 
infection of suckling mice results in 100% mortality, infection of weanling mice only 
rarely progresses to death37. These seemingly minor changes in glycoprotein sequence 
can alter the virus’s ability to bind surface receptors of permissive cells, resulting in 
altered virus replication and thus facilitating increased virulence36-38. 
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Finally, the strain of mouse used also affects the outcome of SINV infection. SJL 
mice infected with the nonfatal AR339 strain of SINV develop more severe disease than 
BALB/c mice and have higher levels of inflammation and reduced IL-4 mRNA 
expression39. When infected with NSV strain of SINV, C57BL/6 mice develop ascending 
paralysis and 100% mortality by 14 days, while BALB/c mice only develop mild disease 
and survive40. Brains of C57BL/6 mice have increased inflammation and apoptosis with 
amplified proinflammatory cytokine expression and production, while BALB/c mice 
possess more infiltrating regulatory T cells and increased levels of anti-SINV antibody41. 
Unlike age receptiveness to SINV infection, differences in virus susceptibility in mouse 
strains appear to be immune-mediated. 
 When C57BL/6 mice are intracranially infected with the nonfatal TE strain of 
SINV, the course of virus infection in the brain can be divided into three main phases 
(Fig 1-2)42. Phase 1 occurs in the first week of infection, and during this time, both 
infectious virus titers and viral RNA levels reach their peak, around 3 to 5 DPI. Infectious 
virus titers then fall precipitously, dropping below detectable levels by about 7 to 8 DPI, 
while viral RNA levels remain at high copy number. During Phase 2 of infection, which 
occurs from about 10 to 60 DPI, infectious virus titers are no longer consistently 
detectable by plaque assay in the brain. Viral RNA levels start out at high copy number 
but steadily decline throughout the rest of the phase. Phase 3 of infection starts at around 
60 DPI and continues for at least a year following infection and presumably for the 
remaining life of the animal43,44. Infectious virus continues to be undetectable, but viral 
RNA reaches a low level steady-state that is consistently detectable by qRT-PCR42. 
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PATHOLOGY OF ALPHAVIRUS INFECTION 
 
 When neurons are infected with a virus, there are three possible outcomes that 
may occur45. First, the virus may directly kill the neuron by inducing processes such as 
apoptosis or necrosis46-48. Second, the neuron may be damaged or die through a 
secondary process, such as by inflammatory effects or by glutamate excitotoxicity49,50. 
Activation of nearby microglia and astrocytes that release reactive oxygen and nitrogen 
species and infiltration of monocytes, neutrophils, and lymphocytes releasing cytokines 
may all facilitate neuronal damage51. And lastly, virus infection of the neuron may be 
controlled through a noncytolytic mechanism, and the cell survives. Because viral RNA 
continues to persist within the cell, the immune system must continually control virus 
reactivation by some mechanism currently unknown. 
 Histopathological changes in the brains of New World alphavirus-infected 
humans and horses are characterized by acute neuronal degeneration and classic 
encephalitic features. Early in the disease process, massive numbers of neutrophils 
infiltrate the brain, though lymphocytes soon replace them as the predominant immune 
cell population52,53. In brains of C57BL/6 mice infected with NSV, marked loss of 
neurons, particularly in the CA regions of hippocampus, is the hallmark feature54. 
Perivascular cuffing and parenchymal infiltration of mononuclear cells is also 
considerable. Grossly, hydrocephalus and dilation of the lateral ventricles may also be 
seen. Together, these pathologic changes result in the neurologic deficits seen with 
alphavirus encephalomyelitis. 
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 The immune system response to alphavirus infection in the central nervous 
system (CNS) presents a double-edged sword: while the immune response is necessary 
for bringing virus replication and production under control, it is also responsible for many 
of the pathological changes and neurological damage produced. When SCID mice, which 
are deficient in both B cells and T cells, are infected with the AR339 strain of SINV, they 
do not develop signs of neurological disease in contrast to their wild-type counterparts24. 
When mice lacking various components of cellular immunity are infected with NSV, 
mortality significantly decreases, indicating T cells play an important role in the 
process55. Furthermore, NSV-induced clinical disease development and mortality 
coincide with infiltration of CD4+ and CD8+ T cells into the brain56. These studies point 
towards the immune response playing an overwhelmingly significant role in alphavirus 
encephalomyelitis. 
 Another secondary consequence of virus infection that contributes to neuronal 
damage and death is glutamate excitotoxicity. Glutamate is a major excitatory 
neurotransmitter that binds to three different receptors on recipient neurons: 2-amino-3-
(5-methyl-3-oxo-1,2-oxazol-4-yl) propranoic acid (AMPA), N-methyl-D-aspartic acid 
(NMDA), and kainate receptors57. Over-activation of these receptors results in a 
substantial influx of calcium into the post-synaptic neuron, which in turn triggers a 
cascade resulting in free radical production and mitochondrial dysfunction, and 
ultimately, cell death58,59. Hippocampal neurons in the brain and motor neurons in the 
spinal cord are especially sensitive to glutamate excitotoxicity60-63, and the process plays 
a role in SINV-induced pathology64,65. Furthermore, treatment with an AMPA receptor 
antagonist protects mice from NSV-induced death, indicating a significant role for 
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IMMUNE RESPONSE TO VIRUS INFECTION IN THE CENTRAL NERVOUS 
SYSTEM 
 
 Response to viral infections of the CNS poses a unique problem for the immune 
system. The restrictive nature of the blood brain barrier limits the ability of proteins and 
immune cells to enter into the brain and spinal cord in response to a virus infection66. 
Resident cells of the CNS, particularly neurons, have a limited-to-nonexistent capacity to 
express MHC molecules67. And arguably most important, preservation of neuronal 
function requires that infected neurons be allowed to survive, necessitating immune cells 
to employ special noncytolytic mechanisms to control virus infection. 
 Upon establishment of a new virus infection in the CNS, activation of the innate 
immune response is triggered. Type I interferons (IFNs), particularly IFN beta (IFN-β), 
are rapidly produced by neurons and glial cells68. Local production of IFN-β and IFN 
alpha (IFN-α) decreases virus replication and restricts virus spread from cell to cell by 
activating antiviral genes and neuroprotective factors69-71. Clinical disease in mice with 
impaired type I IFN signaling is more severe for several viruses that infect the CNS, 
including SINV, West Nile virus (WNV), neurotropic coronavirus, and Theiler’s murine 
encephalitis virus (TMEV)69,71-75. Activated microglia and astrocytes secrete a wide range 
of cytokines and chemokines, including proinflammatory cytokines IL-6, IL-1β, and 
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TNF, and leukocyte chemoattractants CCL-1, CCL-2, CCL-5 (RANTES), CXCL9, and 
CXCL1076-78. Secretion of these molecules enhances leukocyte adhesion and migration to 
the site of infection and up-regulation of MHC molecules on microglia. These innate 
immune processes restrict early virus replication until the adaptive immune response can 
be mounted to further control and clear virus79. 
 Response of adaptive immune cells to infection in the CNS is initiated a few days 
into the course of infection. Antigen presentation in the parenchyma of the CNS is 
severely limited, so most lymphocyte activation occurs in peripheral lymph nodes80. In 
the case of the brain, the draining lymph nodes are the superficial and deep cervical 
lymph nodes (CLNs)81. In C57BL/6 mice infected with SINV TE, CD8+ T cells first 
enter the brain around 5 DPI and peak in number at 7 DPI42. CD4+ T cells and B cells 
soon follow, peaking around 10 DPI. T cells initially accrue around vessels in the brain, 
forming perivascular cuffs, but parenchymal cellularity soon increases. CD4+ T cells 
mostly accumulate around the vessels, while CD8+ T cells travel further into the 
parenchyma82. Cell numbers slowly decrease during Phase 2 of infection, returning to 
baseline by four months42. 
The T cells present in the brain have a variety of antiviral effector functions. 
CD8+ T cells have cytotoxic activity and secrete effector molecules such as IFN-γ and 
granzyme B. While neurons only rarely express MHC I molecules, CD8+ T cells have 
been shown to directly interact with TMEV-infected neurons, providing a possible MHC-
independent mechanism for CD8+ T cell-mediated virus control83. CD4+ T cells support 
migration and survival of CD8+ T cells and secrete a variety of cytokines, including IFN-
γ84. Resident B cells in the brain secrete antibody directed against the virus; IgM is 
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initially produced, followed by IgG and IgA42,85. Together, these responses lead to 





 Because neurons are a valuable yet finite nonrenewable population of cells, 
clearance of viruses that infect them requires a noncytolytic process to avoid permanent 
long-term neurological deficits86. Virus clearance is a multi-component process. Virus 
spread must be inhibited, production of both infectious virus and viral RNA must be 
diminished, and reactivation from persistent viral remnants must be controlled. 
Mechanisms of virus clearance are also cell type- and tissue region-specific. 
 While innate production of type I IFN, particularly IFN-β, can help with the early 
control of SINV replication and spread, the adaptive immune response is responsible for 
long-term virus clearance69,70. While wild-type C57BL/6 mice are able to clear infectious 
SINV by 7 to 8 DPI, SCID mice still possess high titers in CNS tissue at 35 DPI. µMT 
mice, which lack mature B cells and thus antibody, have decreased virus titers but cannot 
fully clear infectious virus, and mice deficient in IFN-γ or IFN-γ receptor show 
reactivation of infectious virus after initial clearance. The course of SINV infection of 
mice double-knockout for antibody and IFN-γ is intermediate between that of SCID mice 
and µMT mice. Therefore, SINV clearance from the CNS is achieved by a synergistic 
cooperation between SINV-specific antibody and IFN-γ70.  
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 Several studies have shown that antibody directed against the E2 glycoprotein of 
SINV plays an important role in clearance of virus. When hyperimmune serum is 
transferred to persistently infected SCID mice, virus clearance occurs within 48 hours24. 
This still occurs in the absence of complement and NK cells, and when sensitized T cells 
are similarly adoptively transferred, no change in virus replication occurs. Viral RNA 
levels also decrease with passive transfer of hyperimmune serum. The most potent 
antibodies for clearance are those directed against the SINV E2 glycoprotein. When cells 
are treated in vitro with monoclonal antibodies against SINV E2, virus production 
decreases, and Na+K+ATPase function and membrane potential are restored24,87. 
However, when passively transferred antibodies are allowed to naturally decay over time, 
virus production resumes, indicating replication-competent viral RNA persists in infected 
cells43. While inflammation reduces the blood brain barrier restrictions to entry of 
immunoglobulins into the brain parenchyma during acute SINV infection, the amount 
found in the brain interstitium following initial clearance of infectious virus is 100 to 200 
times less than that found in the serum88,89. This amount is unlikely to be sufficient to 
suppress virus reactivation, suggesting that a considerable amount of antibody is locally 
produced by resident B cells90. Antibody-secreting B cells remain in the brain following 
initial clearance of infectious virus, likely contributing to long-term control of virus 
reactivation44,91. 
 Though unable to clear infectious virus from the entire brain, uMT mice are 
capable of clearing virus from the brain stem and from the spinal cord92. SCID mice are 
incapable of clearing virus from these regions, suggesting T cells play a significant 
clearance role in certain areas of the brain and in the spinal cord70. Both CD4+ and CD8+ 
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T cells are required for full virus clearance in these regions, suggesting that an antiviral 
cytokine response produced by both cell types facilitates this process rather than a 
cytotoxic effector response, which would exacerbate CNS pathological changes92. SCID 
mice were infected with recombinant SINV viruses expressing constructs for either IFN-γ 
or TNF-α, the two cytokines produced by both CD4+ and CD8+ T cells with antiviral 
activity. Virus clearance in the spinal cord was achieved with the IFN-γ recombinant 
virus, but not the one expressing TNF-α, indicating IFN-γ plays a prominent role in virus 
clearance. Treatment of differentiated neuronal CSM14.1 cells with IFN-γ results in 
decreased production of infectious virus and viral RNA and initiation of virus 
clearance93. SINV-infected athymic nude mice have decreased B cells and antibody 
levels in the CNS, particularly IgG, suggesting T cells influence B cell recruitment into 
the brain and immunoglobulin isotype switching as well85,94. 
Because SINV can reactivate in the brain once anti-SINV antibody decays in 
SCID mice, persistent viral RNA is capable of renewing virus production43. Therefore, 
immune-mediated decreases of viral RNA during Phase 2 of infection is likely very 
important to prevent renewed virus production. Currently the mechanisms by which viral 
RNA is cleared are very poorly understood. When infected with NSV, viral RNA levels 
in the brains and spinal cords of both CD8 and B2m knockout mice remain elevated 
longer than in wild-type mice67. This suggests CD8+ T cells play an important role in 
viral RNA clearance, likely through secretion of an effector protein, such as IFN-γ. Mice 
that are deficient in either IFN-γ or IFN-γ receptor tend to show reactivation of infectious 
virus after initial virus clearance during Phase 2 of infection, around 18 to 21 DPI, 
suggesting IFN-γ is required for decreasing viral RNA levels during this time70. Because 
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CD8+ T cells in the brain contract considerably at the start of Phase 2 of infection, CD4+ 





IFN-γ is predominantly produced by activated CD4+ and CD8+ T cells and by 
natural killer (NK) cells95,96. Because these cells, particularly the T cells, do not enter the 
brain until 3 to 4 DPI, IFN-γ likely exerts its effects by combatting virus already within 
cells, as opposed to preventing virus infection of naïve cells76. In addition to SINV, 
several different neurotropic viruses have been implicated to be cleared at least in part by 
IFN-γ, including measles virus, lymphocytic choriomeningitis virus (LCMV), vesicular 
stomatitis virus (VSV), mouse hepatitis virus (MHV), enterovirus 71, Theiler’s murine 
encephalitis virus (TMEV), and bornavirus97-102. 
IFN-γ, the classic proinflammatory cytokine, exerts its effects by inducing IFN-
stimulated genes (ISGs) through its signaling pathway. The IFN-γ receptor consists of a 
heterotetramer made up of the ligand-binding IFN-γR1 and signaling IFN-γR2103. During 
SINV infection, IFN-γ signals through its receptor to activate the Jak/Stat pathway, and 
phosphorylated Stat proteins, particularly STAT1, translocate to the nucleus where they 
bind to gamma-associated site (GAS) elements on genes104. IFN-γ signaling has been 
shown to activate over 200 ISGs with varying functions, resulting in multifaceted 
modulation of the immune response103,105. These include cellular effects on immune cell 
trafficking, T helper cell differentiation, antigen presentation, IgG class switching, and 
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macrophage activation, and more direct intracellular antiviral activities, such as the 
upregulation of dsRNA-activated protein kinase (PKR) and 2’-5’ oligoadenylate 
synthetase (2-5A synthetase)106-108. The IFN-γ receptor is expressed on many different 
cell types, including neurons103. 
During SINV infection in neuronal cell culture in vitro, STAT1 is phosphorylated 
at both Tyr701 and Ser727104. Viral protein and RNA production transiently increases 
before decreasing markedly, and host protein synthesis is restored93,104. IFN-γ signaling 
also leads to improved cell survival. If cells are treated with Jak inhibitor 1, these effects 
are reversed, indicating the importance of IFN-γ-induced Jak-STAT signaling in SINV 
clearance and cell survival93.  
 
 
LONG-TERM MAINTENANCE OF CELLULAR IMMUNITY DURING VIRAL 
INFECTION 
 
 In acute virus infections, infectious virus is cleared after a few days to weeks by 
the immune system. The T cell response to a virus infection can be divided into three 
major stages: clonal expansion, contraction, and memory formation109. Upon introduction 
of an antigen, naïve T cells are activated through MHC I-CD8 or MHC II-CD4 
interactions with antigen presenting cells, which primarily occur in the peripheral lymph 
nodes during neuronal infections due to the restrictive nature of the blood brain barrier80. 
Upon activation, T cells acquire effector functions, which for CD8+ T cells include 
expression of cytokines such as IFN-γ and TNF-α and chemokines such as RANTES and 
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cytotoxic capability through the granzyme/perforin system110. CD4+ T cells differentiate 
into T helper (Th) cell subsets and produce a wide array of cytokines, including some 
with antiviral properties, such as IFN-γ and TNF-α111. These activated T cells then 
clonally expand, mainly through signaling with IL-2, and migrate to the site of infection. 
These short-term effector T cells (TEFF) have a high capacity for effector function and 
work towards clearing virus through cytolytic and/or noncytolytic means, depending on 
the nature and site of infection.  
After acute virus infection is brought under control, the TEFF population contracts 
considerably, mainly through apoptotic pathways112,113. Approximately five to ten percent 
on these cells will survive, going on to mature into memory cells114,115. These memory T 
cells are generally divided into two main groups: effector memory (TEM) and central 
memory (TCM) T cells116. TCM cells have high proliferative and secretory IL-2 potential, 
but little effector capacity109. These cells tend to express L-selectin (CD62L) and CCR7, 
allowing them to home to lymph nodes and other secondary lymphoid organs where they 
perform immunosurveillance activities. TEM cells in contrast have little to no proliferative 
potential but are capable of immediately producing effector proteins, such as antiviral 
cytokines IFN-γ and TNF-α, and inducing cytotoxic activity. They lack L-selectin or 
CCR7 and so readily circulate through the secondary lymph nodes and previous sites of 
infection via the blood and lymph. These memory T cells establish an effective and 
permanent mechanism to combat future pathogen infections and control persistent virus 
from reactivating. 
A memory T cell population that has only been characterized within the last 
decade is the tissue resident memory (TRM) T cell. These cells express CD103, an integrin 
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protein that serves as a receptor for e-cadherin. E-cadherin is an adhesion molecule found 
on epithelial cells, and so the interaction between e-cadherin and CD103 is thought to 
help TRM cells remain in non-lymphoid tissues and avoid circulation throughout the 
lymphatic system117-119. They develop transcriptional and phenotypic signatures distinct 
from TCM and TEM cells that are dependent on the tissue in which they reside120. Upon 
restimulation, these cells secrete cytokines that rapidly activate the immune response, 
including resident B and T cells, dendritic cells, and NK cells121. TRM cells are most 
commonly seen in barrier tissues such as the skin, gastrointestinal (GI) muscosa, and 
female reproductive tissue but have also been reported in immunoprivileged sites such as 
the brain117,121-126. 
Maintenance and survival of memory T cells are primarily regulated by two 
cytokines: IL-7 and IL-15127. The receptor for IL-7 (CD127) is expressed on naïve and 
memory T cells, but is downregulated on TEFF cells127,128. IL-7 is considered to be 
important for maintenance of memory T cell survival, and is thought to be mediated, at 
least in part, through promoting expression of BCL-2, the anti-apoptotic protein129-131. IL-
15, in contrast, is thought to mainly regulate low-grade proliferation and renewal of 
memory T cells132-134. Together, these two cytokines ensure that memory T cell 
populations remain stable so that they can properly respond to pathogen reintroduction. 
Exhaustion of T cells was first characterized in CD8+ T cells during chronic 
persistent LCMV infection135. During the exhaustion process, T cells progressively lose 
effector functions. For CD8+ T cells, cytotoxic activity, IL-2 secretion, and proliferation 
potential are first lost, followed by TNF-α and IFN-γ production109,136,137. Over time, 
expression of inhibitory T cell markers, such as PD-1, LAG-3, and TIM-3, also 
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increase138,139. Apoptosis of memory T cells becomes more frequent, and if persistent 
viral load is excessively high or infection prolonged, the memory populations may be 
completely eliminated, leading to loss of T cell-mediated virus control136,140. Both CD8+ 
and CD4+ T cells can lose effector function during chronic infection, but CD4+ T cell 
exhaustion is less well understood141-144. T cell exhaustion is commonly found in chronic 
virus infection, such as with hepatitis C virus (HCV), human immunodeficiency virus 
(HIV), LCMV, and hepatitis B virus (HBV), but less is known regarding its role during 
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FIGURES 
Figure 1-1. Replication of SINV. The full-length, positive-sense genome encodes four 
structural proteins at the 5’ end and five structural proteins at the 3’ end. Nonstructural 
proteins are first translated from the full length, positive-sense genome and then 
complementary minus-strand RNA is transcribed. New full length, plus-strand genomes 
are transcribed from the minus-strand RNA for encapsidation into new virons. 
Subgenomic mRNA is transcribed from a subgenomic promoter found in the minus-
strand RNA, and the structural proteins that assemble to form new virions are translated 
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Figure 1-2. Course of SINV infection in C57BL/6 mouse brains. SINV occurs in three
phases. In Phase 1, both infectious virus and viral RNA levels peak, but infectious virus 
titers soon drop below detectable levels. In Phase 2, viral RNA levels slowly decline over 
time, until they reach a low level steady state in Phase 3. This figure was reproduced and 
adapted from Metcalf and Grifin, 2011. 
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INTRODUCTION 
(from Potter and Baxter, et al, 2015) 
 
Arthropod-borne alphaviruses and flaviviruses are plus-strand enveloped RNA 
viruses that pose an increasing worldwide threat to human populations as disease vectors 
expand into new geographic locations20,147-150. The New World alphaviruses, which 
include eastern equine encephalitis virus (EEEV), western equine encephalitis virus 
(WEEV), and Venezuelan equine encephalitis virus (VEEV), cause encephalomyelitis in 
humans and horses with varying rates of mortality8,13. Many patients who recover from 
the acute clinical disease, especially infants and children, are left with lifelong 
debilitating neurological defects, such as cognitive deficits, impaired motor control, and 
emotional and behavioral disturbances14-18,151. Currently, no treatments beyond 
symptomatic care are available, and no licensed human vaccines exist20. All three viruses 
are endemic in the Americas, and encephalomyelitis outbreaks caused by EEEV and 
VEEV have increased over the last few decades9,152. Therefore, it is increasingly 
important to understand the mechanisms responsible for the long-term consequences of 
alphavirus infection and to develop therapeutic interventions. 
Sindbis virus (SINV), the prototypic alphavirus, produces rash and arthritis in 
humans but is neurotropic in mice and provides a valuable model for studying alphavirus-
induced encephalomyelitis. In susceptible mice, nonlethal SINV infection consists of 
three phases in the brain: (1) presence of high levels of both infectious virus and viral 
RNA until about 7– 8 days post-infection (DPI); (2) undetectable infectious virus with 
significant yet declining viral RNA levels from about 10 to 60 DPI; and (3) chronic low-
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but-detectable steady-state viral RNA levels from 60 DPI on, presumably for the 
remaining life of the animal42. However, it is currently unknown whether SINV infection 
results in cognitive dysfunction in mice. The aim of this study was to use this mouse 
model of alphavirus encephalomyelitis to determine the impact of viral infection on 
cognitive function and relate that to changes in brain structure and function. Motor, 
anxiety, and neurocognitive function were tested at each of the three different phases of 
SINV infection in mice. These data were correlated with the presence of infectious virus 
and viral RNA in the brain, along with severity of neuroinflammation and cell death. 
 
 
MATERIALS & METHODS 
 
Sindbis Virus Infection of Mice 
 Five to six-week-old male C57BL/6 mice (Jackson labs) were infected 
intranasally with 105 pfu of the nonfatal TE strain of SINV in 20µL PBS or 20µL PBS 
vehicle for control while under light isoflurane anesthesia37. At 5, 28, or 90 DPI, mice 
underwent a battery of behavioral tests (see below). Following behavioral testing, mice 
were euthanized by isoflurane overdose and perfused with 15mL ice cold PBS. For RNA 
and plaque assay analysis, brains were collected, flash-frozen in liquid nitrogen, and 
stored at -80°C. For histopathology and immunohistochemistry, mice were perfused with 
40mL cold 4% paraformaldehyde (PFA), and brains were cut into three coronal sections 
using a using an Adult Mouse Brain Slicer (Zivic Instruments) and fixed overnight in 4 % 
PFA at 4°C. Brains were washed in ice cold PBS and embedded in paraffin. All studies 
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were approved by the Johns Hopkins University Institutional Animal Care and Use 
Committee. 
 
Open Field (from Potter and Baxter, et al, 2015) 
Animals were placed in the center of the open field arena (San Diego Instruments) 
at the beginning of the test and left undisturbed for 30 minutes. A 16 X 16 photobeam 
configuration was used to track the subject’s path within the arena. The total number of 
beams broken was used as a measure of locomotor activity, and the ratio of center to 
periphery breaks was used as a measure of anxiety153,154. The investigator was blinded to 
the experimental conditions throughout testing. These experiments were performed in 
collaboration with Michelle C. Potter, PhD. 
 
Elevated Plus Maze 
 The mice were placed in the center of the plus maze (two opposite arms open and 
the other two opposite arms closed), and the time spent in each arm was monitored for 
five minutes155. Anxiety was evaluated by calculating the ratio of time spent in the closed 
versus open arms. The investigator was blinded to the experimental conditions 




 Mice were placed on the rotarod for five minutes, and the average time it took for 
mice to fall from the apparatus over three trials was measured. The investigator was 
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blinded to the experimental conditions throughout testing. These experiments were 
performed in collaboration with Michelle C. Potter, PhD. 
 
Y-Maze (from Potter and Baxter, et al, 2015) 
The Y-maze consisted of three arms of equal length interconnected at 120°. This 
test measured working memory by scoring the number of alternations the mouse 
completed (animal visits all three arms without going into the same arm twice in a row) 
over five minutes156. The investigator was blinded to the experimental conditions 
throughout testing. These experiments were performed in collaboration with Michelle C. 
Potter, PhD. 
 
Contextual and Cued Fear Conditioning (from Potter and Baxter, et al, 2015) 
On day 1, mice were placed in the testing chamber for a total of 300 seconds; 
baseline was recorded from 0–120 seconds, and then three tone-shock pairings were 
applied. The first tone was given for 30 seconds between 120 and 150 seconds, which 
was paired with a two-second foot shock (0.5mA) during the last two seconds of the tone 
(148–150 seconds). The second tone was given for 30 seconds between 180 and 210 
seconds with the shock administered during the last 2 seconds (208–210 seconds). 
Finally, the third tone was given for 30 seconds between 240 and 270 seconds, with the 
shock between 268 and 270 seconds. On day 2, mice were placed into the same testing 
chamber and scored for percentage of freezing for five minutes during which time no 
tone or shock was given (contextual fear conditioning). Three hours after contextual 
testing, the mice were introduced to the same testing chamber with altered context. After 
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a 300 second baseline (pretone), five tones were given for 30 seconds each at one-minute 
intervals without the shock pairing (tone). The percent time the mouse spent freezing was 
recorded during the tone phase just described and used as a measure of cued fear 
conditioning155. The investigator was blinded to the experimental conditions throughout 
testing. These experiments were performed in collaboration with Michelle C. Potter, 
PhD. 
 
Histology and Immunohistochemistry 
 Three to four 10µm brain sections per mouse were stained with hematoxylin and 
eosin (H&E), coded, and scored blindly as previously described39 using a 0–3 scale. A 
score of 0 was given for slides with no detectable inflammation, a score of 1 for one to 
two small inflammatory foci per section, a score of 2 for moderate inflammatory foci in 
up to 50% of 10X magnification fields, and a score of 3 for moderate to large 
inflammatory foci in greater than 50% of 10X magnification fields. If excessive 
parenchymal cellularity was present, an additional point was added, allowing for a 
maximal score of 4. 
For SINV antigen staining, 10µm sections of brain were rehydrated and treated 
with 1mg/mL proteinase K (1:200 in distilled water) for 20 minutes, and endogenous 
peroxide was quenched in methanol + 3% H2O2 for ten minutes. Tissues were blocked 
with 10% normal goat serum (NGS) in PBS for 20 minutes and stained with NSV anti-
sera (1:200 in PBS + 5% NGS + 0.04% Triton-X)(Jackson 1987) for 60 minutes, 
biotinylated anti-rabbit IgG secondary (Vector labs, 5mg/mL in PBS + 5% + 0.04% 
Triton-X) for 30 minutes, and avidin-biotin complex (VECTASTAIN Elite ABC kit, 
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Vector Labs) for 40 minutes developed in 3,3’-diaminobenzidine (Vector Labs) for eight 
minutes. Slides were counterstained with hematoxylin for 60 seconds, dehydrated, and 
mounted with Permount (Fisher Scientific). 
For TUNEL staining, 10µm brain sections were rehydrated and treated with 
1mg/mL proteinase K (1:200 in deionized water) for 30 minutes, and endogenous 
peroxide was quenched in 3% H2O2 for five minutes. Sections were immersed in TdT 
Labeling Buffer and stained with TdT Labeling Reaction mix for 60 minutes at 37°C in a 
humidity chamber, immersed in TdT Stop Buffer, and stained with strep-HRP solution 
for ten minutes (TACS 2 TdT kit, Trevigen Inc). Brains were developed in 3,3’-
diaminobenzidine (Vector Labs) for seven minutes, counterstained with hematoxylin for 
60 seconds, dehydrated, and mounted with Permount (Fisher Scientific). Stained sections 
were coded, and the whole visible hippocampus on one brain section per mouse was 
outlined to determine the hippocampus area using a Nikon Eclipse E600 microscope and 
StereoInvestigator software (MBF Bioscience). All TUNEL-positive cells, as indicated 
by brown staining, were counted blindly within the outlined area, and results were 
graphed as TUNEL-positive cells per mm2 hippocampus. 
 
Quantification of Infectious Virus 
 Ice-cold PBS was added to the left halves of brains previously flash frozen and 
stored at -80°C to a concentration of 20% weight per volume (w/v) in Lysing Matrix A 
tubes (MP Biomedicals). Brains were homogenized at 6.0 M/s for 40 sec using a 
FastPrep-24 homogenizer (MP Biomedicals) and clarified by centrifuging at 13,200 rpm 
for 15 minutes at 4°C. Supernatant fluids were collected and serially diluted ten-fold in 
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DMEM + 1% FBS. Diluted homogenates were incubated on baby hamster kidney (BHK) 
cells for one hour, and an agarose overlay was applied. Assay plates were incubated at 
37°C, 5% CO2 for 48 hours, and plaques were counted using 10% neutral red solution to 
aid visualization. 
 
Viral RNA Quantification by qRT-PCR 
 Right brain halves were placed in Lysing Matrix D tubes (MP Biomedicals), and 
samples were homogenized in 1.0mL Qiazol at 6.0 M/s for 40 sec using a FastPrep-24 
homogenizer (MP Biomedicals). RNA was isolated using the Qiagen RNeasy Lipid Mini 
kit, and cDNA was synthesized with random primers using a Life Technologies High 
Capacity cDNA Reverse Transcription Kit following manufacturer’s instructions. 
Quantitative real-time PCR (qRT-PCR) was performed using TaqMan Universal PCR 
Master Mix and TaqMan probe (5’–6-carboxyfluorescein [FAM]-
CGCATACAGACTTCCGCCCAGT–6-carboxytetramethylrhodamine [TAMRA]-3’, 
Applied Biosystems) with primers to the SINV E2 gene (forward, nt 8732-5’-
TGGGACGAAGCGGACGATAA-3’-nt 8752; reverse, nt 8805-5’-
CTGCTCCGCTTTGGTCGTAT-3’-nt 8786). cDNA was amplified for 50 cycles using a 
7500 Fast Real-Time PCR System, and data were analyzed using Sequence Detector 
software, version 1.4 (Applied Biosystems). SINV E2 copies were quantified using a 
standard curve made of ten-fold dilutions of a plasmid containing the SINV subgenomic 
region and normalized to endogenous mouse Gapdh mRNA. 
 
Statistics 
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Statistical analyses were performed using Graphpad Prism 6 software. For 
behavioral tests, an unpaired Student’s t-test was used for two-group comparisons and a 
one-way ANOVA or two-way repeated measures ANOVA with Fisher’s PLSD post-hoc 
analysis was used to compare three or more groups. A p value of < 0.05 was considered 





SINV-infected mice have hippocampus-dependent memory deficits that persist 
beyond recovery from clinical disease 
 To assess the neurocognitive integrity of mice infected with SINV at each phase 
of infection, a battery of behavioral tests was performed on mice infected with the TE 
strain of SINV or mock-infected with PBS at 5, 28, and 90 DPI. SINV-infected mice 
showed increased motor activity (Fig 2-1A) and decreased anxiety (Fig 2-1B) at 5 DPI, 
but these effects were not seen at 28 or 90 DPI. Though SINV-infected mice trended 
towards showing decreased anxiety at 5 DPI as assessed by elevated plus maze (Fig 2-
1C; p = 0.07, Student’s t test), this finding was not significant. To assess motor 
coordination, SINV-infected and mock-infected mice were tested on the rotarod, but no 
difference between groups was found (Fig 2-1D). 
 The effect of SINV infection on working and hippocampus-dependent memory 
was measured using Y maze and fear conditioning, respectively. Working memory, as 
measured by percent spontaneous alterations on the Y maze, was not affected by SINV 
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infection at any of the assessed time points (Fig 2-1E). Mice showed decreased percent 
time spent freezing at 5 DPI for both contextual (Fig 2-1F) and cued (Fig 2-1G) fear 
conditioning. A significant decrease in percent time spent freezing continued to be seen at 
28 and 90 DPI for contextual fear conditioning (p < 0.05, Student’s t test), but not for 
cued fear conditioning. These data show that behavioral deficits continue during Phases 2 
and 3 of SINV infection. 
 
Inflammation and cell death in the brain peak during Phase 1 of infection  
 To better understand the mechanisms behind the behavioral testing results, brain 
sections of SINV-infected and mock-infected mice were examined. Inflammatory cells 
present around vessels and in the brain parenchyma were easily detectable at 5 DPI in 
SINV-infected mice, though less so at later time points and in mock-infected mice (Fig 2-
2A). H&E-stained brains were evaluated for inflammation using a four point scoring 
system, and SINV-infected mice had higher scores at 5 DPI compared to mock-infected 
mice or at later time points (Fig 2-2C). To evaluate cell death in brains, TUNEL staining 
was performed at each time point in both mock-infected and SINV-infected mice, and the 
number of TUNEL-positive cells within the hippocampus was counted. TUNEL-positive 
cells in hippocampus were readily measured in the brains of SINV-infected mice at 5 
DPI, but not at later time points or in mock-infected brains (Figs 2-2B and 2-2D). Based 
on these results, both inflammation and cell death peak during the period when 
behavioral deficits are most apparent in SINV-infected mice. 
 
Detectable SINV peaks during Phase 1 of infection 
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 To correlate SINV infection with behavioral tests and histological findings, 
infectious virus, viral protein, and viral RNA levels were assessed at each time point. 
Viral protein, as assessed by brain polyclonal anti-SINV antibody 
immunohistochemistry, was easily detectable at 5 DPI in SINV-infected mice, but not in 
mock-infected mice or at 28 or 90 DPI (Fig 2-3A). Infectious virus was detectable by 
plaque assay in brains at high levels at 5 DPI, but was undetectable at 28 or 90 DPI (Fig 
2-3B). In contrast, viral RNA, as measured by qRT-PCR for the E2 structural gene, 
peaked at 5 DPI, but was still detectable, though at declining levels, at 28 and 90 DPI 
(Fig 2-3C). These data show that the most marked behavioral and histological changes 
occur when active virus replication is occurring. The persistent hippocampus-dependent 





(from Potter and Baxter, et al, 2015) 
 
In this study, we found that at the peak of active virus infection, SINV-infected 
mice demonstrated increased activity, reduced anxiety, and impaired hippocampus-
dependent contextual and cued fear conditioning memory. Eleven weeks after the 
clearance of infectious virus when only viral RNA was present in the brain, SINV-
infected mice continued to show significant memory impairment as indicated by 
contextual fear conditioning tests.  
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During the early stages of infection, SINV mice were hyperactive and less 
anxious in the open field test compared to uninfected mice. Epidemic encephalitis can 
lead to behavioral abnormalities similar to attention-deficit/hyperactivity disorder 
(ADHD), with damage to the brainstem suggested as a cause157. Other areas that are 
important for locomotor activity are the basal ganglia and the cerebellum. The amygdala 
is a central area of processing fear and anxiety158. Indeed, in cases of viral encephalitis 
such as from human herpesvirus 6 (HHV6), there was significant damage to the medial 
temporal lobe including the amygdala159. Neurological sequelae in patients surviving 
alphavirus encephalomyelitis have been reported to include hyperactivity, emotional 
disinhibition, and temperament disturbances14,15,17,18, and symptoms similar to ADHD 
have been described in patients affected by encephalitis caused by other types of viruses, 
such as HIV157,160. 
The most profound and prolonged abnormalities were identified using fear 
conditioning. Contextual and cued fear conditioning involve different brain circuitry, 
with contextual fear conditioning being more associated with the hippocampus161-165. 
While SINV infects neurons in the cortex, brainstem, and spinal cord35, previous studies 
of mice infected with a lethal neuroadapted strain of SINV (NSV) have noted that 
hippocampal neurons are particularly vulnerable to progressive damage54. Hippocampal 
neurons are also particularly susceptible to glutamate-induced excitotoxic damage, which 
plays a role in SINV-induced cell death60,61,65. In addition, the hippocampus plays a very 
important role in cognition, and factors affecting learning and memory processes can be 
probed using tasks such as fear conditioning165,166. In our study, deficits in fear 
conditioning at 5 DPI correlated with demonstration of active virus replication, 
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inflammation, and cell death in the hippocampus during the acute phase of infection. 
Impairments in contextual, but not cued, fear conditioning persisted for at least 90 days 
after infection, a time when the mice appeared to have fully recovered. Although virus-
induced behavioral alterations in mice have been previously reported167-169, to our 
knowledge, this is the first study of cognitive deficits and other behavioral abnormalities 





















Figure 2-1. Assessment of locomotor activity, anxiety, and memory in SINV-infected 
mice. A batery of behavioral tests were performed on SINV-infected and mock-infected 
mice at 5, 28, and 90 DPI. (A) Locomotor activity was assessed by the open field test by 
measuring the number of beam breaks made by mice in 30 minutes. Anxiety was 
assessed by measuring the ratio of time mice spent in the center versus the periphery of 
the open field (B) and by measuring the ratio of time mice spent in the closed arm versus 
the open arm of the elevated plus maze (C). (D) Motor coordination was assessed by time 
to fal of the rotarod. (E) Working memory was measured as the percent of spontaneous 
alternation performed on the Y maze. Hippocampus-dependent memory was measured as 
the percent time spent freezing during contextual (F) and cued (G) fear conditioning (n = 
12–15 mice per group; data presented as the mean ± SEM; *p < 0.05, **p < 0.01, ***p <
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0.001, ****p < 0.0001, by repeated measures ANOVA for cued fear conditioning and 
unpaired t tests for all other tests;). These experiments were performed in collaboration 
with Michelle C. Potter, PhD. Figures 2-1A, 2-1B, 2-1C, 2-1F, and 2-1G were adapted 
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Figure 2-2. Inflammation and cell death in the brain over the course of SINV 
infection. (A) Representative photomicrographs of H&E-stained coronal brain sections 
from mock-infected mice and mice infected with SINV at 5, 28, or 90 DPI (white 
arrowheads denote perivascular cuffing; 200X magnification; scale bar = 100 µm). (B) 
Representative photomicrographs from TUNEL staining of the hippocampal dentate 
gyrus of mock-infected mice and mice infected with SINV at 5, 28, or 90 DPI (brown 
nuclear staining = TUNEL-positive [denoted by black arrowheads]; 200X magnification; 
scale bar = 100 µm). (C) Inflammation was assessed in mock-infected and SINV-infected 
mouse brains at 5, 28, and 90 DPI using a four point scoring system. (D) TUNEL-
positive cells were quantified in the hippocampus of mock-infected and SINV-infected 
mouse brains at 5, 28, and 90 DPI (for all bar graphs, n = 3–4 mice per group per time 
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Figure 2-3. Detection of SINV and viral RNA in the brain over the course of SINV 
infection. (A) Representative photomicrographs of immunohistochemical staining for 
SINV antigen in mock-infected brains and brains of mice infected with SINV at 5, 28, or 
90 DPI (brown staining=SINV protein; 40X magnification; scale bar=500 µm). Infectious 
virus (B) and viral RNA (C) were measured at 5, 28, and 90 DPI in SINV-infected mice 
by plaque assay and qRT-PCR, respectively (n = 3–4 mice per group per time point; data 
presented as mean ± SEM; dotted line represents limit of detection; ND, not detectable). 

















GLUTAMINE ANTAGONISM DECREASES PATHOLOGY BUT DELAYS VIRUS 
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INTRODUCTION 
 
 Recent epidemics of encephalomyelitis caused by the New World alphaviruses, 
including EEEV, WEEV, and VEEV demonstrate their capacity as a worldwide public 
health concern9-11. Currently no treatments beyond supportive care are available for 
alphavirus encephalomyelitis, and no licensed vaccines are approved for non-military 
human use19. Clinical disease induced by infection with New World alphaviruses can be 
severe14,15,170-183. When humans are infected with one of these viruses, the prodromal 
phase averages five days, but can last as long as four weeks. Patients tend to develop flu-
like symptoms followed by abrupt onset of signs of encephalitis, such as headache, 
restlessness, seizures, and alterations in consciousness. Cerebrospinal fluid (CSF) often 
shows pleocytosis and elevated protein. Cerebral dysfunction is evident by 
electroencephalogram (EEG), and on MRI or CT scan, diffuse abnormalities in the 
parenchyma tend to be seen in the cortex, thalamus, basal ganglia, and brainstem. 
Mortality rates depend on the virus species. EEEV carries the higher mortality rate, 
ranging from 30 to 70%, while the death rate for WEEV is considerably lower, closer to 
4%15,173. Fatalities are most common in infants and children. Neurological sequelae occur 
in approximately 25 to 35% of patients that recover, with higher rates in children15,151,173. 
On autopsy, brains of patients are grossly swollen and edematous52,53,184. 
Microscopically, meningoencephalitis is present with occasional vasculitis. Tissue 
destruction is marked with extensive neuronal death. Inflammatory infiltrates can be 
found around vessels and in the CNS parenchyma. Early in infection neutrophils are the 
primary infiltrating leukocyte, but lymphocytes soon predominate. Spinal cord 
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pathological changes are also commonly seen with EEEV infection. Similar clinical signs 
and pathological changes are seen in horses infected with one of the equine encephalitis 
viruses, though mortality rates tend to be higher compared to humans185,186. 
Neuronal damage resulting from alphavirus infection is due to both the immune 
response and glutamate excitotoxicity, and previous studies have shown that inhibition of 
these mechanisms can protect mice from fatal viral encephalomyelitis49. However, 
treatment has not been evaluated for prevention of sequelae in nonfatal infection. 
Because the glutamine antagonist, 6-diazo-5-oxo-L- norleucine (DON), affects both of 
these pathologic mechanisms187-190, we tested the effects of treatment with DON on the 
development of neurological sequelae.  
DON is an irreversible competitive inhibitor of several glutamine-utilizing 
enzymes191. During growth and proliferation, T cells preferentially use glutamine instead 
of glucose as an energy source, and rapidly dividing activated T cells show increased 
glutamine uptake and metabolism192,193. Therefore, glutamine antagonism can inhibit 
lymphocyte proliferation190. In the CNS, the excitatory neurotransmitter glutamate is 
synthesized from glutamine. Excess production of glutamate leads to neuronal death 
through glutamate excitotoxicity, so inhibition of glutamine metabolism might abrogate 
this process57. DON treatment has been shown to rescue mice from late-stage cerebral 
malaria, indicating it might be a viable treatment option for CNS infections that induce 
immune-mediated neuronal damage194. Therefore, we hypothesized that DON treatment 
would prevent SINV-infected mice from developing clinical disease with neurological 
deficits, and CNS pathological changes will be reduced due to decreased inflammation 
and glutamate excitotoxicity. 
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MATERIALS & METHODS 
 
Sindbis Virus Infection and Clinical Evaluation of Mice 
 Four to six-week-old male C57BL/6 mice (Jackson labs) were infected 
intranasally with 105 pfu of the nonfatal TE strain of SINV in 20µL PBS or 20µL PBS 
vehicle for control while under light isoflurane anesthesia37. Mice were evaluated daily 
for presence of clinical signs indicative of encephalomyelitis (hunched posture, abnormal 
gait, paresis), and body weight was measured each day. At 5 DPI, mice underwent 
behavioral testing (see below), and at 5, 7, 9, or 11 DPI, mice were euthanized by 
isoflurane overdose and perfused with 15mL ice cold PBS following blood collection by 
cardiocentesis. Blood was allowed to coagulate in BD Microtainer serum separator tubes 
and centrifuged for 15 minutes at 1,500 RCF. The resulting serum layer was collected 
and stored at -20°C. For RNA and plaque assay analysis, brains and spinal cords were 
collected, flash-frozen in liquid nitrogen, and stored at -80°C. For histopathology and 
immunohistochemistry, mice were perfused with 40mL cold 4% PFA, and brains, spinal 
columns, and GI tracts were collected. Brains were cut into three coronal sections using a 
using an Adult Mouse Brain Slicer (Zivic Instruments), fixed overnight in 4 % PFA at 
4°C, and washed in ice-cold PBS. Spinal columns were trimmed of excess soft tissue, 
fixed overnight in 4% PFA at 4°C, and then decalcified on a rotator for 24 to 36 hours in 
a 10% sodium citrate/22% formic acid solution. Spinal columns were washed in ice-cold 
PBS and cut to isolate the L4-L6 spinal cord regions. GI tracts were fixed overnight in 
4% PFA, washed in ice-cold PBS, and placed in cassettes either as cross sections 
sampling each portion of the tract or complete using a closed Swiss roll technique. 
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Tissues were embedded in paraffin for sectioning and staining. The Johns Hopkins 
University Institutional Animal Care and Use Committee approved all studies. 
 
Drug Administration (from Potter and Baxter, et al, 2015) 
Daily intraperitoneal injections of DON (Sigma-Aldrich) were administered at 
doses of 0.3 or 0.6 mg/kg beginning the day of SINV inoculation (0 DPI) and continuing 
through 7 DPI. DON working solution was diluted in PBS each day from aliquots of a 
100 mM stock solution in PBS stored at −80 °C. Control group animals received 
injections of PBS. On days of behavioral testing (5 and 6 DPI), the drug or vehicle was 
administered one hour prior to testing. Tissues were collected at two time points during 
drug administration (5 and 7 DPI) and at two time points following cessation of treatment 
(9 and 11 DPI). 
 
DON Measurement in Tissues (from Potter and Baxter, et al, 2015) 
DON was spiked into mouse sera or brains from untreated animals to generate 
standards at concentrations from 10 nM to 100 µM. DON was derivatized into a more 
stable and lipophilic analyte by adding butanol with 3 N HCl (250 µL) to standards and 
samples (50 µL). The brains were homogenized, and all samples were centrifuged at 
16,000  ×  g for five minutes to precipitate proteins. To carry out the derivatization 
reaction, an aliquot of supernatant (200 µL) was incubated at 60 °C for 30 minutes and 
dried at 45 °C under a nitrogen stream. Samples were resuspended in 50-µL 70 %/30 % 
water/acetonitrile, vortexed, and centrifuged again at 16,000  ×  g for five minutes. 
Samples (2 µL) were subsequently injected and separated on an Agilent 1290 HPLC 
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equipped with a C18 column over a 5.5-min gradient from 30 to 70 % 
acetonitrile  +  0.1 % formic acid and quantified on an Agilent 6520 QTOF mass 
spectrometer. Standards within the quantifiable range (30 nM–100 µM) were used to 
generate a standard curve. Samples below the limit of quantification were assigned a 
value of 0. These experiments were performed in collaboration with Jesse Alt and Camilo 
Rojas, PhD. 
 
Open Field (from Potter and Baxter, et al, 2015) 
Animals were placed in the center of the open field arena (San Diego Instruments) 
at the beginning of the test and left undisturbed for 30 minutes. A 16 X 16 photobeam 
configuration was used to track the subject’s path within the arena. The total number of 
beams broken was used as a measure of locomotor activity, and the ratio of center to 
periphery breaks was used as a measure of anxiety153,154. The investigator was blinded to 
the experimental conditions throughout testing. These experiments were performed in 
collaboration with Michelle C. Potter, PhD. 
 
Contextual and Cued Fear Conditioning (from Potter and Baxter, et al, 2015) 
On Day 1 (5 DPI), mice were placed in the testing chamber for a total of 300 
seconds; baseline was recorded from 0–120 seconds, and then three tone-shock pairings 
were applied. The first tone was given for 30 seconds between 120 and 150 seconds, 
which was paired with a two-second foot shock (0.5mA) during the last two seconds of 
the tone (148–150 seconds). The second tone was given for 30 seconds between 180 and 
210 seconds with the shock administered during the last two seconds (208–210 seconds). 
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Finally, the third tone was given for 30 seconds between 240 and 270 seconds, with the 
shock between 268 and 270 seconds. On Day 2 (6 DPI), mice were placed into the same 
testing chamber and scored for percentage of freezing for five minutes during which time 
no tone or shock was given (contextual fear conditioning). Three hours after contextual 
testing, the mice were introduced to the same testing chamber with altered context. After 
a 300 second baseline (pretone), five tones were given for 30 seconds each at one-minute 
intervals without the shock pairing (tone). The percent time the mouse spent freezing was 
recorded during the tone phase just described and used as a measure of cued fear 
conditioning155. The investigator was blinded to the experimental conditions throughout 
testing. These experiments were performed in collaboration with Michelle C. Potter, 
PhD. 
 
Histology and Immunohistochemistry 
Three to four 10µm brain sections per mouse were stained with H&E, coded, and 
scored blindly as previously described39 using a 0–3 scale. A score of 0 was given for 
slides with no detectable inflammation, a score of 1 for brains with one to two small 
inflammatory foci per section, a score of 2 for moderate inflammatory foci in up to 50% 
of 10X magnification fields, and a score of 3 for moderate to large inflammatory foci in 
greater than 50% of 10X magnification fields. If excessive parenchymal cellularity was 
present, an additional point was added, allowing for a maximal score of 4. 
Three to four 10um lumbar spinal cord sections per mouse were stained with 
H&E, coded, and scored using a 0-2 scale adapted from the brain scoring system. A score 
of 0 was given for slides with no detectable inflammation, a score of 1 for spinal cord 
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sections with one to two small inflammatory foci per section, and a score of 2 for greater 
than two inflammatory foci per spinal cord or for spinal cords with moderate to marked 
inflammatory foci. An additional point was awarded if excessive parenchymal cellularity 
was present, allowing for a maximal score of 3. 
For CD3 immunohistochemical staining, 10µm brain sections were rehydrated, 
and antigen retrieved by boiling in 0.01 M sodium citrate (pH 6.0) for ten minutes. After 
quenching endogenous peroxidases in methanol + 3% H2O2 for ten minutes, sections 
were blocked with 10 % NGS in PBS for 30 minutes. Tissues were incubated with 
polyclonal anti-human CD3 (Dako, 1:400 in PBS  +  5 % NGS  +  0.04 % Triton-X) for 
60 minutes, biotinylated anti-rabbit IgG secondary (Vector labs, 5 mg/mL in PBS  +  5 % 
NGS +  0.04 % Triton-X) for 30 minutes, and avidin-biotin-HRP complex 
(VECTASTAIN Elite ABC kit) for 40 minutes. Slides were developed with 3,3′-
diaminobenzidine (Vector labs) for ten minutes, counterstained with hematoxylin for 
60 seconds, dehydrated, and mounted with Permount (Fischer Scientific). 
For TUNEL staining, 10µm brain or spinal cord sections were rehydrated and 
treated with 1mg/mL proteinase K (1:200 in deionized water) for 30 minutes, and 
endogenous peroxidases were quenched in methanol + 3% H2O2 for five minutes. 
Sections were immersed in TdT Labeling Buffer, stained with TdT Labeling Reaction 
mix for 60 minutes at 37°C in a humidity chamber, immersed in TdT Stop Buffer, and 
stained with strep-HRP solution for ten minutes (TACS 2 TdT kit, Trevigen Inc). Tissues 
were developed with 3,3’-diaminobenzidine (Vector Labs) for seven minutes, 
counterstained with hematoxylin for 60 sec, dehydrated, and mounted with Permount 
(Fisher Scientific).  
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Stained CD3 and TUNEL sections were coded, and the whole visible 
hippocampus on one brain section per mouse (both CD3 and TUNEL) or the entire spinal 
cord cross section per mouse (TUNEL only) was outlined to determine the tissue area 
using a Nikon Eclipse E600 microscope and StereoInvestigator software (MBF 
Bioscience). All CD3- or TUNEL-positive cells, as indicated by brown staining, were 
counted blindly within the outlined area, and results were graphed as CD3- or TUNEL-
positive cells per mm2 tissue. In TUNEL-stained 7 DPI brains, cells identified 
morphologically as neurons within the granule cell layer of the dentate gyrus and 
pyramidal cell layers of the CA regions were additionally counted. 
For SINV antigen staining, 10µm sections of brain were rehydrated and treated 
with 1mg/mL proteinase K (Invitrogen, 1:200 in distilled water) for 20 minutes, and 
endogenous peroxide was quenched in methanol + 3% H2O2 for ten minutes. Tissues 
were blocked with 10% NGS in PBS for 20 minutes and stained with NSV anti-sera 
(1:200 in PBS + 5% NGS + 0.04% Triton-X)(Jackson 1988) for 60 minutes, biotinylated 
anti-rabbit IgG secondary (5mg/mL in PBS + 5% NGS + 0.04% Triton-X) for 30 
minutes, and avidin-biotin complex (VECTASTAIN Elite ABC kit) for 40 minutes 
developed with 3,3’-diaminobenzidine (Vector Labs) for eight minutes. Slides were 
counterstained with hematoxylin for 60 seconds, dehydrated, and mounted with 
Permount. 
 
Mononuclear Cell Isolation 
  Single cell suspensions were made from cervical lymph nodes (CLNs), brains, 
and spinal cords pooled from two to three mice per strain per time point. CLNs were 
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dissociated in RPMI + 1% FBS using gentleMACS C tubes and Dissociator (Miltenyi 
Biotech) and filtered through a 70µm-pore-size cell strainer. After pelleting by 
centrifugation, red blood cells were lysed using an ammonium chloride solution (Sigma-
Aldrich). Remaining cells were filtered through another 70µm strainer, pelleted by 
centrifugation, and resuspended in PBS + 2mM EDTA (PE buffer) for counting. Brains 
and spinal cords were placed in RPMI media containing 1% FBS, 1 mg/mL collagenase 
D (Roche), and 0.1 mg/mL DNase I (Roche) and dissociated in C tubes using a 
gentleMACS Dissociator. Tissues were incubated for 30 minutes at 37°C with periodic 
agitation, and dissociated cells were filtered through a 70µm pore size cell strainer and 
pelleted by centrifugation. Cell pellets were resuspended in 30% supplemented Percoll 
(9:1 Percoll [GE Healthcare] : 10X salt solution of 80g NaCl, 3g KCl, 0.73g Na2HPO4, 
0.2g KH2PO4, and 20g glucose in 1L dH2O) in RPMI media in a 15mL conical tube and 
underlaid with 70% supplemented Percoll in RPMI media. Tubes were centrifuged at 850 
x g at 4°C for 30 minutes with slow braking to create a gradient, and cells were collected 
from the 30/70% interface. Cells were pelleted by centrifugation and resuspended in PE 
buffer for counting. Live mononuclear cells were quantified by trypan blue exclusion. 
 
Flow Cytometry 
  106 live cells were plated in a 96-well round bottom plate. A violet LIVE/DEAD 
Fixable Dead Cell Stain (Life Technologies) diluted in PE buffer was applied to cells for 
30 minutes, followed by a 15-minute incubation with anti-mouse CD16/CD32 (BD 
Pharmingen) diluted in PE buffer to block Fc receptors. Cells were stained with 
monoclonal antibodies against CD45 (clone 30-F11), CD3 (clone 17A2), CD4 (clone 
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RM4-5), CD8a (clone 53-6.7), and CD19 (clone 1D3) from Ebioscience or BD 
Pharmingen diluted in PBS + 2mM EDTA + 0.5% BSA (FACS Buffer) for 30 minutes 
on ice. Cells were run on a BD FACSCanto II cytometer using BD FACSDiva software, 
version 8, and analyses were carried out using FlowJo software, version 8. Cells were 
characterized as follows: CD3 T cells (CD45hiCD3+), CD4 T cells (CD45hiCD3+CD4+), 
CD8 T cells (CD45hiCD3+CD8+), and B cells (CD45hiCD3-CD19+). 
 
Quantification of Infectious Virus 
Ice-cold PBS was added to left halves of brains (20% w/v) or whole spinal cords 
(10% w/v) previously flash frozen and stored at -80°C. Tissues were homogenized in MP 
Biomedicals Lysing Matrix A tubes at 6.0 M/s for 40 seconds using a FastPrep-24 
homogenizer (MP Biomedicals) and clarified by centrifuging at 13,200 rpm for 15 
minutes at 4°C. Supernatant fluids were collected and serially diluted ten-fold in DMEM 
+ 1% FBS. Diluted homogenates were incubated on baby hamster kidney (BHK) cells for 
one hour, and an agarose overlay was applied. Assay plates were incubated at 37°C, 5% 
CO2 for 48 hours, and plaques were counted using 10% neutral red solution to aid 
visualization. 
 
Protein Quantification by Enzyme-Linked Immunosorbent Assay 
Anti-SINV antibody was measured in serum and 20% w/v brain homogenates in 
three to six mice per strain per time point using an in-house enzyme-linked 
immunosorbent assay (ELISA). Maxisorp 96-well plates (Thermo Scientific Nunc) were 
coated with 106 pfu PEG-purified SINV TE diluted in 50mM NaHCO3, pH 9.6 coating 
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buffer and incubated overnight at 4°C. Plates were blocked in PBS-0.05% Tween-20 + 
10% FBS (PBST-10% FBS) for two hours at 37°C and incubated overnight at 4°C with 
samples diluted in PBST-10% FBS (1:100 [IgM] or 1:10 [IgG] for serum, 1:4 for brain 
homogenates). Wells were incubated with 1:1000 HRP-conjugated goat anti-mouse IgM 
or IgG (Southern Biotech) for two hours at room temperature, and plates were developed 
with a BD OptEIA TMB Substrate Reagent kit using 2M H2SO4 as stop solution. Plates 
were read at 450nm, and optical density (OD) values for mock-infected mice were 
subtracted from the OD values of infected mice. 
Interferon gamma (IFN-γ) production was quantified in 20% w/v brain 
homogenates in three to five mice per strain per time point by commercial ELISA kit 
(Ebioscience Ready-SET- Go!). Assays were performed according to manufacturer’s 
instructions, and data was presented as pg/g brain tissue with a 312pg/g limit of detection. 
 
qRT-PCR Evaluation of IFN-γ mRNA Expression and Viral RNA Production 
 Right brain halves and whole spinal cords were placed in Lysing Matrix D tubes 
(MP Biomedicals), and samples were homogenized in 1.0mL Qiazol at 6.0 M/s for 40 
seconds using a FastPrep-24 homogenizer (MP Biomedicals). RNA was isolated using 
the Qiagen RNeasy Lipid Mini kit, and cDNA was synthesized with random primers 
using a Life Technologies High Capacity cDNA Reverse Transcription Kit following 
manufacturer’s instructions. qRT-PCR was performed using TaqMan Universal PCR 
Master Mix (Roche) on a 7500 Fast Real-Time PCR System for 50 cycles, and results 
were analyzed using Sequence Detector software, version 1.4. Ifng mRNA was measured 
using a commercially available TaqMan gene expression assay (Integrated DNA 
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Technologies), and relative gene quantification versus mock-infected mice was 
performed by the ΔΔCT method using mouse Gapdh for normalization. SINV RNA 
copies were measured using TaqMan probe (5’–6-carboxyfluorescein [FAM]-
CGCATACAGACTTCCGCCCAGT–6-carboxytetramethylrhodamine [TAMRA]-3’, 
Applied Biosystems) with primers to the SINV E2 gene (forward, 5’-
TGGGACGAAGCGGACGATAA-3’; reverse, 5’-CTGCTCCGCTTTGGTCGTAT-3’). 
SINV E2 copies were quantified using a standard curve made of ten-fold dilutions of a 




Statistical analyses were performed using Graphpad Prism 6 software or Statview 
(SAS Institute Inc.). For clinical disease evaluation, a Mantel-Cox log-rank test was used 
to compare Kaplan-Meier curves, and for body weights, one-way ANOVA with 
Bonferroni’s multiple comparisons post-test were employed. Behavioral tests were 
evaluated using a one-way ANOVA with Bonferroni’s multiple comparisons post-hoc for 
open field and contextual fear conditioning and a two-way repeated measures ANOVA 
with Fisher’s PLSD post-hoc for cued fear conditioning. Time-course studies were 
analyzed by two-way ANOVA with Tukey’s multiple comparison post-test. Experiments 
comparing three or more groups at a single time point employed Kruskal-Wallis tests 
with Dunn’s multiple comparisons post-hoc. A p value of <0.05 was considered 
significant in all analyses. 
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RESULTS 
 
DON is easily detectable in serum, but less so in the brain one hour following 
administration 
 Previous studies have shown that the pathological changes seen during SINV 
infection is primarily due to a combination of glutamate toxicity and inflammatory effects 
produced by the immune response, rather than directly due to the virus itself49. To see if 
administration of a drug that counteracts both of these pathways would prevent 
development of clinical disease and CNS pathology, the glutamine antagonist DON was 
used to treat mice during SINV infection. Mice were intranasally infected with the TE 
strain of SINV and treated daily for the first 7 DPI with either a low (0.3mg/kg) dose or 
high (0.6mg/kg) dose of DON intraperitoneally.  
One hour following drug administration on 7 DPI, serum and brains were 
collected, and DON concentration was measured by mass spectrometry. DON was not 
detectable in sera or brains of untreated mice, but was easily detected in the sera of mice 
treated with both the low (0.3mg/kg) and high (0.6mg/kg) dose of DON (Fig 3-1A). DON 
was detectable in the brains of mice treated with the high (0.6mg/kg) dose of DON, 
though at considerably lower concentrations than in the serum, and was not consistently 
measurable in brains of mice receiving the low (0.3mg/kg) dose of DON (Fig 3-2B). 
Mock-infected and SINV-infected mice showed similar concentrations of DON. 
  
DON treatment partially prevents development of clinical disease but causes GI 
toxicity at high doses 
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 To evaluate the effect of glutamine antagonism on development of clinical disease 
during SINV infection, mice were weighed and observed daily for the development of 
clinical signs throughout the period of DON administration. By 7 DPI, when almost all 
SINV-infected, untreated mice had development signs consistent with encephalomyelitis 
(hunched posture, abnormal gait, paresis), less than half of the DON-treated mice were 
showing clinical signs (Fig 3-2A; p < 0.0001, Mantel-Cox log rank test). Mock-infected 
mice did not develop signs of encephalomyelitis through 7 DPI. DON treatment did have 
a significant effect on body weight at 4, 5, 6, and 7 DPI among groups (Fig 3-2B; p < 
0.0001, one-way ANOVA). While untreated, SINV-infected mice lost approximately 10-
15% of their body weight by 7 DPI, SINV-infected mice receiving the low (0.3mg/kg) 
dose of DON lost significantly less weight (p < 0.01, Bonferroni’s multiple comparisons 
test). Significantly more weight loss was seen in the SINV-infected, low (0.3mg/kg) dose 
DON-treated group compared to mock-infected, untreated and mock-infected, low 
(0.3mg/kg) dose DON-treated groups (p < 0.0001 and p < 0.01, respectively, 
Bonferroni’s multiple comparisons test). Regardless of infection status, mice receiving 
high (0.6mg/kg) dose DON treatment lost the most body weight of any of the groups by 7 
DPI. 
 Because DON has previously been reported to cause GI toxicity in human clinical 
trials188,195-198, the intestines of the mice were examined for gross pathology and 
histopathology. Compared to mock-infected, untreated intestines, intestines from mock-
infected mice receiving the high (0.6mg/kg) DON dose were grossly dilated. 
Histologically, large intestines of mice treated with the high (0.6mg/kg) dose of DON 
showed loss of architecture with dilation of glands and disruption of the epithelial layer 
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(Fig 3-2C). When examining body weights at 28 DPI of SINV-infected mice that had 
been treated with either low (0.3mg/kg) or high (0.6mg/kg) doses of DON through the 
first 7 DPI, mice regained the body weight they had initially lost (Fig 3-2D). These data 
show that DON treatment does partially prevent development of clinical disease in SINV-
infected mice, though at high doses, drug administration causes GI toxicity, resulting in 
increased loss of body weight. 
 
Glutamine antagonism partially prevents development of hippocampus dependent 
memory defects 
 To evaluate whether DON treatment prevents or mitigates development of 
neurological sequelae during SINV infection, open field and fear conditioning tests were 
performed at 5 DPI, the period when the most marked deficits were previously noted. In 
the open field test, there was a significant difference in the number of beam breaks 
recorded among groups (Fig 3-3A; p < 0.0001, one-way ANOVA), with untreated SINV-
infected mice crossing more beams than all other groups (p < 0.01, Fisher’s PLSD). Mice 
in the untreated, mock-infected and SINV-infected, low (0.3mg/kg) and high (0.6mg/kg) 
DON-treated groups did not significantly differ in the number of beam breaks recorded, 
though mock-infected, high (0.6mg/kg) dose DON-treated mice had significantly fewer 
recorded beam breaks than all other groups (p < 0.01, Fisher’s PLSD). These results 
indicate that DON treatment can help prevent SINV-induced hyperlocomotion at 5 DPI, 
but long-term treatment may affect motor ability. 
 Anxiety was also assessed by the open field test at 5 DPI (Fig 3-3B). The ratio of 
time spent in the center of the open field compared to the periphery significantly differed 
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among groups (p < 0.001, one-way ANOVA), with untreated, SINV-infected mice 
showing a significantly increased ratio compared to all other groups (p < 0.05, Fisher’s 
PLSD). The central:periphery ratio did not significantly differ among the other groups, 
indicating that DON protects mice from developing the disinhibitory behavior seen in 
during SINV infection in untreated mice at 5 DPI. 
 To evaluate hippocampus-dependent memory at 5 DPI, contextual (Fig 3-3C) and 
cued (Fig 3-3D) fear conditioning tests were performed on mice treated with DON. The 
percent time spent freezing significantly differed among the groups in both contextual 
and cued tests (p < 0.0001, one-way ANOVA). During contextual fear conditioning, 
SINV-infected mice treated with the high (0.6mg/kg) dose, but not the low (0.3mg/kg) 
dose, of DON showed a significant increase in the percent time spent freezing compared 
to the untreated, SINV-infected mice (p < 0.01, Fisher’s PLSD). DON treatment did not 
affect cued fear conditioning performance among SINV-infected groups, though the 
effect seen previously between SINV-infected and mock-infected groups remained (p < 
0.0001, Fisher’s PLSD). Treatment of mice with the high (0.6mg/kg) dose of DON did 
not affect performance for either contextual or cued fear conditioning in mock-infected 
mice. These results show that high (0.6mg/kg) dose DON treatment prevents 
development of hippocampus-dependent memory deficits as measured by contextual, but 
not cued, fear conditioning in SINV-infected mice at 5 DPI. 
 
Glutamine antagonism prevents lymphocyte proliferation in the CLNs and 
infiltration into CNS during SINV infection 
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 After determining that DON treatment partially prevents the development of 
clinical neurological disease in SINV-infected mice, the mechanisms behind these effects 
were examined. Production of T cells and B cells was evaluated in the CLNs 
(representing the periphery), brains, and spinal cords of SINV-infected mice during DON 
administration (5 and 7 DPI) and after cessation of treatment (9 and 11 DPI). Trypan blue 
exclusion was used to count the total mononuclear cells (Fig 3-4A) in each tissue, and 
absolute counts of CD3+ T cells (Fig 3-4B), CD4+ T cells (Fig 3-4C), CD8+ T cells (Fig 
3-4D), and CD19+ B cells (Fig 3-4E) were measured by flow cytometry.  
In the CLNs, all cell types increased in untreated, SINV-infected mice, with total 
mononuclear cells and CD3+, CD4+, and CD8+ T cells peaking at 7 DPI, and CD19+ B 
cells peaking in number at 9 DPI. In the CLNs of mock-infected and SINV-infected, 
DON-treated mice, cell numbers did not increase during the period of DON treatment (5 
and 7 DPI). Following cessation of treatment at 9 and 11 DPI, cell counts began to 
increase in SINV-infected mice that had been previously administered DON at the low 
(0.3mg/kg) dose. In the brains and spinal cords of untreated, SINV-infected mice, total 
mononuclear cell counts markedly increased starting at 7 DPI and peaked at 9 DPI. In 
both tissues, individual CD3+, CD4+, CD8+, and CD19+ cell populations steadily 
increased in number, peaking at 11 DPI. During the period of DON treatment at 5 and 7 
DPI, infiltration of any cell population into the brain or spinal cord were not seen in 
SINV-infected mice receiving either the low (0.3mg/kg) or high (0.6mg/kg) dose of 
DON. However, at 9 DPI, total mononuclear cells and CD19+ B cells, and at 11 DPI, 
CD3+, CD4+, and CD8+ T cells began increasingly infiltrating the brains of SINV-
infected mice previously treated with the low (0.3mg/kg) DON dose. Similar increases in 
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infiltrating cells into the spinal cords of DON-treated mice were not seen following 
cessation of treatment. 
Infiltration of CD3+ T cells into the brains of DON-treated, SINV-infected mice 
was also evaluated by immunohistochemistry at 7 DPI. Positive-staining cells were 
readily detectable in untreated, SINV-infected mice, but less so in mock-infected mice or 
SINV-infected mice treated with either low (0.3mg/kg) or high (0.6mg/kg) DON (Fig 3-
5A). Total counts of CD3+ cells in the hippocampi significantly differed among groups 
(p < 0.05, Kruskal-Wallis test), with more CD3+ cells found in untreated, SINV-infected 
mice (Fig 3-5B). Taken together, these findings indicate that DON treatment inhibits 
proliferation of T and B cells in the periphery in response to SINV infection, resulting in 
impaired infiltration of immune cells into the CNS. This effect is only transient though, 
because cessation of DON treatment resulted in gradual activation of the immune 
response. 
  
Glutamine antagonism decreases CNS inflammation and pathology during SINV 
infection 
 To examine the effect of glutamine antagonism on CNS pathology during SINV 
infection, coronal brain sections and transverse lumbar spinal cord sections of SINV-
infected mice treated with low (0.3mg/kg) dose or high (0.6mg/kg) dose DON were 
stained with H&E and evaluated for pathological changes. In the hippocampi (Fig 3-6A) 
and spinal cords (Fig 3-6B) of untreated, SINV-infected mice, perivascular cuffing and 
increased parenchymal cellularity were appreciable by 7 DPI. At 7 and 9 DPI, there was 
loss of neuronal architecture in the dentate gyrus of the hippocampus (Fig 3-6A), and at 9 
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DPI, tissue necrosis was noted in the lateral gray horn of the spinal cord (Fig 3-6B). 
Increased inflammation and pathological changes were no longer noted at 11 DPI. 
Compared to mock-infected controls (data not shown), increased inflammation and 
pathological changes were not noted in brains or spinal cords of SINV-infected mice 
receiving low (0.3mg/kg) dose or high (0.6mg/kg) dose DON during the period of drug 
administration. Following cessation of treatment at 9 and 11 DPI, perivascular cuffing 
became apparent in the hippocampi and spinal cords of SINV-infected mice previously 
treated with low (0.3mg/kg) dose and high (0.6mg/kg) dose DON. Disruption of normal 
architecture in the granule layer of the dentate gyrus was noted in SINV-infected mice 
previously treated with low (0.3mg/kg) dose DON at 11 DPI. 
 To further evaluate the level of inflammation in the brains and spinal cords of 
SINV-infected mice treated with DON, H&E-stained slides were blindly scored. Brain 
inflammation scores significantly differed among groups (Fig 3-6A; p < 0.001, two-way 
ANOVA), with untreated, SINV-infected mice having significantly higher scores than 
SINV-infected, low (0.3mg/kg) dose DON-treated mice at 5 and 7 DPI (p < 0.001, 
Tukey’s multiple comparisons test), and SINV-infected, high (0.6mg/kg) dose DON-
treated mice at 7 and 9 DPI (p < 0.001, Tukey’s multiple comparisons test). 
Inflammation scores began to decrease at 11 DPI in untreated mice. Starting at 9 DPI, 
following cessation of DON treatment, brain inflammation scores in SINV-infected, low 
(0.3mg/kg) dose DON-treated mice began to increase, becoming significantly higher than 
those of SINV-infected, high (0.6mg/kg) dose DON-treated mice at 9 DPI (p < 0.001, 
Tukey’s multiple comparisons test) and significantly higher than those of untreated, 
SINV-infected mice at 11 DPI (p < 0.05, Tukey’s multiple comparisons test). 
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Inflammation scores in SINV-infected, high (0.6mg/kg) dose DON-treated mouse brains 
began to increase at 11 DPI. 
 Lumbar spinal cords scored for inflammation showed similar trends to brains (Fig 
3-6D). Inflammation scores differed significantly among groups (p < 0.001, two-way 
ANOVA), with scores in untreated, SINV-infected mice significantly higher than those 
of SINV-infected, low (0.3mg/kg) dose DON-treated mice at 7 DPI (p < 0.0001, Tukey’s 
multiple comparisons test) and significantly higher than those of SINV-infected, high 
(0.6mg/kg) dose DON-treated mice at 7 and 9 DPI (p < 0.0001, Tukey’s multiple 
comparisons test). Following cessation of treatment, inflammation scores began to 
increase in SINV-infected, low (0.3m/kg) dose DON-treated and SINV-infected, high 
(0.6mg/kg) dose DON-treated mice at 9 and 11 DPI, respectively. By 11 DPI, spinal cord 
inflammation scores were comparable among treatment groups. These data show that 
glutamine antagonism transiently suppresses inflammation and CNS pathological 
changes during SINV infection, but cessation of treatment results in dose-dependent 
appearance of inflammation. 
 
DON treatment decreases apoptosis in the CNS during SINV infection 
 Death of cells, particularly neurons, during viral infection results in significant 
organ dysfunction. To evaluate whether DON treatment affects cell death in the brain and 
spinal cord during SINV infection, coronal brain sections and transverse lumbar spinal 
cord sections in SINV-infected mice treated with low (0.3mg/kg) dose or high (0.6mg/kg) 
dose DON were examined by TUNEL assay. Increased numbers of TUNEL-positive cells 
were present at 7 and 9 DPI in the hippocampi of untreated, SINV-infected mice (Fig 3-
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7A). During the period of DON treatment, TUNEL-positive cells were only rarely 
detectable in hippocampi of SINV-infected, low (0.3mg/kg) dose or high (0.6mg/kg) dose 
DON-treated mice, but positive cells increased in frequency at 9 DPI. At 11 DPI, 
TUNEL-positive cells were only rarely found in the hippocampi of all groups. TUNEL-
positive cells were present throughout the spinal cord sections of untreated, SINV-
infected mice at 7 and 9 DPI, but less so at 5 and 11 DPI (Fig 3-7B). In comparison, 
TUNEL-positive cells were only rarely seen in spinal cords of SINV-infected, low 
(0.3mg/kg) dose or high (0.6mg/kg) dose DON-treated mice at any of the time points. 
Quantification of positive cells revealed untreated, SINV-infected mice had more 
apoptotic cells than SINV-infected, low (0.3mg/kg) dose or high (0.6mg/kg) dose DON-
treated mice in the hippocampus at 7 DPI (Fig 3-7C; p < 0.01, Tukey’s multiple 
comparisons test) and in the spinal cord at 7 and 9 DPI (Fig 3-7D; p < 0.01 for 7 DPI and 
p < 0.001 for 9 DPI, Tukey’s multiple comparisons test). Cell death was comparable 
among groups at 5 and 11 DPI in both tissues. Further examination of TUNEL-positive 
neurons in the granule cell layer of the dentate gyrus and pyramidal cell layers of the CA 
regions in the hippocampus at 7 DPI revealed a significant difference among infection 
and treatment groups in number of apoptotic cells morphologically consistent with 
neurons (Fig 3-7E; p < 0.05, Kruskal-Wallis test), with more dead neurons found in the 
hippocampi of untreated, SINV-infected mice. 
 
Glutamine antagonism suppresses antiviral effects of the immune response during 
SINV infection 
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 Because glutamine antagonism suppresses lymphocyte proliferation187,189,190, the 
antiviral effector function of these cells was evaluated during and following DON 
treatment during SINV infection. Previous studies have shown that clearance of 
infectious SINV from the CNS is facilitated synergistically by antibody directed against 
the SINV E2 glycoprotein and by IFN-γ, produced predominantly by B cells and T cells, 
respectively24,92. SINV-specific IgM and IgG were evaluated in the sera and brains of 
SINV-infected, DON-treated mice at 5, 7, 9 and 11 DPI by ELISA (Figs 3-8A-D). Serum 
IgM (Fig 3-8A) and IgG (Fig 3-8B) ODs significantly differed among treatment groups 
(p < 0.01 for IgM, p < 0.0001 for IgG, two-way ANOVA) and were both significantly 
higher in untreated mice compared to both low (0.3mg/kg) dose and high (0.6mg/kg) 
dose DON-treated mice at all timepoints for IgM (p < 0.05, Tukey’s multiple 
comparisons test) and at 7, 9, and 11 DPI for IgG (p < 0.05, Tukey’s multiple 
comparisons test). Increases in anti-SINV IgM and IgG were present in the sera of low 
(0.3mg/kg) dose and high (0.6mg/kg) dose DON-treated mice following cessation of 
treatment at 11 DPI.  
Brain SINV-specific IgM (Fig 3-8C) and IgG (Fig 3-8D) ODs significantly 
differed among treatment groups (p < 0.0001 for both IgM and IgG, two-way ANOVA) 
but increases were delayed compared to the sera of corresponding mice. Brain anti-SINV 
ODs were significantly higher in untreated mice compared to both low (0.3mg/kg) dose 
and high (0.6mg/kg) dose DON-treated mice at 11 DPI for IgM (p < 0.0001, Tukey’s 
multiple comparisons test) and at 9 and 11 DPI for IgG (p < 0.0001, Tukey’s multiple 
comparisons test). Increases in anti-SINV IgM and IgG were present in the brains of low 
(0.3mg/kg) dose DON-treated, but not high (0.6mg/kg) dose DON-treated mice following 
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cessation of treatment at 11 DPI. These results show that glutamine antagonism decreases 
anti-SINV antibody production in the serum and brain during SINV infection, and that 
cessation of treatment allows increases in production. Additionally, development of anti-
SINV IgM and IgG production is later in the brain than the serum. 
 IFN-γ represents the other main facilitator of virus clearance92, and the effect of 
glutamine antagonism on its production in the brain during SINV infection was examined 
by measuring mRNA expression by qRT-PCR and protein levels by ELISA at 5, 7, 9, and 
11 DPI. Overall IFN-γ mRNA expression, when normalized to that of untreated, mock-
infected mouse brains, significantly differed among groups (Fig 3-8E; p < 0.001, two-
way ANOVA), with untreated, SINV-infected mice having significantly increased 
expression at 7 DPI compared to low (0.3mg/kg) dose and high (0.6mg/kg) dose DON-
treated mice (p < 0.0001, Tukey’s multiple comparisons test). Ifng expression in brains 
of SINV-infected, low (0.3mg/kg) dose and high (0.6mg/kg) dose DON-treated mice was 
approximately 100- to 1,000-fold higher than untreated-mock-infected mice. Following 
cessation of DON treatment, Ifng expression increased in mice starting at 9 DPI, with 
SINV-infected, low (0.3mg/kg) dose DON-treated mice having significantly increased 
expression compared to untreated, SINV-infected mice at 11 DPI (p < 0.05, Tukey’s 
multiple comparisons test). Ifng expression in mock-infected, high (0.6mg/kg) dose 
DON-treated mouse brains was comparable to that of untreated, mock-infected mouse 
brains (data not shown).  
IFN-γ protein levels in the brain significantly differed among groups (Fig 3-8F; p 
< 0.0001, two-way ANOVA), with untreated, SINV-infected mice having significantly 
increased expression at 7 DPI compared to low (0.3mg/kg) dose and high (0.6mg/kg) 
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dose DON-treated mice (p < 0.0001, Tukey’s multiple comparisons test). Following 
cessation of DON treatment, IFN-γ expression increased in mice previously treated 
starting at 9 DPI, with both SINV-infected, low (0.3mg/kg) dose and high (0.6mg/kg) 
dose DON-treated mice having significantly increased expression compared to untreated, 
SINV-infected mice at 11 DPI (p < 0.01, Tukey’s multiple comparisons test). IFN-γ was 
not detected in the brains of mock-infected mice at any time point, regardless of 
treatment status (data not shown), nor was it detectable in brains of SINV-infected, low 
(0.3mg/kg) dose and high (0.6mg/kg) dose DON-treated mice during the period of drug 
administration at 5 and 7 DPI. These data show that glutamine antagonism impairs the 
two major adaptive antiviral responses involved in clearance of SINV. 
 
DON treatment delays virus clearance in the brain and spinal cord  
 Because the two major avenues by which the immune response clears SINV from 
the CNS are affected by glutamine antagonism, virus production was examined over time 
in mice treated with DON. SINV protein production was visualized in coronal brain and 
lumbar spinal cord sections by immunohistochemistry. Positive staining for SINV 
antigen in the hippocampus (Fig 3-9A) and spinal cord (Fig 3-9B) of untreated mice was 
readily observed at 5, 7, and 9 DPI and 7 and 9 DPI, respectively. Comparable levels of 
positive SINV antigen staining were found in mice treated with low (0.3mg/kg) dose or 
high (0.6mg/kg) dose DON in both tissues at the above times. Additionally, SINV 
antigen was readily visualized in the brains and spinal cords of DON-treated, but not 
untreated, mice at 11 DPI. Following cessation of DON administration, levels of SINV 
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protein did begin to decrease in DON-treated mice at 9 and 11 DPI, indicating progress 
towards virus clearance. 
 Clearance of infectious virus was evaluated by measuring virus titers by plaque 
assay at 5, 7, 9, and 11 DPI. Infectious virus clearance was delayed in DON-treated mice 
in a dose-dependent manner, with titers significantly lower in untreated mice at 9 and 11 
DPI in the brain (Fig 3-9C; p < 0.05 at 9 DPI and p < 0.01 for untreated vs low 
[0.3mg/kg] dose DON, p < 0.001 at 9 DPI and p < 0.0001 at 11 DPI for untreated vs high 
[0.6mg/kg] dose DON, p < 0.0001 at 11 DPI for low [0.3mg/kg] dose DON vs high 
[0.6mg/kg] dose DON, all Tukey’s multiple comparisons test) and at 7, 9, and 11 DPI in 
the spinal cord (Fig 3-9D; p < 0.05 at 7 and 9 DPI for untreated vs low [0.3mg/kg] dose 
DON, p < 0.05 at 7 DPI and p < 0.01 at 9 and 11 DPI for untreated vs high [0.6mg/kg] 
dose DON, all Tukey’s multiple comparisons test). 
 Initiation of viral RNA clearance was evaluated by measuring viral RNA levels 
by qRT-PCR at 5, 7, 9, and 11 DPI. Viral RNA clearance was delayed in DON-treated 
mice, with RNA copies significantly lower in untreated mice at 7, 9, and 11 DPI in the 
brain (Fig 3-9E; p < 0.05 at 7 DPI, p < 0.01 9 DPI, and p < 0.0001 at 11 DPI for 
untreated vs low [0.3mg/kg] dose DON, p < 0.01 at 7 DPI, p < 0.001 9 DPI, and p < 
0.0001 at 11 DPI for untreated vs high [0.6mg/kg] dose DON, all Tukey’s multiple 
comparisons test) and at 9 and 11 DPI in the spinal cord (Fig 3-9F; p < 0.05 at 9 DPI and 
p < 0.01 at 11 DPI for untreated vs low [0.3mg/kg] dose DON, p < 0.05 at 9 DPI and p < 
0.001 at 11 DPI for untreated vs high [0.6mg/kg] dose DON, all Tukey’s multiple 
comparisons test). Viral RNA levels did decrease in brains of DON-treated mice 
following cessation of drug administration, though not to the same dose-dependent effect 
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as was seen with infectious virus. These findings show that in addition to suppressing the 





(adapted from Potter and Baxter, et al, 2015) 
 
Glutamatergic drugs such as AMPA and NMDA receptor antagonists have been 
previously shown to enhance survival of hippocampal neurons and increase lifespan in 
NSV-infected mice by prevention of immune-mediated damage and inhibition of 
excitotoxicity49,65. In the current study, we tested the effects of a glutamine antagonist, 
DON, for its potential to mitigate the consequences of nonfatal SINV infection seen at 
the peak of infection. DON blocks the conversion of glutamine to glutamate, thus 
decreasing the potential for glutamate excitotoxicity in the brain, but also suppresses 
proliferation of lymphocytes, which require glutamine to support rapid cell division 
induced by antigen stimulation187,189,190. DON was examined as a potential 
chemotherapeutic agent in the 1970s and 1980s, but it was not well tolerated in clinical 
trials due primarily to GI toxicity188,195-198. In our study, mice in the high (0.6 mg/kg) 
dose DON treatment group developed severe intestinal pathologic changes, likely 
explaining the marked weight loss seen regardless of infection status. These signs may 
also help explain why we observed a reduced motor ability in DON-treated mice. We do 
not believe that this influenced the cognitive tests since there was no difference in 
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freezing levels between mock-infected mice with or without DON during fear 
conditioning testing. Previous studies using DON199,200 have also reported that issues with 
drug toxicity and dosing regimens were modified to counteract these negative side 
effects. In its present form, DON does not represent a viable treatment for alphavirus 
encephalomyelitis. However, by serving as a prototype, different glutamine antagonists 
or different formulations or derivatives of DON can be further evaluated as potential 
therapeutic options. 
The glutamine antagonist DON partially prevented development of the deficit in 
contextual, but not cued, fear conditioning. This result suggests that cued and contextual 
conditioning are differentially susceptible to the effects of DON, which may be related to 
differences between anatomical structures and circuitry that support both types of 
learning. While the amygdala is essential for both cued and contextual fear conditioning, 
the hippocampus is not essential for cued fear conditioning but does contribute to 
contextual fear conditioning161,201-204. Indeed, this disconnect between effects on cued and 
contextual conditioning has been shown with other glutamate antagonists such as MK-
801 205,206. 
Long-term persistence of a viral RNA reservoir in neurons presents the possibility 
of viral reactivation, relapse of disease, and progressive pathological changes43. Both 
infectious virus and SINV RNA typically peak in the brains of infected mice at 3–5 DPI, 
and while infectious virus quickly decreases to undetectable levels by 8–10 DPI, RNA 
levels slowly decline but remain measureable for at least a year42. DON had significantly 
higher titers and viral RNA levels than untreated mice, due to a delay in virus clearance 
likely associated with a decrease in immune cell infiltration into the CNS.  
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Previous studies using the more neurovirulent NSV strain of SINV have shown 
that the immune response to infection plays a significant role in the neuronal damage and 
death seen during fatal alphavirus encephalomyelitis54, as well as in virus clearance. 
While neuronal cell death is independent of DNA fragmentation in motor neurons of the 
spinal cord during NSV infection, neuronal damage in the hippocampus appears to follow 
the classical apoptotic pathway and can be detected through TUNEL staining48. In the 
present study, treatment with DON resulted in decreased inflammatory cell infiltration, 
including CD3+ T cells, and lower levels of cell death in the brain, despite increased 
levels of infectious virus and comparable levels of viral antigen and RNA. Moreover, 
fewer DON-treated mice developed neurological signs by 7 DPI compared to untreated 
SINV-infected mice. The numbers of apoptotic neurons in the granule cell layer of the 
dentate gyrus and pyramidal cell layers of the CA regions differed between infection and 
treatment groups, with the highest number of positive cells seen in the untreated SINV-
infected group. This loss of neurons across the hippocampal subfields, areas key to intact 
cognitive abilities, helps to explain the significantly impaired performance this group 
displayed in behavior tests. 
Despite obtaining high serum levels, DON did not penetrate the brain well, 
suggesting that the drug’s effect on alphavirus pathological changes primarily occurs 
through peripheral suppression of the antiviral immune response. DON treatment resulted 
in both decreased proliferation of T and B cells in the CLNs and fewer infiltrating T and 
B cells into the brain and spinal cord during the period of drug administration. Decreased 
inflammatory cell infiltration into the CNS reduces neuronal damage and thus explains 
the lack of clinical signs and weight loss in the low (0.3 mg/kg) dose DON group. 
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Following cessation of treatment, increased proliferation of lymphocytes in CLNs was 
seen at 9 DPI, while increased infiltration of cells into the brain was not observed until 11 
DPI (and still not observed in the spinal cord), further supporting this hypothesis. 
Previous studies have shown that alphavirus clearance from the CNS is primarily 
facilitated by antibody against the SINV E2 glycoprotein24 and IFN-γ produced by NK 
cells and T cells92. In contrast to untreated, SINV-infected mice, SINV-specific antibody 
levels in sera and brains and Ifng expression and IFN-γ production in brains were 
considerably lower or undetectable in DON-treated mice during the period of drug 
administration. Following cessation of treatment, levels of antibody and IFN-γ increased, 
corresponding to increased proliferation and infiltration of immune cells into the CNS. 
While infectious virus titers and viral RNA levels were comparable among treatment 
groups during the period of DON administration, they remained significantly elevated in 
the brains and spinal cords of DON-treated mice compared to untreated mice at 9 and 11 
DPI. However, they did decrease in titer and copy number during this period, indicating 
successful initiation of clearance. Therefore, while compromised immune cell 
proliferation in the periphery and infiltration into the brain and spinal cord results in 
decreased CNS pathological changes, it also results in impaired virus clearance from 
neurons. Once the immune response is no longer inhibited, virus clearance resumes. This 
supports the importance of the immune response in the pathogenesis of the less virulent 
SINV TE strain, as well as NSV, and suggests that immunosuppression in the periphery 
plays an important role in the mitigation of nonfatal alphavirus encephalomyelitis by 
glutamine antagonism. 
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The continued emergence of viral encephalomyelitis outbreaks around the world 
emphasizes the need to identify novel approaches to improve outcome using an animal 
model. These findings may also be applicable to treatment of other virus infections of the 
nervous system that share similar cognitive and pathological features including immune 
activation, inflammation, and excitotoxicity207-209. Additionally, the immunosuppressive 
nature of DON makes it a useful tool to further elucidate the mechanisms and 



















Figure 3-1. DON levels in tissues of SINV-infected and mock-infected mice. (A, B) 
Levels of DON were measured by HPLC in sera (A) and brains (B) of mock-infected 
(PBS) and SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or 
high (0.6mg/kg)  dose DON (n = 3 mice per group; data presented as mean ± SEM; 
ND=not detectable). These experiments were performed in colaboration with Jesse Alt 
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Figure 3-2. Clinical disease in DON-treated, SINV-infected mice. (A) Mock-infected 
(PBS) and SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or 
high (0.6mg/kg) dose DON were observed daily for the development of clinical signs (n 
= 9–32 mice over three separate independent experiments; ****p < 0.0001 by log-rank 
[Mantel-Cox] test). (B) Body weights were recorded daily in mock-infected (PBS) and 
SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or high 
(0.6mg/kg) dose DON (n = 9–32 mice over three separate independent experiments; 
****p < 0.0001, one-way ANOVA with p < 0.01 by Bonferroni’s multiple comparison 
tests). (C) Representative photomicrographs were taken of H&E-stained large intestine 
from untreated, mock-infected (left panel) and high (0.6mg/kg) dose DON-treated (right 
panel) mice (100X magnification; scale bar = 500µm). (D) Body weight was recorded in 
SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or high 
(0.6mg/kg) dose DON following recovery from clinical disease at 28 DPI (n = 3-4 mice 
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per group; data presented as mean ± SEM). Figures were adapted from Potter and Baxter, 












Figure 3-3. Efect of DON on locomotor activity, anxiety, and hippocampal 
dependent memory. (A, B) The open field test was used to assess locomotor activity (A) 
and anxiety (B) in mock-infected (PBS) and SINV-infected mice receiving no treatment, 
low (0.3mg/kg) dose DON, or high (0.6mg/kg)  dose DON at 5 DPI by measuring the 
number of beam breaks made by mice in 30 minutes and the ratio of time mice spent in 
the center versus the periphery, respectively. (C, D)  Hippocampus-dependent  memory 
was assessed by contextual (C) and cued (D) fear conditioning in mock-infected (PBS) 
and SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or high
(0.6mg/kg)  dose DON at 5 DPI (n = 11-27 mice per group; data presented as mean ± 
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These experiments were performed in collaboration with Michelle C. Potter, PhD. 























Figure 3-4. Efect of DON treatment on immune cel proliferation in the CLNs and 
infiltration into the CNS during SINV infection. (A) Total live mononuclear cels in 
the  CLNs (left panel), brains (middle panel), and spinal cords (right panel) of mock-
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infected and SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or 
high (0.6mg/kg) dose DON at 5, 7, 9, and 11 DPI by trypan blue exclusion. (B-E) 
Absolute numbers of CD3+ T cells (B), CD4+ T cells (C), CD8+ T cells (D), and B cells 
(E) in the CLNs (left panel), brains (middle panel), and spinal cords (right panel) by of 
mock-infected and SINV-infected mice receiving no treatment, low (0.3mg/kg) dose 
DON, or high (0.6mg/kg) dose DON at 5, 7, 9, and 11 DPI by flow cytometry (n = 2-3 
pooled mice per group per time point; data presented as the mean ± SEM; double-headed 
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Figure 3-5. Effect of DON treatment on CD3+ T cell infiltration into the brain 
during SINV infection at 7 DPI. (A) Representative photomicrograph CD3+ staining of 
the hippocampus were taken of brains from mock-infected or SINV-infected mice 
receiving no treatment, low (0.3mg/kg) dose DON, or high (0.6mg/kg) dose DON at 7 
DPI (CD3+ cells= brown staining; 200X magnification; scale bar=100 µm). (B) CD3+ 
cells were counted in the hippocampus of mock-infected or SINV-infected mice 
receiving no treatment, low (0.3mg/kg) dose DON, or high (0.6mg/kg) dose DON at 7 
DPI (n = 3 mice per group per time point; data presented as the mean ± SEM; p < 0.05 by 
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Figure 3-6. Effect of DON treatment on CNS inflammation and pathology during 
SINV infection. (A, B) Representative photomicrographs were taken of H&E sections of 
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the (A) brain and (B) spinal cord of SINV-infected mice receiving no treatment (top 
row), low (0.3mg/kg) dose DON (middle row), or high (0.6mg/kg) dose DON (bottom 
row) at 5, 7, 9 and 11 DPI. White arrowheads denote perivascular cuffing, and black 
arrowheads denote disruption of the granule cell layer of the hippocampus or loss of 
proper tissue architecture in the spinal cord (100X magnification; scale bar=100 µm). (C, 
D) H&E sections of brains (C) and spinal cords (D) of SINV-infected mice receiving no 
treatment, low (0.3mg/kg) dose DON, or high (0.6mg/kg) dose DON were scored for 
inflammation at 5, 7, 9 and 11 DPI using a four-point (brain) or three-point (spinal cord) 
system (n = 3-4 mice per group per time point; data presented as the mean ± SEM; 
double-headed arrows indicate the period of DON treatment; *p < 0.05, **p < 0.01, ***p 
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Figure 3-7. Effect of DON-treatment on cell death in the CNS during SINV 
infection. (A, B) Representative photomicrographs were taken of TUNEL staining in the 
	   82	  
dentate gyrus in the hippocampus (A) and spinal cord (B) of SINV-infected mice 
receiving no treatment (top row), low (0.3mg/kg) dose DON (middle row), or high 
(0.6mg/kg) dose DON (bottom row) at 5, 7, 9 and 11 DPI (brown nuclear 
staining=TUNEL-positive [denoted by black arrowheads]; 200X magnification; scale 
bar=100 µm). (C, D) Quantification of TUNEL-positive cells in brains (C) and spinal 
cords (D) of SINV-infected mice receiving no treatment, low (0.3mg/kg) dose DON, or 
high (0.6mg/kg) dose DON at 5, 7, 9 and 11 DPI (n = 3-4 mice per group per time point; 
double-headed arrows indicate the period of DON treatment; **p < 0.01, ***p < 0.001, 
by Tukey’s multiple comparisons test). (E) Quantification of apoptotic/necrotic neuronal 
cell bodies in the granule layer of the dentate gyrus and pyramidal layer of the CA 
regions at 7 DPI (n = 3 mice per group; data presented as the mean ± SEM; p < 0.05 by 













Figure 3-8. Efect of DON treatment on SINV-specific antibody and IFN-γ 
production. (A-D) SINV-specific IgM (A, C) and IgG (B, D) levels were measured by 
ELISA in the serum (A, B) and brain (C, D) of  SINV-infected mice receiving no 
treatment, low (0.3mg/kg) dose DON, or high (0.6mg/kg)  dose DON at 5, 7, 9 and 11 
DPI. (E, F) Ifng mRNA expression (E) was measured by qPCR and IFN-γ protein levels 
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low (0.3mg/kg) dose DON, or high (0.6mg/kg) dose DON at 5, 7, 9 and 11 DPI (n = 3-4 
mice per group per time point; data presented as the mean ± SEM; double-headed arrows 
indicate the period of DON treatment; dotted line indicates assay level of detection; *p < 
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Figure 3-9. Effect of DON treatment on SINV production. (A, B) Representative 
photomicrographs of immunohistochemical staining for SINV antigen in SINV-infected 
mice receiving no treatment (top row), low (0.3mg/kg) dose DON (middle row), or high 
(0.6mg/kg) dose DON (bottom row) in the brain (A) and spinal cord (B) at 5, 7, 9, and 11 
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DPI (SINV antigen = brown staining; brain 40X magnification, scale bar=500µm; spinal 
cord 100X magnification, scale bar=100µm). (C, D) Infectious virus titers were measured 
by plaque assay in the brains (C) and spinal cords (D) of SINV-infected mice receiving 
no treatment (black circle and line), low (0.3mg/kg) dose DON (gray square and line), 
and high (0.6mg/kg) dose DON (white diamond and black line). (E, F) Viral RNA levels 
were measured by qRT-PCR in the brains (E) and spinal cords (F) of SINV-infected mice 
receiving no treatment (black circle and line), low (0.3mg/kg) dose DON (gray square 
and line), and high (0.6mg/kg) dose DON (white diamond and black line) (n = 3-6 mice 
per group per time point; data presented as the mean ± SEM; double-headed arrows 
indicate the period of DON treatment; dotted line indicates assay level of detection; *p < 
0.05, **p < 0.01, ****p < 0.0001, untreated vs low [0.3 mg/kg] dose DON; #p < 0.05, 
##p < 0.01, ###p < 0.001, ####p < 0.0001, untreated vs high [0.6 mg/kg] dose DON; ††††p 
< 0.0001, low [0.3mg/kg] dose DON vs high [0.6mg/kg] dose DON, all by Tukey’s 
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INTRODUCTION 
 
Mosquito-borne viruses that produce encephalomyelitis are becoming an 
increasing worldwide concern as arthropod vectors expand into new territories147-150,210. 
The New World alphaviruses, which include eastern, western, and Venezuelan equine 
encephalitis viruses, produce encephalomyelitis with varying fatality rates in dead-end 
hosts such as humans and horses8,13. However, humans who survive the initial disease 
syndrome, particularly those infected as infants or children, have a high probability of 
being left with debilitating life-long physical and mental disabilities14-18. Currently there 
are no treatments beyond supportive care for alphavirus encephalomyelitis20.  
  Sindbis virus (SINV) is the prototypic member of the alphaviruses, and infection 
of susceptible mice with well characterized strains provides a valuable model for 
studying the pathogenesis of and host immune response to alphavirus encephalomyelitis. 
When C57BL/6 mice are intracranially infected with the nonfatal TE strain, the course of 
infection proceeds in three phases 42. In Phase 1, which occurs through 7 to 8 days post 
infection (DPI), both infectious virus and viral RNA are readily detectable at high levels 
until infectious virus undergoes a precipitous drop in titers. In Phase 2, which occurs 
from approximately 10 to 60 DPI, infectious virus is no longer detectable, but viral RNA 
is still readily measureable at high but declining levels. Finally in Phase 3, which occurs 
from 60 DPI though at least a year following infection and presumably for the life of the 
animal, viral RNA reaches a low but detectable steady state in the CNS. Currently, the 
mechanisms that facilitate clearance of viral RNA are unknown. Understanding how the 
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immune response is able to clear both infectious virus and viral RNA while 
simultaneously controlling reactivation is critical to developing potential therapies. 
 As neurons are a valuable yet finite population with little regenerative capacity, 
clearance of virus by the immune system requires a noncytolytic mechanism to maintain 
functional neurological performance. While initial control of virus replication and 
production is dependent on type I interferon (IFN)69,70,79, the adaptive immune response 
is responsible for later virus clearance and control. Previous work using SCID mice, 
which are incapable of naturally clearing SINV, has shown that treatment with 
hyperimmune serum results in successful clearance of both infectious virus and viral 
RNA from all regions of the CNS, indicating antibody directed against SINV plays a 
central role in clearance24. However, virus clearance from the brain stem and spinal cord 
is possible in antibody knockout mice, but requires IFN gamma (IFN-γ) produced by 
CD4+ and CD8+ T cells92. Mice that lack both antibody and IFN-γ produce an infectious 
virus titer profile similar to SCID mice and are less successful at clearing infectious virus 
compared to single antibody- or IFN-γ-knockout mice70, indicating synergistic 
cooperation between the two in facilitating virus clearance. However, the mechanisms 
through which this occurs have not been elucidated. 
 IFN-γ, the sole type II IFNs, is primarily produced by activated T cells and natural 
killer (NK cells)95,96. Its antiviral activity is achieved through a Jak/STAT-dependent 
signaling pathway by binding IFN-γ to its heterotetrameric receptor, which is found on 
neurons 97,103,104. IFN-γ signaling results in STAT activation and binding to gamma-
associated sites (GAS) on over 200 genes, many with antiviral activity, including PKR 
and 2’-5’ oligoadenylate synthetases103,105. IFN-γ also has immunomodulatory effects, 
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such as MHC class I induction, cytokine and chemokine secretion, and leukocyte 
activation and differentiation106-108. 
 IFN-γ is known to help facilitate clearance of infectious virus during SINV 
infection. However, the mechanisms by which this occurs are not fully understood. 
Furthermore, the role IFN-γ plays in clearance of viral RNA has not yet been studied. We 
hypothesize that like infectious virus, IFN-γ facilitates clearance of viral RNA through 
induction of antiviral genes. By using both in vitro and in vivo systems, we sought to 
understand the antiviral and immunomodulatory role IFN-γ plays during SINV clearance 
in the CNS. 
 
 
MATERIALS & METHODS 
 
Cell Cultures 
AP-7 cells, a gift from Dale Hunter at Tufts University211, were derived from rat 
olfactory neurons and immortalized with a temperature-sensitive simian virus 40 (SV-40) 
T antigen. Cycling AP-7 (cAP-7) cells were grown at 33°C at 7% CO2 in DMEM + 10% 
FBS + 2mM L-glutamine + 100U/mL penicillin + 100µg/mL streptomycin and for 
differentiation were transferred to 39°C at 5% CO2 in DMEM + 10% FBS + 2mM L-
glutamine + 100U/mL penicillin + 100µg/mL streptomycin + 1µg/mL insulin + 20 µM 
dopamine + 100µM ascorbic acid (dAP-7 cells). Cells were allowed to differentiate for 
five to seven days prior to infection. 
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 CSM14.1 cells, a gift from Dale E. Bredesen of the Buck Institute of Age 
Research212,213, were derived from rat nigral-striatal neurons and immortalized with a 
temperature-sensitive SV-40 T antigen. Cycling CSM14.1 cells were grown at 31°C at 
5% CO2 in DMEM + 10% FBS + 2mM L-glutamine + 100U/mL penicillin + 100µg/mL 
streptomycin and were transferred to 39°C at 5% CO2 in DMEM + 1% FBS + 2mM L-
glutamine + 100U/mL penicillin + 100µg/mL streptomycin for differentiation 
(dCSM14.1 cells). Cells were allowed to differentiate for at least three weeks prior to 
infection. 
 
Virus and Infection of Cells 
 Titers of the TE strain of SINV37 were determined by plaque assay using BHK 
cells. cAP-7, dAP-7, and dCSM14.1 cells were plated in six well culture dishes, and after 
forming a monolayer, were infected with SINV TE for one hour in DMEM + 1% FBS at 
a multiplicity of infection of 1 (cAP-7 and dAP-7 cells) or 5 (cAP-7, dAP-7, and 
dCSM14.1 cells). dAP-7 cells were treated for one hour with 500U/mL recombinant rat 
IFN-γ (PBL Interferon Source) in DMEM + 1% FBS at two hours prior to infection (IFN-
γ Pre-Txt), two hours post infection (HPI, IFN-γ Txt 2 HPI), or 24 HPI (IFN-γ Txt 24 
HPI). dCSM14.1 cells were treated at 24 HPI with 100U/mL recombinant rat IFN-γ in 
DMEM + 1% FBS for one hour. Supernatant fluids for plaque assays and cell pellets for 
protein and RNA were collected in triplicate at various time points following infection 
and stored at -80°C. 
 
Sindbis Virus Infection of Mice 
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Four to six week-old wild-type C57BL/6 mice, mice deficient in IFN-γ receptor 1 
(Ifngr1-/-, strain B6.129S7-Ifngtm1Ts/J), and mice deficient in IFN-γ (Ifng-/-, strain 
B6.129S7-Ifngr1tm1Agt/J, Jackson Labs) were intracranially inoculated with 103 pfu of the 
nonfatal TE strain of SINV diluted in 20µL PBS or 20µL PBS vehicle while under light 
isoflurane anesthesia. At sacrifice, mice were euthanized by an overdose of isoflurane 
anesthesia, and serum, cervical lymph nodes (CLNs), brains, and/or spinal cords were 
collected. Equal numbers of male and female mice were used in experiments whenever 
possible. The Johns Hopkins University Institutional Animal Care and Use Committee 
approved all studies performed. 
 
Clinical Evaluation of Mice 
Mice were weighed daily and evaluated for signs of encephalitis, characterized by 
kyphosis, abnormal gait, and paresis. For feed intake studies, mice were housed in groups 
of two or three, and total feed weight was recorded daily. The amount of feed consumed 
per day per mouse was calculated and normalized to that of mock-infected control mice 
for each strain. Body temperature was measured rectally each day using a Physitemp 
Thermalert TH-5 with a RET-3 rectal probe. Investigators were blinded to the strain or 
infection status of mice during these experiments, and evaluations were conducted at the 
same time of each day.  
 
Quantification of Infectious Virus 
 Left-brain halves were placed in Lysing Matrix A tubes (MP Biomedicals), and 
20% weight/volume (w/v) concentrations were made using ice-cold PBS. Alternatively, 
	   93	  
whole spinal cords were placed in Lysing Matrix A tubes, and ice-cold PBS was added to 
make 10% w/v concentrations. Tissues were dissociated using a FastPrep-24 
homogenizer (MP Biomedicals) at 6.0 M/s for 40 seconds and clarified by centrifugation 
for 15 minutes at 13,2000 rpm at 4°C. Supernatant fluids were collected and stored at -
80°C for subsequent analyses. Infectious virus was quantified by plaque assay with 
homogenates or supernatant fluids from cell culture that were serially diluted 10-fold and 
incubated for one hour on BHK cells. An agar overlay was then applied, and cells were 
incubated at 37°C, 5% CO2 for 48 hours, after which plaques were counted using 10% 
neutral red in PBS to help with visualization.   
 
Immunoblot Analysis 
 Collected dAP-7 cells were incubated on ice for 30 minutes in RIPA buffer 
(50mM Tris, 150mM NaCl, 1% SDS, 1% NP-40, 0.5% Na-deoxycholate, 1mM EDTA) 
and centrifuged at 12,000 rpm for 15 minutes. Total protein was quantified by DC Protein 
assay (Bio-Rad) using a BSA standard curve, and ten µg was boiled in 6X SDS loading 
buffer (0.5M Tris [pH 6.8], 30% glycerol, 10% SDS, 0.12% bromophenol blue, 6% β -
mercaptoethanol) for five minutes. Samples were run on a 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) gel and transferred to a nitrocellulose membrane (Bio-Rad). 
Immunoblots were blocked in TBS-0.1% Tween-20 (TBST) + 5% milk for one hour at 
room temperature on a rocker and incubated overnight at 4°C on a rocker with primary 
antibody diluted in TBST + 5% BSA (1:2,000 rabbit polyclonal anti-nsp3; 1:10,000 
rabbit polyclonal NSV anti-sera; 1:10,000 mouse monoclonal anti-β-actin, 
Millipore)214,215. Membranes were incubated with secondary antibody diluted in TBST + 
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5% milk (1:5,000 horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG for 
nsp3 and poly-NSV, GE Healthcare; 1:5,000 HRP-conjugated sheep anti-mouse IgG for 
β-actin, GE Healthcare) for one hour at room temperature on a rocker and developed 
using Amersham ECL Western Blotting Detection Reagent (GE Healthcare) according to 
manufacturer’s instructions. 
 
Gene Expression Measurement by Real-Time PCR 
 RNA was isolated from dCSM1.1 and AP-7 cells using the Qiagen RNeasy or 
RNeasy Plus Mini kit following the manufacturer’s directions. For mouse CNS tissue, 
right brain halves or whole spinal cords were homogenized in one mL QIAzol in Lysing 
Matrix D tubes (MP Biomedicals) at 6.0 M/s for 40 seconds using a FastPrep-24 
homogenizer, and the Qiagen RNeasy Lipid Tissue Mini kit was used to isolate RNA. 
cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit with 
random primers (Life Technologies), and quantitative real-time PCR (qRT-PCR) was 
performed using TaqMan Universal PCR Master Mix (Roche) on a 7500 Fast Real-Time 
PCR System. SINV RNA copies were measured using TaqMan probe (5’–6-
carboxyfluorescein [FAM]-CGCATACAGACTTCCGCCCAGT–6-carboxytetra-
methylrhodamine [TAMRA]-3’, Applied Biosystems) with primers to the SINV E2 gene 
(forward, 5’-TGGGACGAAGCGGACGATAA-3’; reverse, 5’-
CTGCTCCGCTTTGGTCGTAT-3’). SINV E2 copies were quantified using a standard 
curve made of ten-fold dilutions of a plasmid containing the SINV subgenomic region 
genes and normalized to endogenous rodent Gapdh. mRNA was measured using 
commercially-available TaqMan gene expression assays (Applied Biosystems or 
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Integrated DNA Technologies), and relative quantification was performed by the ΔΔCT 
method using endogenous rodent Gapdh mRNA for normalization.  
 
Microarray 
 dCSM14.1 cell pellets were submitted to the Johns Hopkins Malaria Research 
Institute Gene Array Core for microarray analysis using a rat exon library. Microarray 
data were analyzed with Partek Genomic Suite, version 6.6, using a 1.5 fold-change 
cutoff, and Ingenuity Pathway Analysis. Genes with putative antiviral function that were 
significantly upregulated with IFN-γ treatment were selected for further evaluation. 
 Comparative gene expression in WT B6, Ifngr1-/-, and Ifng-/- mouse brains at 7 
DPI was examined using the Mouse Innate & Adaptive Immune Responses RT² Profiler 
PCR Array (SABiosciences) according to manufacturer’s instructions. RNA was pooled 
from three to four mice per strain. Results were analyzed using the online GeneGlobe 
Data Analysis Center (Qiagen), and genes with marked up- or down-regulation in Ifngr1-
/- or Ifng-/- mice compared to WT B6 mice were selected for further evaluation. 
 
Protein Quantification by Enzyme-Linked Immunosorbent Assay 
 Serum leptin was quantified by enzyme-linked immunosorbent assay (ELISA) 
using a commercial kit (Millipore) according to manufacturer’s directions. Data was 
presented as ng/mL serum with a 0.2 ng/mL limit of detection. 
Production of types I and II IFN was quantified by ELISA in 20% w/v brain 
homogenates. Verikine Mouse Interferon Alpha and Interferon Beta ELISA kits (PBL 
Interferon Source) were used to measure IFN alpha (IFN-α) and IFN beta (IFN-β), 
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respectively, and IFN-γ was measured using the mouse IFN gamma ELISA Ready-SET-
Go! kit (Ebioscience). Assays were performed according to manufacturer’s instructions, 
and data were presented as pg/g brain tissue with a 125, 156, and 312pg/g limit of 
detection for IFN- α, IFN- β, and IFN-γ, respectively. 
 Anti-SINV antibody was measured in serum, brain homogenates, and spinal cord 
homogenates using an in-house ELISA. Maxisorp 96-well plates (Thermo Scientific 
Nunc) were coated with 106 pfu PEG-purified SINV TE in coating buffer (50mM 
NaHCO3, pH 9.6) and incubated overnight at 4°C. Plates were blocked in PBS-0.05% 
Tween-20 + 10% FBS (PBST-10% FBS) for two hours at 37°C and incubated overnight 
at 4°C with samples diluted in PBST-10% FBS (1:100 for serum, 1:4 for brain 
homogenates, 1:2 for spinal cord homogenates). Wells were incubated with 1:1000 HRP-
conjugated goat anti-mouse IgG2a, IgG2b, or IgG3 or 1:2000 HRP-conjugated goat anti-
mouse IgM, IgG, or IgG1 (Southern Biotech) for two hours at room temperature, and 
plates were developed with a BD OptEIA TMB Substrate Reagent kit using 2M H2SO4 as 
stop solution. Plates were read at 450nm, and optical density (OD) values for mock-
infected mice of each strain were subtracted from the OD values of infected mice. 
 
Mononuclear Cell Isolation 
 Single cell suspensions were made from cervical lymph nodes (CLNs) and brains 
pooled from three to seven mice per strain per time point. CLNs were dissociated in 
RPMI + 1% FBS using gentleMACS C tubes and Dissociator (Miltenyi Biotech) and 
filtered through a 70µm-pore-size cell strainer. After pelleting by centrifugation, red 
blood cells were lysed using an ammonium chloride solution (Sigma-Aldrich or 
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Ebioscience). Remaining cells were filtered through another 70µm strainer, pelleted by 
centrifugation, and resuspended in PBS + 2mM EDTA (PE buffer) for counting. Brains 
were placed in RPMI media containing 1% FBS, 1 mg/mL collagenase D (Roche), and 
0.1 mg/mL DNase I (Roche) and dissociated in C tubes using a gentleMACS Dissociator. 
Tissues were incubated for 30 minutes at 37°C with periodic agitation, and dissociated 
cells were filtered through a 70µm-pore-size cell strainer and pelleted by centrifugation. 
Cell pellets were resuspended in 30% supplemented Percoll [9:1 Percoll (GE Healthcare) 
: 10X salt solution of 80g NaCl, 3g KCl, 0.73g Na2HPO4, 0.2g KH2PO4, and 20g glucose 
in 1L dH2O] in RPMI media in a 15mL conical tube and underlaid with 70% 
supplemented Percoll in RPMI media. Tubes were centrifuged at 850 x g at 4°C for 30 
minutes with slow braking, and cells were collected from the 30/70% interface. Cells 
were pelleted by centrifugation and resuspended in PE buffer for counting. Live 
mononuclear cells were quantified by trypan blue exclusion. 
 
Flow Cytometry 
 106 live cells were placed in the wells of a 96-well round bottom plate. A violet 
LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) diluted in PE buffer was 
applied to cells for 30 minutes, followed by a 15-minute incubation with anti-mouse 
CD16/CD32 (BD Pharmingen) diluted in PE buffer to block Fc receptors. Cells were 
stained with monoclonal antibodies against CD45 (clone 30-F11), CD3 (clone 17A2), 
CD4 (clone RM4-5), CD8 (clone 53-6.7), CD19 (clone 1D3), and CD25 (clone PC61.5) 
from Ebioscience or BD Pharmingen diluted in PBS + 2mM EDTA + 0.5% BSA (FACS 
Buffer) for 30 minutes on ice. For intracellular staining of Foxp3, cells were fixed for 20 
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minutes using Fixation/Permeabilization solution from the Ebioscience 
Foxp3/Transcription Factor Staining Buffer kit. Cells were stained for 30 minutes on ice 
with a monoclonal antibody against Foxp3 (clone FKJ-16S, BD Pharmingen) diluted in 
Permeabilization Buffer. 
For intracytoplasmic cytokine staining (ICS), 2-3 x 106 cells were stimulated for 
four hours at 37°C with 50 ng/mL of phorbol-12-myristate 13-acetate (PMA, Sigma) and 
1 µg/mL ionomycin (Sigma) in the presence of brefeldin A (GolgiPlug, BD Pharmingen) 
in RPMI + 1% FBS. Following LIVE/DEAD and surface antibody staining (see above), 
cells were fixed for 20 minutes using Fixation/Permeabilization solution from the BD 
Cytofix/Cytoperm kit. Cells were stained for 30 minutes on ice with monoclonal 
antibodies against IFN-γ (clone XMG1.2), IL-4 (clone 11B11), IL-17a (clone eBio17B7), 
granzyme B (clone NGZB), and TNF-α (clone MP6-XT22) from Ebioscience or BD 
Pharmingen diluted in BD Perm/Wash buffer. 
Cells were resuspended in 200uL FACS Buffer and run on a BD FACSCanto II 
cytometer using BD FACSDiva software, version 8, and analyses were carried out using 
FlowJo software, version 8. Cells were characterized as follows: CD4 T cells 
(CD45hiCD3+CD4+), CD8 T cells (CD45hiCD3+CD4+), B cells (CD45hiCD3-CD19+), 
Th1 cells (CD3+CD4+IFN-γ+), Th2 cells (CD3+CD4+IL-4+), Th17 cells 
(CD3+CD4+IL-17a+), and Tregs (CD3+CD4+CD25+Foxp3+). All flow cytometry data 
are averaged representations of three independent experiments. 
 
Statistics 
Statistical analyses were performed using Graphpad Prism 6 software. Time-
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course studies were analyzed by two-way ANOVA with Bonferroni’s or Tukey’s 
multiple comparison post-test for two group and three group comparisons, respectively. 
Comparisons between three groups at a single time point were made using one-way 
ANOVA with Tukey’s multiple comparisons post-test. Three outliers were identified in 
the IFN-γ protein production data by the ROUT method with a Q = 1% and removed 
from analyses (one data point each for WT B6 at 3 and 7 DPI and for Ifngr1-/- at 21 DPI). 
One outlier was identified at 11 DPI in the Ifngr1-/- group of the feed intake study by the 
same method as above and was removed from analysis. A p value of < 0.05 was 





IFN-γ facilitates virus clearance in neurons in vitro 
 Because neurons are a valuable but finite and minimally renewable cell 
population, clearance of neurotropic viruses requires a noncytolytic process. Previous 
studies have shown that clearance of infectious virus is primarily facilitated through a 
cooperative effort between anti-SINV antibody and the cytokine IFN-γ, though the 
mechanisms by which this occurs remain to be fully understood24,70,92. To better elucidate 
the role IFN-γ plays in virus clearance, cultured AP-7 cells, which are derived from rat 
olfactory neurons, were selected for in vitro studies. cAP-7 cells, which morphologically 
resemble epithelial cells and represent immature neurons, and dAP-7 cells, which 
resemble mature neurons with bipolar morphology and dendrite-like processes211, were 
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infected with the TE strain of SINV at a MOI of 5, and culture supernatant fluids were 
collected for assay of virus titers. Both cell types supported virus replication and 
production, though cAP-7 cells reached higher peak titers (Fig 4-1A). dAP-7 cells 
continued to produce virus through 72 HPI and were used for subsequent studies. 
 To examine the effect IFN-γ has on virus clearance in neurons, dAP-7 cells were 
infected with SINV TE at a MOI of 1, and cells were treated with 500U/mL rat 
recombinant IFN-γ at two hours prior to infection, at 2 HPI, or at 24 HPI. Virus readily 
replicated in all treatment groups, with titers peaking at about 32 HPI (Fig 4-1B). dAP-7 
cells treated with IFN-γ prior to infection and at 2 HPI had significantly decreased virus 
titers relative to untreated cells at 24, 32, and 48 HPI, with the greatest effect seen in 
pretreated cells (p < 0.0001 for untreated vs IFN-γ Pre-Txt at 24, 32, and 48 HPI, p < 
0.05, p < 0.01, and p < 0.001 for untreated vs IFN-γ Txt 2 HPI at 24, 32, and 48 HPI, 
respectively, all Tukey’s multiple comparisons test). Treatment with IFN-γ at 24 HPI did 
not significantly alter virus titers. 
 Production of different SINV proteins was examined by immunoblot in dAP-7 
cells infected with SINV alone or treated with 500U/mL IFN-γ at 2 HPI. In untreated 
SINV-infected cells, production of the nonstructural nsp3 protein and structural capsid 
protein reached high levels starting at 24 HPI (Fig 4-1C). Production of the structural 
glycoproteins E1 and E2 (along with the precursor to E2, pE2) was readily evident by 48 
HPI. In contrast, production of SINV proteins in neurons treated with IFN-γ was 
markedly diminished. These results show that IFN-γ decreases the production of SINV 
proteins and can facilitate clearance of infectious virus. 
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 Since IFN-γ is capable of clearing infectious virus by inhibiting production of 
SINV proteins, we next examined whether it could also facilitate clearance of viral RNA. 
dAP-7 cells infected with SINV TE at a MOI of 1 were treated with 500U/mL IFN-γ at 2 
HPI, and cell pellets were collected to quantify viral RNA by qRT-PCR. Viral RNA 
copies were comparable between treated and untreated cells at 8 HPI, but copy number in 
untreated cells continued to rise, peaking at 72 HPI (Fig 4-1D). In contrast, SINV RNA 
levels plateaued in treated cells, and by 72 HPI had begun to decrease, indicating 
clearance. Overall viral RNA synthesis was significantly inhibited by IFN-γ treatment 
compared to untreated dAP-7 cells at 24, 32, 48, 56, and 72 HPI (p < 0.0001 for all time 
points, Bonferroni’s multiple comparisons test). These studies show that IFN-γ signaling 
is capable of clearing both infectious virus and viral RNA from neurons in vitro. 
 
IFN-γ induces expression of antiviral ISGs in vitro 
 Because IFN-γ is capable of clearing virus from neurons, we next examined what 
antiviral genes were activated by IFN-γ signaling during SINV infection. dCSM14.1 
cells, a differentiated neuronal cell line derived from rat nigral-striatal cells, were infected 
with SINV TE at a MOI of 5 and treated with 100U/mL IFN-γ at 24 HPI. RNA from 
mock-infected cells, untreated SINV-infected cells collected at 24 and 27 HPI, and IFN-
γ-treated, mock-infected and SINV-infected cells collected at 27 HPI were analyzed on a 
microarray, and results plotted using Partek Genomics Suite. Cluster analysis showed 
gene expression profiles were similar among cells treated with IFN-γ, regardless of SINV 
infection status (Fig 4-2A). Six hundred twenty-five genes were found to have at least a 
±1.5 fold-change in gene expression among groups (Appendix A), and five genes with 
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putative antiviral function that were significantly up-regulated in SINV-infected, IFN-γ 
treated cells compared to mock-infected cells were selected for further examination 
(Table 4-1). 
 mRNA expression of the selected antiviral IFN-stimulated genes (ISGs) were 
examined by qRT-PCR for cAP-7 and dAP-7 cells that were infected with SINV TE at a 
MOI of 1 and treated with 500U/mL IFN-γ at 2 HPI. Gbp2 (Fig 4-2B) and Irgm (Fig4-
2C), two genes associated with autophagy216, were highly expressed by SINV-infected 
dAP-7 cells treated with IFN-γ, as was Oasl2 (Fig 4-2D), a member of the 2'-
5'oligoadenylate/RNaseL system217, and Rsad2 (Fig 4-2E), which encodes viperin, a 
protein that interferes with assembly and release of many viruses218. Zc3hav1 (Fig 4-2F), 
which encodes ZAP, a protein involved in viral RNA degradation and induction of the 
innate immune response219, was less highly upregulated. All of these genes required IFN-
γ for induction of any substantial expression, and SINV alone was generally not sufficient 
to mount a pronounced response. In cAP-7 cells, expression of each of these genes at 24 
HPI was higher in mock-infected cells treated with IFN-γ compared to SINV-infected 
cells treated with IFN-γ. The opposite effect was seen in dAP-7 cells, highlighting the 
fact that the maturation status of neurons influences their ability to respond to infection 
and immune mediators. 
 
Impaired IFN-γ signaling affects protein production, but not Ifng mRNA 
expression, in mice during SINV infection 
To examine the role IFN-γ plays in the immunopathogenesis and clearance of 
alphavirus infection, production of IFN-γ in the brain was first examined. Relative to 0 
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DPI controls, during SINV infection, IFN-γ mRNA expression levels in WT B6 mouse 
brains increased sharply, peaking at 5 DPI (Fig 4-3A). Expression then slowly decreased 
but had not returned to baseline levels by 90 DPI. Ifngr1-/- mice showed a similar time 
course, with no significant difference in Ifng expression compared to the WT B6 mice (p 
= 0.9988, two-way ANOVA). IFN-γ protein production, as measured by ELISA, also 
sharply increased following SINV infection, peaking at 7 DPI in WT B6 mice before 
precipitously dropping to below detectable limits by 10 DPI (Fig 4-3B). In contrast to 
mRNA expression, production of IFN-γ over time differed between WT B6 and Ifngr1-/- 
mice (p < 0.01, two-way ANOVA), with Ifngr1-/- mouse brains having significantly 
higher peak production at 7 DPI (p < 0.0001, Bonferroni’s multiple comparisons test). 
IFN-γ production also did not decrease as quickly in Ifngr1-/- mice, with protein still 
detectable through 14 DPI. These data suggest that while mRNA expression of IFN-γ 
does not differ between WT B6 and Ifngr1-/- mouse brains during SINV infection, 
impaired IFN-γ signaling results in a modified post-transcriptional regulation of protein 
production. 
 
WT B6 mice lose more body weight than Ifngr1-/- or Ifng-/- mice during SINV 
infection due to changes in feed intake 
After evaluating virus clearance and ISG induction in response to IFN-γ signaling 
during SINV infection in vitro, we sought to better understand the role of IFN-γ in virus 
immunopathogenesis and control in vivo by using mice deficient in either the IFN-γ 
receptor (Ifngr1-/-) or IFN-γ itself (Ifng-/-) and comparing them to mice with intact IFN-γ 
signaling (WT B6). While mice infected with the virulent NSV strain of SINV develop 
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progressive ascending paralysis prior to death, WT B6 mice infected with the less 
virulent TE strain of SINV generally do not progress beyond mild to moderate signs of 
encephalomyelitis. To assess the clinical disease produced by nonfatal SINV infection in 
Ifngr1-/- and Ifng-/- mice, animals were weighed and evaluated for signs of 
encephalomyelitis (a combination of abnormal posture and gait) daily. Ifngr1-/- and Ifng-/- 
mice developed clinical signs earlier than WT B6 mice (Fig 4-4A; median of 3 DPI vs 5 
DPI). Almost all mice were showing clinical signs by 6 DPI, but Ifngr1-/- mice recovered 
from clinical disease earlier than Ifng-/- or WT B6 mice (median 11 DPI vs 13 DPI vs 14 
DPI for Ifngr1-/-, Ifng-/-, and WT B6 mice, respectively). In all three strains, 
approximately 20% redeveloped clinical signs around 18 to 21 DPI. 
 Significant differences in body weight were seen in the different strains during 
SINV infection (Fig 4-4B; p < 0.01, two-way ANOVA). WT B6 mice lost approximately 
13% of their initial body weight, reaching a nadir at 8 DPI, before recovering and 
surpassing their 0 DPI body weight by 17 DPI. In contrast, Ifngr1-/- and Ifng-/- mice lost 
an average of 7% and 1% of their initial body weight, respectively, by 6 DPI before 
recovering and surpassing their 0 DPI body weight by 11 and 7 DPI, respectively. While 
the rate of weight gain following recovery was approximately the same among strains, by 
28 DPI, Ifng-/- mice were significantly heavier than the WT B6 and Ifngr1-/- mice that lost 
more weight (p < 0.0001 and p < 0.01 vs WT B6 and Ifngr1-/-, respectively). No 
difference in body weights was found in mock-infected mice (Fig 4-4C). Prior to 
infection, WT B6 mice weighed slightly more than Ifngr1-/- mice but were not 
significantly heavier than Ifng-/- mice (mean body weight 17.9g, 16.9g, and 17.6g for WT 
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B6, Ifngr1-/-, and Ifng-/-, respectively; p < 0.05 for WT B6 vs Ifngr1-/-, Tukey’s multiple 
comparisons test; data not shown). 
 To determine the cause of the weight loss in SINV-infected mice, three 
parameters were measured: body temperature, feed intake, and serum leptin levels. The 
body temperature of all three strains did not increase or decrease with SINV infection, 
fluctuating only about 0.5 °C throughout the first 14 DPI (Fig 4-4D). When normalized to 
mock-infected strain controls at each day and then the amount of food consumed at 0 
DPI, all three strains decreased their feed intake during the first week following infection 
(Fig 4-4E). However, while Ifngr1-/- and Ifng-/- mice increased the amount of feed they 
consumed starting at 7 DPI, WT B6 mice continued to show a decrease in daily feed 
consumption through 8 DPI. These patterns coincided with the times during which mice 
of each strain lost or regained body weight. To examine whether neurological changes in 
satiety were responsible for the weight loss, serum leptin was measured by ELISA at 
three time points following infection: when all three strains were losing weight (5 DPI), 
when Ifngr1-/- and Ifng-/-, but not WT B6 mice were starting to recover body weight (7 
DPI), and when all three strains were starting to recover (10 DPI) (Fig 4-4F). Despite 
serum being collected at the same time of day (mid-morning), no clear patterns were 
elucidated. Based on these data, the differences in body weight loss and gain among 
strains can likely be attributed to differences in the amount of feed consumed following 
infection. 
 
Impaired IFN-γ signaling results in delayed clearance of infectious virus but earlier 
initiation of viral RNA clearance 
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 As has been shown previously, clearance of infectious SINV from the CNS is 
altered in mice with impaired IFN-γ signaling. When examining infectious virus levels in 
the brains (Fig 4-5A) and spinal cords (Fig 4-5B) of WT B6, Ifngr1-/-, and Ifng-/- mice by 
plaque assay, titers peaked at 1 to 3 DPI in all three strains, though brains reached 100-
fold higher titers than spinal cords. However, while infectious virus titers were below 
detectable levels in WT B6 spinal cords by 7 DPI, infectious virus could still be detected 
in Ifngr1-/- and Ifng-/- mice. In both tissues of all three strains, infectious virus could 
periodically be detected through 28 DPI, but were only consistently detectable in the 
brains of Ifngr1-/- mice at 21 DPI. These data show that IFN-γ signaling is important in 
clearance of infectious virus, particularly from the spinal cord. 
 Because IFN-γ is capable of initiating clearance of viral RNA in vitro, its role in 
vivo was examined by quantifying SINV E2 RNA copies in brains and spinal cords of 
WT B6, Ifngr1-/-, and Ifng-/- mice by qRT- PCR. Viral RNA peaked at 3 to 5 DPI in the 
brains (Fig 4-5C) and spinal cords (Fig 4-5D) of all three strains at comparable amounts. 
However, viral RNA levels were significantly lower in the brains of Ifngr1-/- and Ifng-/- 
mice compared to WT B6 mice at 7 DPI (p < 0.001 for WT B6 vs each strain, Tukey’s 
multiple comparisons) and in the spinal cords of Ifngr1-/- and Ifng-/- mice compared to 
WT B6 mice at 5 and 7 DPI (p < 0.001 at 5 DPI and p < 0.05 at 7 DPI for WT B6 vs 
Ifngr1-/-, p < 0.01 at 5 DPI and p < 0.05 at 7 DPI for WT B6 vs Ifng-/-, all Tukey’s 
multiple comparisons test). Viral RNA levels were comparable among strains throughout 
Phase 2 of infection; however, at occasional times during Phase 3, when viral RNA 
typically has reached a low-level steady state, viral RNA levels increased to those 
generally seen at Phase 2 time points, especially in Ifng-/- mice and in the spinal cord. The 
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results indicate that while impaired IFN-γ signaling results in delayed infectious virus 
clearance, it leads to accelerated initiation of viral RNA clearance. Furthermore, IFN-γ 
appears to prevent reactivation of viral RNA synthesis, and thus potentially infectious 
virus, during Phase 3 of infection, particularly in the spinal cord. 
 
 Ifngr1-/- and Ifng-/- mice have diminished induction of ISG expression in the CNS 
compared to WT B6 mice 
 As IFN-γ appeared to play a multi-dimensional role in virus clearance in vivo, we 
next examined the effect of impaired IFN-γ signaling on antiviral ISG expression. The 
five antiviral ISGs previously selected for in vitro analysis, Gbp2, Irgm1, Oasl2, Rsad2, 
and Zc3hav1, were examined by qPCR in the brains and spinal cords of WT B6, Ifngr1-/-, 
and Ifng-/- mice infected intracranially with SINV TE. Oas1a, which encodes another 
protein associated with the 2'-5'oligoadenylate/RNaseL system considered to have more 
activity than Oasl2 in mice217, was additionally examined. Expression of each of these 
genes was considerably upregulated during SINV infection in all strains, regardless of 
IFN-γ signaling capacity, and returned to baseline levels by Phase 3 of infection. Peak 
expression levels of Gbp2 (Fig 4-6A) and Irgm1 (Fig 4-6B) at 7 DPI in the brain and 5 
DPI in the spinal cord were significantly lower in Ifngr1-/- and Ifng-/- mice compared to 
WT B6 mice (p < 0.0001 for WT B6 vs both strains at both time points in both tissues, 
all Tukey’s multiple comparisons test). Less pronounced, but still significant, differences 
in peak expression levels were seen with Oasl2 (Fig 4-6C) and Oas1a (Fig 4-6D) at 3 
DPI, though increased expression of Oas1a in WT B6 spinal cords was considerable (p < 
0.0001 at 3 DPI for WT B6 vs both strains, Tukey’s multiple comparisons test). Rsad2 
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(Fig 4-6E) and Zc3hav1 (Fig 4-6F) expression both peaked at 7 DPI in the brain and at 3 
DPI in the spinal cord, but significantly increased peak expression in WT B6 mice 
compared to both Ifngr1-/- and Ifng-/- mice was mostly found in the brains (p < 0.001 for 
Rsad2 and p < 0.0001 for Zc3hav1 for WT B6 vs Ifngr1-/-, p < 0.0001 for both genes for 
WT B6 vs Ifng-/-, all Tukey’s multiple comparisons test). These results show that while 
ISGs are induced during SINV infection in the CNS of mice with impaired IFN-γ 
signaling, expression is generally diminished compared to that of mice with intact 
signaling. 
 
Mice with impaired IFN-γ signaling have a modulated cytokine and chemokine 
immune response during SINV infection 
One of the ways IFN-γ influences the immune response to virus infection is 
through its modulation of leukocyte differentiation and chemotaxis. To determine the role 
that IFN-γ signaling plays in the brains of SINV-infected mice, production and 
expression of cytokines and chemokines during the first two weeks following infection 
were examined. To narrow the numbers of genes examined, a microarray with 84 genes 
involved in the innate or adaptive immune response was first used to examine 7 DPI 
brains from SINV-infected mice of each strain (Fig 4-7A). Genes that were markedly up- 
or downregulated in Ifngr1-/- or Ifng-/- brains relative to WT B6 brains were selected for 
further examination by qRT-PCR in individual mice. The complete gene list and relative 
fold changes for both the brain and spinal cord at 7 DPI may be found in Appendix B. 
Type I IFN protein production was examined by ELISA in the brains of WT B6, 
Ifngr1-/-, and Ifng-/- mice. WT B6 mice produced the most IFN-α during SINV infection, 
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with levels peaking at 3 DPI (Fig 4-7B). Production was impaired in Ifngr1-/- and Ifng-/- 
brains, though IFN-α levels peaked in Ifng-/- mice earlier than the other two strains at 1 
DPI. Following peak production, IFN-α quickly dropped to below detectable limits. In 
contrast, after reaching peak levels at 3 DPI, IFN-β production declined more slowly in 
WT B6 mice, dropping below detectable levels by 10 DPI (Fig 4-7C). IFN-β production 
was diminished in mice with impaired IFN-γ signaling, with levels only detectable at 5 
and 1 DPI in Ifngr1-/- and Ifng-/- brains, respectively. IFN-γ signaling not only affects the 
amounts of IFN-α and IFN-β produced in brains during SINV infection but also the time 
of peak levels that corresponds with peak virus titers. 
The immune response is responsible for virus clearance during SINV infection, 
but can also be neurotoxic, resulting in physiologic damage to neurons and thus clinical 
disease54. To determine how IFN-γ modulates immune response signaling, mRNA 
expression of several pro-inflammatory cytokines were examined by qRT-PCR and 
compared to mock-infected controls. A 7 DPI, when WT B6 mice no longer had 
detectable infectious virus in the brain but were still losing weight, brain mRNA 
expression of Tnf (Fig 4-7D) and Csf2 (Fig 4-7E) were significantly higher compared to 
Ifngr1-/- and Ifng-/- mice (p < 0.0001 for WT B6 vs both strains, Tukey’s multiple 
comparisons test). Il6 mRNA expression (Fig 4-7F) was also significantly higher at 7 DPI 
in WT B6 mice compared to Ifngr1-/- and Ifng-/- mice (p < 0.01 and p < 0.0001 for WT 
B6 vs Ifngr1-/- and Ifng-/-, respectively, Tukey’s multiple comparisons test). While Il1b 
expression was highest in WT B6 mice (Fig 4-7G), mRNA expression was significantly 
lower in Ifng-/- mice at 7 DPI (p < 0.0001 and p < 0.01 for Ifng-/- vs WT B6 and Ifngr1-/-, 
respectively, Tukey’s multiple comparisons test).  
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The potential role of IFN-γ signaling for immune cell chemotaxis was examined 
by measuring mRNA expression for chemokines previously found to be regulated during 
nonfatal SINV infection in Ifngr1-/- and Ifng-/- mouse brains. Ccl1 expression (Fig 4-7H) 
was significantly upregulated in Ifng-/- mice compared to both WT B6 and Ifngr1-/- mice 
at 5, 7, and 10 DPI (p < 0.05 at 5 DPI and p < 0.0001 at 7 and 10 DPI for Ifng-/- vs both 
WT B6 and Ifngr1-/-, Tukey’s multiple comparisons test). In contrast, WT B6 mice had 
higher mRNA expression of Ccl2 (Fig 4-7I; p < 0.0001 for WT B6 vs both Ifngr1-/- and 
Ifng-/-, Tukey’s multiple comparisons) and Ccl5 (Fig 4-7J; p < 0.01 and p < 0.001 for 
WT B6 vs Ifngr1-/- and Ifng-/-, respectively, Tukey’s multiple comparisons test) at 7 DPI. 
Alpha chemokine mRNAs Cxcl9 (Fig 4-7K), Cxcl10 (Fig 4-7L), and Cxcl13 (Fig 4-7M) 
were all significantly upregulated in WT B6 mice at 7 DPI compared to Ifngr1-/- and Ifng-
/- mice (p < 0.0001 for WT B6 vs both strains for all chemokines, Tukey’s multiple 
comparison test). These data show that during SINV infection, IFN-γ likely plays an 
important role in stimulating the chemotaxis of inflammatory cells into the brain. 
 IFN-γ also influences differentiation of T helper (Th) cell subsets, and four 
cytokines associated with specific Th profiles, Il2 (Fig 4-7N) for Th1 cells, Il4 (Fig 4-7O) 
for Th2 cells, Il17a (Fig 4-7P) for Th17 cells, and Il10 (Fig 4-7Q) for Tregs, were 
examined. At 7 DPI, mRNA expression of Il2 and Il10 was significantly lower in Ifng-/- 
mice (p < 0.01 for Il2 and p < 0.001 for Il10 for Ifng-/- vs both strains, Tukey’s multiple 
comparisons test), and expression of Il17a was significantly higher in Ifngr1-/- mice (p < 
0.001 for Ifngr1-/- vs both strains, Tukey’s multiple comparisons test). Il4 expression did 
not significantly differ among strains at 7 DPI. Th differentiation was further examined 
by measuring expression of transcription factors Tbx21 (Fig 4-7R) for Th1 cells, Gata3 
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(Fig 4-7S) for Th2 cells, Rorc (Fig 4-7T) for Th17 cells, and Foxp3 (Fig 4-7U) for Tregs. 
While significant differences were found between strains at various time points, no major 
trends were identified. These results show that at least at the cytokine level, IFN-γ 
signaling modulates Th profiles during SINV infection and warrants further examination. 
 
Mice deficient in IFN-γ signaling have impaired expression of genes associated with 
pathogen recognition 
IFN-γ has been reported to affect the ability of cells to sense pathogens220. To 
determine if IFN-γ plays a role in pathogen recognition and detection during SINV 
infection, mRNA expression of several surface and intracytoplasmic pattern recognition 
receptors (PRR’s) was examined by qRT-PCR. Expression of four endosomal toll-like 
receptor genes, Tlr3, Tlr7, Tlr8, and Tlr9, and the associated adaptor protein Myd88 were 
first examined (Fig 4-8A-E). Expression of Tlr3 (Fig 4-8A), which recognizes dsRNA, 
and Tlr9 (Fig 4-8D), which recognizes CpG DNA, were significantly higher in WT B6 
mouse brains compared to Ifngr1-/- and Ifng-/- brains, as was Myd88 (Figs 4-8A, 4-8D, 
and 4-8E; p < 0.01 and p < 0.001 for Tlr3, both p < 0.0001 for Tlr9, and p < 0.01 and p 
< 0.00001 for MyD88 in WT B6 mice vs Ifngr1-/- and Ifng-/-, respectively, all Tukey’s 
multiple comparisons test). Differences in Tlr7 (Fig 4-8B) and Tlr8 (Fig 4-8C) 
expression, which both detect ssRNA, were less pronounced. 
 Expression of several proteins involved in intracellular pathogen recognition and 
signaling were next examined (Fig 4-8F-I). Nod-like receptor genes, Nod1 and Nlrp3, 
which lead to NFkB activation and inflammasome formation, respectively, were both 
significantly upregulated in WT B6 mice relative to Ifngr1-/- and Ifng-/- mice at 7 DPI 
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(Figs 4-8F and 4-8G; p < 0.0001 for Nod1 for WT B6 vs both Ifngr1-/- and Ifng-/-, p < 
0.01 and p < 0.0001 for Nlrp3 for WT B6 vs Ifngr1-/- and Ifng-/-, respectively, all Tukey’s 
multiple comparisons test). IFN-γ has previously been found to mediate virus clearance 
through activation of the Jak/STAT signaling pathway, and expression of Stat1 and Stat3 
were both significantly decreased in Ifngr1-/- and Ifng-/- mice compared to WT B6 mice at 
7 DPI (Figs 4-8H and 4-8I; p < 0.001 and p < 0.0001 for Stat1 and p < 0.001 and p < 
0.0001 for Stat3 in WT B6 mice vs Ifngr1-/- and Ifng-/-, respectively, all Tukey’s multiple 
comparisons test). Based on these data, IFN-γ signaling affects activation of the innate 
immune response through alteration of PRR gene expression. 
 
IFN-γ signaling affects proliferation and infiltration of immune cells into the brain 
during SINV infection 
Resident T cells secreting IFN-γ and B cells secreting SINV-specific antibody 
against the E2 glycoprotein in the are important facilitators of virus clearance24,92. To see 
if IFN-γ signaling affects recruitment and infiltration of T and B cells into the brain 
during SINV infection, quantification of total mononuclear cells by trypan blue exclusion 
and CD4+ T cells, CD8+ T cells, and CD19+ B cells by flow cytometry in the CLNs and 
brain during key times of the virus clearance process were performed. In the CLNs, WT 
B6 mice had significantly more total mononuclear cells than Ifng-/- mice at 5 DPI (Fig 4-
9A; p < 0.05, Tukey’s multiple comparisons test), but no significant differences among 
strains were found at 7 and 10 DPI. In the brain, Ifngr1-/- and Ifng-/- mice had significantly 
fewer total infiltrating mononuclear cells at 7 DPI compared to WT B6 mice (Fig 4-9B; p 
< 0.01 for WT B6 vs both strains, Tukey’s multiple comparisons test). Neither the 
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percentage nor absolute number of CD4+ T cells (Fig 4-9C), CD8+ T cells (Fig 4-9E), or 
CD19+ B cells (Fig 4-9G) were affected by impaired IFN-γ signaling in CLNs, though 
numbers for each cell population generally decreased overall from 5 DPI to 10 DPI.  
In contrast, differences in cell populations among mouse strains were found in the 
brain. Numbers of infiltrating CD8+ T cells peaked at 7 DPI, while infiltration of CD4+ 
T cells and B cells occurred later with peaks at 10 DPI. WT B6 mice had significantly 
more CD4+ T cells than Ifng-/- mice at 10 DPI (Fig 4-9D; p < 0.01, Tukey’s multiple 
comparisons test). In contrast, both the percentage of live cells and absolute numbers of 
CD8+ T cells were higher in brains of Ifngr1-/- and Ifng-/- mice compared to WT B6 mice 
at 7 DPI (Fig 4-9F; p < 0.01 for WT B6 vs Ifngr1-/- [percentage only] and Ifng-/- 
[percentage and absolute count], Tukey’s multiple comparisons test). This occurred 
despite WT B6 mice having more overall numbers of mononuclear cells in the brain at 
this time (Fig 4-9B). The percentage of live cells at 10 DPI and absolute number of B 
cells at 7 DPI and 10 DPI were significantly increased in WT B6 mice compared to 
Ifngr1-/- and Ifng-/- mice (Fig 4-9H; p < 0.05 for WT B6 vs both strains, Tukey’s multiple 
comparisons test). Therefore, while the absence of IFN-γ signaling does not affect the 
proliferation of T and B cells in response to SINV infection, it does affect recruitment of 
these cells to the site of infection in the brain. 
 
IFN-γ affects CD4+ and CD8+ T cell function in the brain during SINV infection 
 Because impaired IFN-γ signaling altered the numbers of CD4+ and CD8+ T cells 
infiltrating the brain during SINV infection, we sought to determine if the effector 
function of these cells was also affected. CD4+ T cells were further characterized by 
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measuring production of cytokines associated with different Th subsets in the brains of 
each strain at 7 DPI. IFN-γ was measured to evaluate Th1 cells, IL-4 for Th2 cells, and 
IL-17a for Th17 cells. Tregs were characterized as cells expressing both CD25 and 
producing Foxp3. IFN-γ was not produced by CD4+ T cells in Ifng-/- mice, and the 
percentage of CD4+ T cells producing IFN-γ did not differ between WT B6 and Ifngr1-/- 
mice (Fig 4-10A). The percentage of CD4+ T cells producing IL-4 was significantly 
lower in Ifng-/- mice compared to WT B6 or Ifngr1-/- mice (Fig 4-10B; p < 0.05 for Ifng-/- 
vs both strains, Dunn’s multiple comparisons test). Though not significant, more CD4+ T 
cells in Ifngr1-/- mice produced IL-17a compared to WT B6 and Ifng-/- mice (Fig 4-10C), 
and the percentage of CD4+ T cells expressing both CD25 and Foxp3 was comparable 
among strains. These results show that IFN-γ signaling does affect CD4+ T cell function 
at 7 DPI during SINV infection, but impaired signaling does not result in a major change 
in Th profile. 
 Function of CD8+ T cells can be evaluated by their production of effector 
proteins. To examine how IFN-γ signaling affects this process, production of IFN-γ, 
TNF-α, and granzyme B was examined at 7 DPI in brains of WT B6, Ifngr1-/-, and Ifng-/- 
mice. As for CD4+ T cells, IFN-γ was not produced by CD8+ T cells in Ifng-/- mice, and 
the percentage of CD8+ T cells producing IFN-γ did not differ between WT B6 and 
Ifngr1-/- mice (Fig 4-11A). The percentage of CD8+ T cells producing TNF-α trended 
higher in WT B6 mice, though this was not significant (Fig 4-12B). In contrast, CD8+ T 
cells producing granzyme B were significantly increased in both Ifngr1-/- and Ifng-/- mice 
compared to WT B6 mice (Fig 4-12C; p < 0.01, Dunn’s multiple comparisons test). 
Furthermore, the mean fluorescence intensity (MFI) of granzyme B produced by CD8+ T 
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cells was significantly higher in Ifngr1-/- mice compared to WT B6 mice (Fig 4-12D; p < 
0.05, Dunn’s multiple comparisons test), indicating that individual CD8+ T cells in the 
brains of mice with impaired IFN-γ signaling produce more IFN-γ than cells with intact 
IFN-γ signaling. 
 Because CD8+ T cell production of granzyme B was significantly increased in 
Ifngr1-/- and Ifng-/- mice, we then examined mRNA expression of other granzymes in the 
brains of the different strains. At 7 DPI, expression of granzyme A (Fig 4-11E) and 
granzyme B (Fig 4-11F) was significantly lower in Ifng-/- mice compared to WT B6 (p < 
0.01 for granzyme B, Dunn’s multiple comparisons test) and Ifngr1-/- mice (p < 0.001 for 
both granzyme A and B, Dunn’s multiple comparisons test). Expression differences 
among strains for granzyme K (Fig 4-11G), granzyme M (Fig 4-11H), and perforin (Fig 
4-11I) were less pronounced. These results support that IFN-γ may inhibit production of 
granzyme B by CD8+ T cells in the brain during SINV infection, though this is not seen 
with granzyme B mRNA expression. 
 
IFN-γ signaling alters the local antibody response during SINV infection 
 IFN-γ and antibody against the E2 glycoprotein work synergistically to facilitate 
virus clearance70. To determine how IFN-γ signaling influences antibody production, 
SINV-specific IgM and IgG were measured by ELISA in the sera and brains of WT B6, 
Ifngr1-/-, and Ifng-/- mice. Serum IgM did not significantly differ over time among strains 
(Fig 4-12A; p = 0.7564, two-way ANOVA), with impaired IFN-γ signaling resulting in 
less prolonged IgM production in Ifngr1-/- and Ifng-/- mice and lower levels of SINV-
specific IgM at 10 DPI compared to WT B6 mice (p < 0.05 for both Ifngr1-/- and Ifng-/- vs 
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WT B6, Tukey’s multiple comparison test). Serum SINV-specific IgG levels steadily 
rose through 90 DPI and did not differ among strains (Fig 4-12B; p = 0.1292, two-way 
ANOVA).  
In contrast to serum, SINV-specific antibody production in the brain significantly 
differed among strains over time (Figs 4-12C and 4-12D; p < 0.0001 for both IgM and 
IgG, two way ANOVA). IgM levels were higher in WT B6 brains at 10 and 14 DPI (Fig 
4-12C; p < 0.0001 for WT B6 vs Ifngr1-/- at both time points; p < 0.001 and p < 0.0001 
for WT B6 vs Ifng-/- at 10 and 14 DPI, respectively, all Tukey’s multiple comparison 
test). IgG levels steadily increased in the brain of all three strains up to 14 DPI, where 
levels plateaued in Ifngr1-/- and Ifng-/- mice (Fig 4-12D). In contrast, IgG in WT B6 
brains continued to increase through 21 DPI, where it remained significantly higher than 
in Ifngr1-/- and Ifng-/- mice through 90 DPI (p < .001, p < 0.05, and p < 0.001 for 21, 28, 
and 90 DPI, respectively for WT B6 vs Ifngr1-/-, p < 0.001, p < 0.001, and p < 0.0001 at 
21, 28, and 90 DPI, respectively for WT B6 vs Ifng-/-, all Tukey’s multiple comparison 
test).  
Similar to brains, SINV-specific antibody production in the spinal cord 
significantly differed among strains over time (Figs 4-12E and 4-12F; p < 0.01 for IgM, p 
< 0.001 for IgG, two way ANOVA). IgM levels were higher in WT B6 spinal cords at 10 
and 14 DPI (Fig 4-12E; p < 0.01 vs Ifngr1-/- at both time points; p < 0.0001 and p < 
0.001 vs Ifng-/- at 10 and 14 DPI, respectively, all Tukey’s multiple comparison test). 
Also similar to brains, IgG increased through 90 DPI, with Ifngr1-/- and Ifng-/- mice 
having significantly lower amounts at 21, 28, and 90 DPI compared to WT B6 mice (Fig 
4-12F; p < .001, p < 0.05, and p < 0.001 for 21, 28, and 90 DPI, respectively for WT B6 
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vs Ifngr1-/-; p < 0.001, p < 0.001, and p < 0.0001 at 21, 28, and 90 DPI, respectively for 
WT B6 vs Ifng-/-, all Tukey’s multiple comparisons test). As these data show, IFN-γ 
signaling did not affect the antibody response in the periphery but did affect production 
of SINV-specific IgM and IgG at the site of infection. 
 In mice, there are four IgG subclasses: IgG1, IgG2a, IgG2b, and IgG3221-223. 
Because overall production of IgG in the brain is affected by impaired IFN-γ signaling, 
we next examined whether only certain subclasses were affected by measuring SINV-
specific levels in the brains of WT B6, Ifngr1-/-, and Ifng-/- mice. IgG1 levels did not 
significantly differ between strains (Fig 4-13A; p = 0.7824, two-way ANOVA). IgG2a 
levels, in contrast, significantly differed among strains over time (Fig 4-13B; p < 0.0001, 
two-way ANOVA) and followed a similar pattern to overall IgG, with production 
continuing to increase in WT B6 mice while plateauing in Ifngr1-/- and Ifng-/- mice (p < 
0.05 for WT B6 vs Ifngr1-/- and p < 0.05 for WT B6 vs Ifng-/- at 10 DPI, p < 0.0001 for 
WT B6 vs both strains at 14, 21, 28, and 90 DPI, all Tukey’s multiple comparisons test). 
IgG2b levels also significantly differed among strains over time (Fig 4-13C; p < 0.01, 
two-way ANOVA). WT B6 mice had increased IgG2b production compared to knockout 
strains, with significantly higher levels at 14 DPI (p < 0.01 for WT B6 vs Ifngr1-/- and p 
< 0.01 for WT B6 vs Ifng-/-, Tukey’s multiple comparisons test). SINV infection did not 
stimulate production of IgG3 in the brains of any strains except for a transient mild 
increase at 14 DPI in WT B6 mice (Fig 4-13D; p < 0.05 for WT B6 vs Ifngr1-/- and p < 
0.001 for WT B6 vs Ifng-/-, all Tukey’s multiple comparison tests) and did not 
significantly differ among strains overall (p = 0.0556, two-way ANOVA). Therefore, 
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these data show that impaired IFN-γ signaling during SINV infection did not affect 





 IFN-γ affected multiple aspects of disease and the local CNS immune response to 
SINV infection. Mice with impaired IFN-γ signaling lost less weight and had an altered 
course of clinical disease compared to WT B6 mice. In vitro, multiple antiviral genes 
were upregulated in SINV-infected neurons by IFN-γ treatment, likely contributing to 
virus clearance. In vivo, these genes were induced at lower levels in the absence of IFN-γ 
signaling. IFN-γ also had multiple immunomodulatory effects, such as altered cytokine 
and chemokine signaling in the brain. Ifngr1-/- and Ifng-/- mice had fewer brain infiltrating 
CD4+ T cells and B cells producing SINV-specific antibody but more CD8+ T cells 
producing granzyme B compared to WT B6 mice. Finally, though IFN-γ was capable of 
clearing viral RNA from neurons in vitro, viral RNA clearance from the brain and spinal 
cord was initiated later in WT B6 mice compared to Ifngr1-/- and Ifng-/- mice. These 
findings highlight the multifaceted effects IFN-γ exerts during virus infection. 
 IFN-γ primarily exerts its antiviral effects through antiviral gene expression 
upregulation via its signaling pathway. Using microarray, we identified several different 
genes upregulated by IFN-γ treatment during SINV infection. Gbp2 and Irgm1, genes 
encoding proteins associated with autophagy, were the most highly induced by IFN-γ 
signaling in SINV-infected mouse brains and spinal cords. Autophagy is an autonomous 
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process by which cells can destroy virus or viral replication components present in the 
cytosol or deliver them to TLR-associated endosomes for induction of the innate immune 
response, particularly Type I IFNs224-227. IRGM associates with four proteins that 
contribute to autophagy and interacts with mitochondria via cardiolipin, suggesting that it 
mediates autophagosome biogenesis from the mitochondrial membrane228,229. Several 
RNA viruses target IRGM to inhibit autophagosome maturation or induce 
autophagosome formation to promote virus replication, including measles virus, CHIK, 
Japanese encephalitis virus (JEV), HIV, and HCV229-235. The localization of GBP2, a 
guanylate binding protein member of the dynamin protein superfamily implicated in 
vacuolar processing, to autophagosomes is influenced by IRGM 216,236. GBP2 inhibits 
replication of VSV and EMCV in vitro and also combats other pathogens, such as 
protozoa and bacteria237-241. 
 Another antiviral protein system that is highly induced by IFN-γ signaling during 
SINV infection was the 2’-5’-oligoadenylate synthetase (OAS) family. Oasl2 was 
identified as a gene of interest by microarray analysis of rat neuronal cells, and Oas1a 
was additionally examined in mouse CNS tissue, as it is considered to have more OAS 
activity217. When bound by dsRNA, 2’-5’ OAS proteins catalyze the production of short 
2’-5’ oligoadenylates (2-5’A) from ATP, which in turn activate latent RNase L, an 
endonuclease that degrades both cellular and viral ssRNAs106,242. Mechanisms by which 
RNase L can restrict virus propagation include viral genome and mRNA degradation, 
rRNA degradation (which restricts viral mRNA translation), and amplification of type I 
IFN signaling243. Several neurotropic viruses, including rabies virus and JEV induce this 
pathway244. Similar to autophagy, the 2’-5’ OAS/RNase L system is commonly targeted 
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by viruses via mechanisms such as dsRNA sequestration, 2-5’A degradation, production 
of inactive or inhibitory 2-5’A, competitive inhibition or binding of RNase L, and genetic 
avoidance of RNase L cleavage243. 
 Two other antiviral genes usually more robustly induced by type I, rather than 
type II, IFNs, Rsad2 and Zc3hav1, were also examined. Rsad2 encodes viperin, a protein 
that associates with the cytosolic face of the endoplasmic reticulum (ER) and with lipid 
droplets245,246. Viperin disrupts lipid rafts and increases plasma membrane fluidity, 
leading to impaired budding of enveloped viruses such as influenza A and HIV-1247-249. It 
also associates with flavivirus and alphavirus proteins on lipid droplets and the ER, 
respectively, inhibiting virus replication and assembly250-253. Type I IFN production by 
dendritic cells is also influenced by viperin through modulation of TLR7 and TLR9 
signaling254. Unsurprisingly, certain viruses utilize viperin to their advantage by 
disrupting the cytoskeleton to increase virus infectivity or degrading it to circumvent its 
antiviral effects255,256. Zc3hav1 encodes ZAP, also know as PARP13, a RNA binding 
protein that modulates the cellular response to stress257. ZAP decreases production of 
several different viruses by recruiting RNA decay factors to degrade viral RNA and 
inhibiting viral RNA translation107,258-261. It also represses the miRNA pathway, leading 
to upregulation of antiviral transcripts and induction of the antiviral state262. Induction of 
all of these genes during SINV infection highlights the multi-faceted approach by which 
IFN-γ may mediate virus clearance. 
 Microarray analysis of brains of SINV-infected WT B6, Ifngr1-/-, and Ifng-/- mice 
revealed that expression of multiple genes involved in the innate and adaptive immune 
response were affected by IFN-γ signaling. Compared to WT B6 mice, expression of Tlr3 
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and Tlr9, as well as the TLR-associated adaptor protein Myd88, were all decreased in 
mice with impaired IFN-γ signaling. TLR3, which recognizes dsRNA, and TLR9, which 
recognizes CpG motifs, are expressed intracellularly within endosomes, lysosomes, and 
multivesicular bodies263. Expression of certain intracellular PRR genes, including Nod1 
and the inflammasome-associated Nlrp3, were also decreased in mice with IFN-γ-
impaired signaling. Signaling through these proteins leads to transcriptional activation of 
both innate and adaptive immune responses264. Innate response effectors include type I 
IFN’s, proinflammatory cytokines, complement, and phagocytosis. Adaptive immune 
response effectors include T cell activation through induction of dendritic cell maturation 
and cytokine production, such as IFN-γ.  
 IFN-γ affects production of the type I IFNs, IFN-α and IFN-β. Local production 
of type I IFN’s is important for the initial control of virus replication, and mice deficient 
in type I IFN signaling are highly susceptible to many neurotropic viruses69-72,265. IFN-α 
and IFN-β production were decreased in the brains of Ifngr1-/- and Ifng-/- mice compared 
to WT B6 mice at 5 and 3 DPI, respectively. Interestingly, both IFN-α and IFN-β levels 
were significantly higher in the brains of Ifng-/- mice at 1 DPI compared to WT B6 and 
Ifngr1-/- mice. Expression of Stat1 and some of the antiviral ISGs examined were also 
significantly upregulated in Ifng-/- mice at 1 DPI. This might have been driven by higher 
levels of both infectious virus and viral RNA in the brain and viral RNA in the spinal 
cord at 1 DPI in these mice. This suggests that IFN-γ plays a role early in infection, even 
before T cells are able to infiltrate the site of infection. These differences in virus 
replication and immune gene expression, as well as clinical disease, seen between Ifng-/- 
and Ifngr1-/- mice serve as a reminder that the two strains should not be considered 
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equivalent, and suggest that some IFN-γ signaling still occurs in Ifngr1-/- mice, either 
through the mutated receptor or another mechanism266-269. 
 Most of the pathological changes seen with alphavirus encephalomyelitis are 
associated with the inflammatory effects of infiltrating immune cells, rather than direct 
virus-induced cell death39,41,49,55,56,270. IFN-γ signaling significantly affected expression of 
several proinflammatory cytokines, including Tnf, Csf2, Il1b, and Il6. These genes can be 
expressed by both infiltrating leukocytes and activated resident microglia to contribute to 
immune cell recruitment and CNS pathological changes86. Upregulation of these genes, 
particularly Tnf, can have a profound effect on clinical disease and provides a possible 
explanation for the decreased appetites leading to weight loss seen in WT B6 mice 
compared to Ifngr1-/- and Ifng-/- mice271,272. Future studies microscopically examining 
brains affected by nonfatal alphavirus encephalomyelitis in the absence of IFN-γ 
signaling are warranted to better understand this mechanism. 
 Expression of several chemokines was up-regulated in the brains of WT B6 mice 
more than in Ifngr1-/- and Ifng-/- mice, including Ccl2, Ccl5 (RANTES), Cxcl9, Cxcl10, 
and Cxcl13. CCL-2, RANTES, CXCL9, and CXCL10 all play important roles in 
microglial activation and leukocyte migration in the CNS during flavivirus, alphavirus, 
and coronavirus infection and during experimental autoimmune 
encephalomyelitis41,91,269,273-278. CXCL9 and CXCL10 in particular are important for 
chemotaxis of B cells into the brain during SINV infection, and CXCL13 is important in 
non-lymphoid tissue formation of B cell follicles for local antibody production91. 
Interestingly, Ifng-/- mice have much higher expression of Ccl1 than WT B6 or Ifngr1-/- 
mice during the first 10 DPI. CCL1, also known as I-309, is an important chemoattractant 
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of monocytes, natural killer (NK) cells, and regulatory T cells and is generally associated 
with a Th2 response279-281. Upregulation of Ccl1 has been associated with T cell growth 
transformation during herpesvirus infection and eosinophil migration into the CNS during 
bornavirus infection99,282. 
Previous studies have shown that IFN-γ facilitates clearance of infectious virus 
from neurons during SINV infection93. In this study, we found that IFN-γ is capable of 
clearing both infectious virus and viral RNA in neurons in vitro. In examining mice 
deficient in IFN-γ or IFN-γ receptor, infectious virus was cleared more quickly from the 
spinal cords of mice with intact IFN-γ signaling. Surprisingly however, clearance of viral 
RNA was initiated earlier in the brains and spinal cords of Ifng-/- and Ifngr1-/- mice 
compared to WT B6 mice. This indicates that while IFN-γ is capable of clearing viral 
RNA from neurons, alternative effects produced by IFN-γ, likely via immunomodulation, 
influence viral RNA clearance from the CNS.  
During SINV TE infection, CD8+ T cells are the first lymphocyte population to 
infiltrate the brain42. Peak numbers of infiltrating mononuclear cells are reached at 7 DPI 
in the brain, with CD8+ T cells the predominant population. Following decline in CD8+ 
T cell numbers, increased numbers of CD4+ T cells and B cells enter the brain. At 7 
and/or 10 DPI, fewer CD4+ T cells and CD19+ B cells infiltrated the brain in Ifngr1-/- 
and Ifng-/- mice compared to WT B6 mice. Interestingly, at 7 DPI, significantly more 
CD8+ T cells were present in the brains of mice with impaired IFN-γ signaling compared 
to mice with intact IFN-γ signaling. This occurred despite WT B6 mice having overall 
higher numbers of mononuclear cells in the brain at this time. As the effector functions of 
each of these lymphocyte cell populations can influence both the neuronal damage 
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inflicted during infection and the clearance and control of the virus, further examination 
of how these cells functioned in response to IFN-γ signaling was warranted. 
 CD4+ T cells primarily exert their effects via cytokine secretion, which 
differentiates the cells into Th subsets and influences the actions of other immune cells, 
such as activation of CD8+ T cells and antibody class switching in B cells283. To 
understand how IFN-γ influenced the functionality of the CD4+ T cells, we assessed the 
cytokine profiles of CD4+ T cells at 7 DPI in mice with intact and deficient IFN-γ 
signaling by flow cytometry and qRT-PCR for mRNA expression. As IFN-γ is the 
signature cytokine secreted by Th1 cells, these cells could not be defined in Ifng-/- mice, 
and expression of Il2, another cytokine associated with Th1 cells, was significantly lower 
in Ifng-/- mice. Despite this, Ifng-/- mice did not compensate by skewing to a different Th 
profile. In fact, IL-4 production, which is used to define Th2 cells, was significantly 
lower in Ifng-/- mice, despite increased Ccl1 expression, which is associated with a Th2 
response. Treg cells, defined by expression of both Foxp3 and CD25, also trended to be 
lower in Ifng-/- mouse brains, and mRNA expression of the regulatory cytokine IL-10 was 
significantly lower compared to WT B6 and Ifngr1-/- mice at 7 DPI. This could be 
important, as IL-10 promotes the recruitment, proliferation, and cytotoxic activity of 
CD8+ T cells and promotes antibody class switching in B cells284-288. Ifngr1-/- mice had 
significantly increased Il17a mRNA expression and trended towards increased IL-17a 
production in CD4+ T cells compared to WT B6 and Ifng-/- mice. Similar results were 
seen in Ifngr1-/- mice infected with NSV and suggest Th17 cells are preferentially 
expanded269. Il-17 has been associated with fatal encephalomyelitis and virus persistence 
during infection with several viruses, such as SINV NSV, TMEV, JHMV, and HSV-1, 
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especially in the absence of IFN-γ56,289-292. These results show that IFN-γ signaling does 
affect CD4+ function, through dramatic Th profile skewing is not seen, and reiterates the 
differences between mice lacking IFN-γ production and mice with impaired receptor 
function and thus signaling, in the immune response to SINV infection. 
CD8+ T cells, frequently known as cytotoxic lymphocytes (CTLs), primarily 
exert their effector function against virus infections though cytotoxic activity. They 
secrete proinflammatory cytokines with antiviral activity, such as IFN-γ and TNF-α, and 
produce granzyme B and perforin293. Classically, granzyme B and perforin are known for 
their contributions to cytolytic activity upon delivery into a target cell via the granule 
exocytosis pathway, where apoptosis is induced by activation of caspases294-296. By 
specifically targeting infected cells by this mechanism, the immune response can provide 
a more focused and direct response to virus infection beyond what IFN’s can provide. 
However, this process is classically achieved through direct contact between CTLs and 
an infected cell expressing MHC Class I molecules. Neurons have at best limited capacity 
for MHC Class I expression, and induction of apoptosis by CTLs results in loss of 
valuable cells with limited regenerative capacity297-301. Despite this, CD8+ T cells have 
been shown to form T cell extended processes and directly engage with TMEV-infected 
neurons, indicating the CD8+ T cells can interact with neurons83. Granzymes have long 
been considered to be exclusively cytotoxic, but recently non-cytotoxic roles of 
granzymes have become recognized. Though the suggestion of granzymes performing 
non-apoptotic roles was first made almost 30 years ago, the proinflammatory capacity of 
granzymes has only been confirmed within the last ten years302-305. Mouse granzyme K 
induces macrophages to release IL-1β and has been suggested to play a pro-
	   126	  
inflammatory, non-cytotoxic role during LCMV infection306. Clearance of both WNV 
and LCMV from neurons is dependent on the granzyme/perforin pathway307,308. 
 We found that mice deficient in IFN-γ signaling had more CD8+ T cells 
producing granzyme B in the brain during peak infiltration time than WT B6 mice. 
During SINV NSV infection, increased perforin production is also seen in the brains of 
Ifngr1-/- and Ifng-/- mice269. In contrast, absence of IFN-γ correlates with decreased MHC 
Class I expression by resident microglia and impaired perforin-mediated effector function 
during JHMV infection, and IFN-γ has been shown to promote granzyme B production 
during experimental coronavirus retinopathy309,310. Therefore, the effect of IFN-γ on the 
granule exocytosis pathway during CNS infection appears to be virus-specific, and the 
mechanisms by which IFN-γ influences granzyme B production during SINV infection 
remain to be understood. 
 Recently, granzyme substrates with direct antiviral activity, either viral proteins or 
host cell proteins essential for virus replication, have been identified. Granzymes A, H, 
and M have each been shown to cleave viral proteins important in virus replication for 
Moloney mouse leukemia virus, adenovirus, and HCMV, respectively311-313. CD8+ T 
cells can also recognize neurons latently infected with HSV-1 and inhibit reactivation via 
a non-cytolytic mechanism314-316. Granzymes B and H both cleave the RNA-binding 
protein La, which is important in viral RNA metabolism for several viruses, including 
HCV, HBV, and JEV317-319. The RNA-binding protein hnRNP K, which modulates viral 
RNA replication of CHIKV, enterovirus 71, dengue virus, and HIV-1, is a substrate for 
granzyme B cleavage320-323. hnRNP K interacts with SINV nsp2 and subgenomic mRNA, 
and silencing of hnRNP K leads to decreased SINV RNA replication in vitro324,325. Based 
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on these studies, we postulate that the increased granzyme B produced by Ifngr1-/- and 
Ifng-/- CD8+ T cells cleaves cellular proteins important for SINV RNA replication and 
stability to explain the accelerated viral RNA clearance seen in the brain and spinal cord 
of these mice. Further studies regarding viral RNA clearance, as well as non-cytotoxic 
roles of granzymes during SINV infection, are warranted. 
 Previous mouse studies have shown that clearance of infectious SINV is 
accomplished cooperatively between anti-SINV antibody and IFN-γ, but the mechanisms 
by which this occurs are not well understood. Production of SINV-specific IgM and IgG 
in the sera did not significantly differ among WT B6, Ifngr1-/-, and Ifng-/- mice70. Here, 
while we confirmed that IFN-γ signaling does not affect anti-SINV IgM and IgG levels in 
the serum, both IgM and IgG in the brain and spinal cord were decreased in Ifngr1-/- and 
Ifng-/- mice compared to WT B6 mice. Because the number of B cells present in the 
CLNs did not differ among strains but were significantly lower in the brains of mice with 
impaired IFN-γ signaling, these findings are likely due to differences in local B cell 
production of anti-SINV antibody during infection. Expression of chemokine mRNAs 
Cxcl9, Cxcl10, and Cxcl13, which are all important for inducing migration and promoting 
survival of antibody-secreting cells (ASCs) during SINV infection91, were reduced in 
Ifngr1-/- and Ifng-/- mouse brains compared to WT B6 mice. Therefore, IFN-γ-induced 
expression of B cell-associated chemokines affects migration and maintenance of ASCs 
in the CNS and thus local production of antibody. The promotion of local antibody 
production provides a mechanism by which IFN-γ may clear infectious SINV from the 
CNS. 
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 As previously reported, absence of IFN-γ signaling did not affect levels of IgG 
subclass-specific SINV antibody in the sera of SINV-infected mice70. However, the 
current studies showed that production of IgG2a and IgG2b, but not IgG1, were 
decreased in the brains of Ifngr1-/- and Ifng-/- mice compared to WT B6 mice. Our results 
are consistent with previous observations that Th1 cells producing IFN-γ induce IgG 
subclass switching towards IgG2a, while Th2 cells producing IL-4 and IL-13 promote 
subclass switching towards IgG1 and away from IgG2a326,327. This also suggests that IgG 
subclasses IgG2a and IgG2b specifically play a role in antibody-mediated clearance of 
SINV. 
 In conclusion, IFN-γ signaling mediates clearance of both infectious SINV and 
viral RNA from neurons. However, beyond induction of antiviral ISGs, clearance of 
SINV is also influenced by IFN-γ through modulation of the immune response. During 
SINV infection in the CNS, IFN-γ promotes local B cell production of anti-SINV IgM 
and IgG and inhibits infiltration of granzyme B-producing CD8+ T cells. Understanding 
the non-cytolytic functions of granzyme B/perforin during SINV infection could help 
better understand the mechanisms by which virus, specifically viral RNA, are cleared 











Figure 4-1. Effect of IFN-γ treatment on virus clearance in vitro. (A,B) Infectious 
virus titers were measured by plaque assay for cAP-7 (gray line) and dAP-7 (black line) 
cells (A) infected at a MOI of 5, and for dAP-7 cells (B) infected with SINV at a MOI of 
1 and treated with 500U/mL IFN-γ 2 hours prior to infection (gray square and solid line; 
SINV, IFN-γ Pre-Txt), at 2 HPI (white circle and black dashed line; SINV, IFN-γ Txt 2 
HPI), at 24 HPI (white square and gray dashed line; SINV, INF-γ Txt 24 HPI) or 
untreated (black circle and solid line; SINV Alone) (n = 3 replicates per cell line per 
treatment group; data presented as the mean ± SEM; dashed line indicates level of 
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detection; ****p < 0.0001, SINV Alone vs SINV, IFN-γ Pre-Txt; #p < 0.05, ##p < 0.01, 
###p < 0.001, SINV Alone vs SINV, IFN-γ Txt 2 HPI by Tukey’s multiple comparisons 
test). (C,D) dAP-7 cells were infected with SINV at a MOI of 1 and were either left 
untreated or treated with 500U/mL IFN-γ at 2 HPI. (C) Nonstructural (nsp3) and 
structural (pE2, E1/E2, capsid) SINV protein production was evaluated by western blot 
using beta actin as control. (D) Viral RNA levels were evaluated by qPCR in untreated 
(black circle and solid line) and IFN-γ-treated (white circle and black dashed line) dAP-7 
cells (n = 3 replicates per treatment group; data presented as the mean ± SEM; ****p < 
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Figure 4-2. Effect of IFN-γ treatment on ISG expression during SINV infection in 
vitro. (A) A cluster analysis was performed and a heat map was constructed to display 
microarray results examining relative gene expression for dCSM14.1 cells that were 
mock-infected (red), SINV-infected but untreated and collected at 24 HPI (green) or 27 
HPI (purple), and mock-infected (blue) or SINV-infected (orange) and treated at 24 HPI 
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with 100U/mL IFN-γ and collected at 27 HPI. Red represents a positive relative fold-
change in gene expression, and blue represents a negative relative fold-change in gene 
expression. The positions of the five genes with putative antiviral activity are denoted to 
the left of the heat map. (B-F) ISGs selected for further examination by qRT-PCR in 
cAP-7 (left graphs) and dAP-7 cells (right graphs) infected with SINV at a MOI of 1 and 
left untreated (black circle and solid line), mock-infected and treated with 500U/mL IFN-
γ at 2 HPI (gray square and solid line), or SINV-infected with a MOI of 1 and treated 
with 500U/mL IFN-γ at 2 HPI (white circle and black dashed line) included Gbp2 (B), 
Irgm (C), Oasl2 (D), Rsad2 (E), and Zc3hav1 (F) (n = 3 replicates per group; data 
represented as mean ± SEM; dashed line indicates gene expression of untreated, mock-
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Figure 4-3. Ifng mRNA expression and IFN-γ protein production in mice with intact 
and impaired IFN-γ signaling. (A) Ifng mRNA expression was determined by qRT-
PCR in SINV-infected WT B6 (black circle and line) and Ifngr1-/- (gray square and line) 
mouse brains normalized to mock-infected controls for each strain. (B) IFN-γ protein 
production was measured by ELISA in SINV-infected WT B6 (black circle and line) and
Ifngr1-/- (gray square and line) mouse brains (n = 3-11 mice per strain per time point; data 
presented as the mean ± SEM; doted line represents the limit of detection for the assay; 
****p < 0.0001 by Bonferoni’s multiple comparisons test). 
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Figure 4-4. Clinical disease in SINV-infected WT B6, Ifngr1-/-, and Ifng-/- mice. (A) 
SINV-infected WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), 
and Ifng-/- (white circle and black dashed line) mice were evaluated daily for the presence 
of clinical disease (n = 23-38 mice per strain combined from three to five independent 
experiments) (B,C) Body weights of SINV-infected (B) and mock-infected (C) mice 
were measured daily and normalized to the body weight at 0 DPI (n = 13-38 mice per 
strain combined from three to five independent experiments; dashed line indicates initial 
body weight). (D) Body temperature was measured rectaly daily (n = 8 mice per strain; 
dashed line indicates reported normal rectal temperature for mice). (E) Daily feed 
consumption was measured for 2-3 mice housed per cage, with feed intake of SINV-
infected mice normalized first to that of mock-infected mice for each strain for each day 
and then to the feed intake at 0 DPI for that cage (n = 7-10 cages per strain combined 
from two independent experiments; dashed line indicates baseline feed intake). (F) Serum 
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leptin levels were measured by ELISA at 0, 5, 7, and 10 DPI in SINV-infected WT B6 
(black bars), Ifngr1-/- (gray bars), and Ifng-/- (white bars) mice (n = 4-11 mice per strain 
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Figure 4-5. Infectious virus and viral RNA clearance in mice with impaired IFN-γ
signaling. Infectious virus titers (A, B) were examined by plaque assay, and viral RNA 
levels (C, D) were examined by qRT-PCR in brains (A, C) and spinal cords (B, D) of 
WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), and Ifng-/-
(white circle and black dashed line) mice (n = 3-8 mice per strain per time point; data 
presented as the mean ± SEM; dashed line indicates limit of detection for the plaque 
assay; *p < 0.05, ***p < 0.001, WT B6 vs Ifngr1-/-; #p < 0.05, ##p < 0.01, ###p < 0.001, 
WT B6 vs Ifng-/-, al by Tukey’s multiple comparisons test).
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Figure 4-6. ISG expression in SINV-infected mice with impaired IFN-γ signaling. 
Expression of Gbp2 (A), Irgm1 (B), Oasl2 (C), Oas1a (D), Rsad2 (E), and Zc3hav1 (F) 
were examined by qRT-PCR in the brains (left panels) and spinal cords (right panels) of 
WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), and Ifng-/-
(white circle and black dashed line) mice (n = 3-6 mice per strain per time point; data 
presented as the mean ± SEM; dashed line indicates gene expression of 0 DPI tissue for 
each strain to which other time points were normalized; *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001, WT B6 vs Ifngr1-/-; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p <
0.0001 WT B6 vs Ifng-/-; †p < 0.05, ††p < 0.01, †††p < 0.001, ††††p < 0.0001, Ifngr1-/- vs 
Ifng-/-, al by Tukey’s multiple comparisons test). 
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Figure 4-7. Expression of immune response genes in SINV-infected mice  with 
impaired IFN-γ signaling. (A) A heat map was constructed to display microaray results 
examining relative expression of 84 genes in WT B6, Ifngr1-/-, and Ifng-/- mouse brains at 
7 DPI. Red represents a positive relative fold-change in gene expression, and green 
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represents a negative relative fold-change in gene expression. (B, C) Protein levels of 
IFN-α (B) and IFN-β (C) were examined by ELISA in WT B6 (black circle and solid 
line), Ifngr1-/- (gray square and solid line), and Ifng-/- (white circle and black dashed line) 
mouse brains (n = 3-4 mice per strain per time point; dashed line indicates level of 
detection of assay). (D-U) Selected genes examined for mRNA levels by qRT-PCR in 
individual WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), and 
Ifng-/- (white circle and black dashed line) mouse brains included Tnf (D), Csf2 (E), Il6 
(F), Il1b (G), Ccl1 (H), Ccl2 (I), Ccl5 (J), Cxcl9 (K), Cxcl10 (L), Cxcl13 (M), Il2 (N), 
Il4 (O), Il17a (P), Il10 (Q), Tbx21 (R), Gata3 (S), Rorc (T), and Foxp3 (U) (n = 3-4 mice 
per strain per time point; data presented as the mean ± SEM; dashed line indicates gene 
expression of 0 DPI brains for each strain to which other time points were normalized; *p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, WT B6 vs Ifngr1-/-; #p < 0.05, ##p < 
0.01, ###p < 0.001, ####p < 0.0001 WT B6 vs Ifng-/-; †p < 0.05, ††p < 0.01, †††p < 0.001, 
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Figure 4-8. Expression of pathogen recognition receptor and associated signaling 
genes in SINV-infected mice with impaired IFN-γ signaling. Select genes involved in 
pathogen-associated molecular patern recognition were examined by qRT-PCR in 
individual WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), and
Ifng-/- (white circle and black dashed line) mouse brains and included Tlr3 (A), Tlr7 (B), 
Tlr8 (C), Tlr9 (D), Myd88 (E), Nod1 (F), Nlrp3 (G), Stat1 (H), and Stat3 (I) (n = 3-4 
mice per strain per time point; data presented as the mean ± SEM; dashed line indicates 
gene expression of 0 DPI brains for each strain to which other time points were 
normalized; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, WT B6 vs Ifngr1-/-; 
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#p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 WT B6 vs Ifng-/-, all by Tukey’s 
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Figure 4-9. Role of IFN-γ signaling in lymphocyte proliferation and infiltration into 
the brain during SINV infection. (A, B) Total live mononuclear cells were evaluated in 
the CLNs (A) and brains (B) of WT B6 (black bars), Ifngr1-/- (gray bars), and Ifng-/- 
(white bars) mice by trypan blue exclusion at 5, 7, and 10 DPI (n = 3-7 pooled mice per 
strain per time point from five independent experiments). (C-H) Flow cytometry was 
used to evaluate changes in the CLNs (C, E, G) and infiltration into the brain (D, F, H) 
of CD4+ T cells (C, D), CD8+ T cells (E, F), and CD19+ B cells (G, H). Cell data are 
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graphs) (n = 3-7 pooled mice per strain per time point from three independent 
experiments; data presented as the mean SEM; *p < 0.05, **p < 0.01, ***p < 0.001, by 
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Figure 4-10. T helper cel profiles in brains of mice with impaired IFN-γ signaling at 
7 DPI. Flow cytometry was used to examine the percentage of CD4+ T cels producing 
IFN-γ (A), IL-4 (B), IL-17a (C), or expressing both Foxp3 and CD25 (D) in WT B6 
(black bars), Ifngr1-/- (gray bars), and Ifng-/- (white bars) mice at 7 DPI. These markers 
denoted Th1, Th2, Th17, and Treg cel populations, respectively (n = 3-7 pooled mice per 
strain per time point from three independent experiments; data presented as the mean
SEM; *p < 0.05 by Dunn’s multiple comparisons test). 
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Figure 4-11. CD8+ T cel function during SINV infection in WT B6, Ifngr1-/-, and 
Ifng-/- mouse brains at 7 DPI. (A-C) Flow cytometry was used to evaluate the 
percentage of CD8+ T cels producing IFN-γ (A), TNF-α (B), and granzyme B (C) in WT 
B6 (black bars), Ifngr1-/- (gray bars), and Ifng-/- (white bars) mice at 7 DPI. (D) MFI 
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presented in graph form (left) and as a histogram (right) was used to evaluate the amount 
of granzyme B produced by individual CD8+ T cells among strains (n = 3-7 pooled mice 
per strain per time point from three independent experiments; *p < 0.05, **p < 0.01 by 
Dunn’s multiple comparisons test). (E-I) Relative mRNA expression of granzyme A (E), 
granzyme B (F), granzyme K (G), granzyme M (H), and perforin (I) were examined by 
qRT-PCR in WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), 
and Ifng-/- (white circle and black dashed line) mouse brains (n = 3-4 mice per strain per 
time point; data presented as the mean ± SEM; dashed line indicates gene expression of 0 
DPI tissue for each strain to which other time points were normalized; *p < 0.05, WT B6 
vs Ifngr1-/-; ##p < 0.01, WT B6 vs Ifng-/-, †p < 0.05, †††p < 0.001, Ifngr1-/- vs Ifng-/-, all by 
Tukey’s multiple comparisons test). 
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Figure 4-12. Efect of IFN-γ on SINV-specific antibody production. Anti-SINV IgM 
(A, C, E) and IgG (B, D, F) were measured in the serum (A, B), brains (C, D), and spinal 
cords (E, F) of WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), 
and Ifng-/- (white circle and black dashed line) mice by ELISA (n = 3-4 mice per strain 
per time point, except for Ifngr1-/- 90 DPI spinal cords, where n = 2; data are presented as 
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Ifngr1-/-; #p < 0.05, ###p < 0.001, ####p < 0.0001, WT B6 vs Ifng-/-; †p < 0.05, ††p < 0.01, 
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Figure 4-13. Efect of IFN-γ on production of anti-SINV IgG subclasses in the brain.
Anti-SINV IgG1 (A), IgG2a (B), IgG2b (C), and IgG3 (D) were measured in brains of 
WT B6 (black circle and solid line), Ifngr1-/- (gray square and solid line), and Ifng-/-
(white circle and black dashed line) mice by ELISA (n = 3-4 mice per strain per time 
point; data are presented as mean ODs± SEM; *p <0.05, **p <0.01, ***p <0.001, 
****p < 0.0001, WT B6 vs Ifngr1-/-; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, 
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TABLES 
Table 4-1. Relative fold-change expression of select ISGs in SINV-infected, IFN-γ-
treated dCSM14.1 cels 
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INTRODUCTION 
 
 Sindbis virus (SINV) is the prototypic member of the alphaviruses, a genus of 
enveloped, positive-sense, single stranded RNA viruses belonging to the Togaviridae 
family8. SINV is neurotropic in mice, and when susceptible mice are infected with the 
nonfatal TE strain, infection in the CNS occurs in the three phases42. High levels of both 
infectious virus and viral RNA characterize Phase 1, which occurs from 0 to 
approximately 7 or 8 DPI. Phase 2, which occurs from 10 to 60 DPI, is characterized by 
undetectable infectious virus and high but declining levels of viral RNA. By Phase 3 of 
infection, which starts around 60 DPI and continues for at least a year following 
infection, viral RNA has reached a detectable low-level steady state. Because the 
alphavirus genomic RNA is infectious, the immune system must control persistent viral 
RNA present in the brain and spinal cord from reactivating and causing disease relapse. 
Anti-SINV antibody and interferon gamma (IFN-γ) are known to synergistically mediate 
clearance of infectious SINV, but the immune mechanisms that control RNA clearance 
and prevent virus reactivation are not well elucidated24,92.  
 During acute virus infection, the T cell response can be categorized into three 
main phases109. During the clonal expansion phase in the local draining lymph nodes, 
activated CD4+ and CD8+ T cells expand primarily via IL-2 production, leave the lymph 
nodes, and migrate to the site of infection. These cells acquire effector function during 
this time and can secrete antiviral cytokines such as IFN-γ and tumor necrosis factor 
alpha (TNF-α) and produce cytotoxic proteins such as granzyme and perforin for CD8+ T 
cells110. Once active virus replication is brought under control, the short-term effector 
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(TEFF) T cell population contracts considerably, and memory T cells become the 
predominant population128.  
 Memory T cells are generally categorized as central memory (TCM) or effector 
memory (TEM) cells based on their proliferative and functional capacities116. TCM cells 
express CD62L and home to secondary lymphoid organs; they possess considerable 
proliferative potential but have little effector capacity. TEM cells in contrast lack CD62L 
and readily circulate throughout the body; they possess little proliferative capacity but are 
primed to immediately release effector proteins upon encountering viral antigen to which 
they are sensitized. Maintenance of these memory T cells is primarily achieved through 
IL-7 and IL-15 signaling127. IL-7 is thought to support T cell survival through promotion 
of anti-apoptotic protein expression, and IL-15 promotes low-level proliferation of T cells 
to maintain the memory population pool132,328.  
 A recently characterized T cell population found to play an increasingly important 
role in long-term cellular immunity is the tissue-resident memory T (TRM) cell. TRM cells 
express CD103 and permanently reside at previous sites of infection without recirculating 
through the blood or lymph to secondary lymphoid tissues120. Similar to TEM cells, they 
possess a high effector capacity and serve as a first line of defense against reencountered 
pathogens in nonlymphoid tissues, providing an accelerated antiviral response and 
presumably virus clearance121. TRM presence in tissues has been shown following 
clearance of several viruses, including vaccinia virus in the skin, LCMV in the intestinal 
epithelium, salivary glands, and female reproductive tract, VSV in the salivary glands 
and brain, influenza A in the lung, and herpes simplex virus (HSV) in the skin and 
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sensory ganglia117,119,121-126,315,329-331. The role of TRM cells following initial clearance of 
SINV in the CNS has not yet been characterized. 
 Because cellular immunity likely plays a significant role in controlling SINV 
long-term, it is important to characterize the populations of T cells present in the brains at 
each phase of SINV infection. We hypothesize that following clearance of infectious 
virus, memory T cells will be present in the brain and provide protection against virus 
reactivation through production of antiviral effector cytokines, such as IFN-γ. To test 
this, we infected C57BL/6 with the nonfatal TE strain of SINV and used flow cytometry 
to define the different T cell populations and assess their effector capacity.  
  
 
MATERIALS & METHODS 
 
Sindbis Virus Infection of Mice 
Four to six week-old wild-type C57BL/6 mice, mice deficient in IFN-γ receptor 1 
(Ifngr1-/-, strain B6.129S7-Ifngtm1Ts/J), and mice deficient in IFN-γ (Ifng-/-, strain 
B6.129S7-Ifngr1tm1Agt/J, Jackson Labs) were intracranially inoculated with 103 pfu of the 
nonfatal TE strain of SINV diluted in 20µL PBS or 20µL PBS vehicle while under light 
isoflurane anesthesia37. At sacrifice, mice were euthanized by an overdose of isoflurane 
anesthesia, and cervical lymph nodes (CLNs) and brains were collected. Equal numbers 
of male and female mice were used in experiments whenever possible. The Johns 
Hopkins University Institutional Animal Care and Use Committee approved all studies 
performed.  
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Mononuclear Cell Isolation 
 Single cell suspensions were made from CLNs and brains pooled from two to 
seven mice per strain per time point. CLNs were dissociated in RPMI + 1% FBS using 
gentleMACS C tubes and Dissociator (Miltenyi Biotech) and filtered through a 70µm-
pore-size cell strainer. After pelleting by centrifugation, red blood cells were lysed using 
an ammonium chloride solution (Sigma-Aldrich or Ebioscience). Remaining cells were 
filtered through another 70µm strainer, pelleted by centrifugation, and resuspended in 
PBS + 2mM EDTA (PE buffer) for counting. Brains were placed in RPMI media 
containing 1% FBS, 1 mg/mL collagenase D (Roche) or 0.5 mg/mL collagenase IV 
(Worthington labs), and 0.1 mg/mL DNase I (Roche) and dissociated in C tubes using a 
gentleMACS Dissociator. Tissues were incubated for 30 minutes at 37°C with periodic 
agitation, and dissociated cells were filtered through a 70µm-pore-size cell strainer and 
pelleted by centrifugation. Cell pellets were resuspended in 30% supplemented Percoll 
[9:1 Percoll (GE Healthcare) : 10X salt solution of 80g NaCl, 3g KCl, 0.73g Na2HPO4, 
0.2g KH2PO4, and 20g glucose in 1L dH2O] in RPMI media in a 15mL conical tube and 
underlaid with 70% supplemented Percoll in RPMI media. Tubes were centrifuged at 850 
x g at 4°C for 30 minutes with slow braking to create a gradient, and cells were collected 
from the 30/70% interface. Cells were pelleted by centrifugation and resuspended in PE 
buffer for counting. Live mononuclear cells were quantified by trypan blue exclusion. 
 
Flow Cytometry 
	   156	  
 106 live cells were placed in the wells of a 96-well round bottom plate. A violet 
LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) diluted in PE buffer was 
applied to cells for 30 minutes, followed by a 15-minute incubation with anti-mouse 
CD16/CD32 (BD Pharmingen) diluted in PE buffer to block Fc receptors. Cells were 
stained with monoclonal antibodies against CD45 (clone 30-F11), CD3 molecular 
complex (clone 17A2), CD3e (clone 145-2C11), CD4 (clone RM4-5), CD8 (clone 53-
6.7), NK1.1 (clone PK136), CD44 (clone IM7), CD62L (clone MEL-14), CD127 (clone 
A7R34), CD103 (clone 2E7), PD-1 (clone J43), and TIM-3 (clone RMT3-23) from 
Ebioscience or BD Pharmingen diluted in PBS + 2mM EDTA + 0.5% BSA (FACS 
Buffer) for 30 minutes on ice. For intracellular staining of Ki67, cells were fixed for 20 
minutes using Fixation/Permeabilization solution from the Ebioscience 
Foxp3/Transcription Factor Staining Buffer kit. Cells were stained for 20 minutes at 4°C 
with a mouse anti-human monoclonal antibody against Ki67 (clone B56, BD 
Pharmingen) diluted in Permeabilization Buffer. 
For intracytoplasmic cytokine staining (ICS), 2-3 x 106 cells were stimulated for 
four hours at 37°C with 50 ng/mL of phorbol-12-myristate 13-acetate (PMA, Sigma) and 
1 µg/mL ionomycin (Sigma) in the presence of brefeldin A (GolgiPlug, BD Pharmingen) 
in RPMI + 1% FBS. Following LIVE/DEAD and surface antibody staining (see above), 
cells were fixed for 20 minutes using Fixation/Permeabilization solution from the BD 
Cytofix/Cytoperm kit. Cells were stained for 30 minutes at 4°C with monoclonal 
antibodies against IFN-γ (clone XMG1.2), IL-2 (clone JES6-5H4), and TNF-α (clone 
MP6-XT22) from Ebioscience or BD Pharmingen diluted in BD Perm/Wash buffer. 
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Cells were resuspended in 200µL FACS Buffer and run on a BD FACSCanto II 
cytometer using BD FACSDiva software, version 8, and analyses were carried out using 
FlowJo software, version 8. Polyfunctionality of T cells were analyzed by applying 
Boolean gating to IL-2, IFN-γ, and TNF-α-gated populations. Cells were characterized as 
follows: CD4+ T cells (CD45hiCD3+CD4+), CD8+ T cells (CD45hiCD3+CD8+), NK 
cells (CD45hiCD3-NK1.1+), naïve T cells (CD44loCD62L+), short-term effector T cells 
(TEFF cells, CD44hiCD62L-CD127-), effector memory T cells (TEM cells, CD44hiCD62L-
CD127+), central memory T cells (TCM cells, CD44hiCD62L+CD127+), tissue resident 
memory T cells (TRM cells, CD44hiCD62L-CD103+), proliferating T cells 
(CD3e+Ki67+), and exhausted T cells (CD44hiPD-1+TIM-3+). All flow cytometry data 
are averaged representations of three to four independent experiments per time point. 
 
Gene mRNA Expression Measurement by Real-Time PCR 
 Right brain hemispheres from three to four mice per strain per time point were 
homogenized in Lysing Matrix D tubes (MP Biomedicals) at 6.0 M/s for 40 seconds 
using a FastPrep-24 homogenizer (MP Biomedicals). Qiagen RNeasy Lipid Tissue Mini 
kit was used to isolate RNA, and cDNA was synthesized using a High Capacity cDNA 
Reverse Transcription Kit with random primers (Life Technologies). Quantitative real-
time PCR (qRT-PCR) was performed using TaqMan Universal PCR Master Mix (Roche) 
on a 7500 Fast Real-Time PCR System. IL-7 and IL-15 mRNA was measured using 
commercially available TaqMan gene expression assays (Integrated DNA Technologies), 
and relative quantification was performed by the ΔΔCT method using rodent 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA for normalization. 
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Statistics 
 Statistical analyses were performed using Graphpad Prism 6 software. Time 
course studies comparing multiple mouse strains were analyzed by two-way ANOVA 
with Tukey’s multiple comparison post-test. A p value of < 0.05 was considered 





CD4+ and CD8+ T cells produce IFN-γ in the brain throughout SINV infection 
  As a positive sense, single-stranded RNA virus, SINV RNA is infectious, so low 
levels that persist in the brain throughout Phase 3 of infection represent a possible nidus 
from which virus may reactivate43. T cells, which remain in brain for at least six months 
following infection, offer a possible mechanism to control or prevent virus reactivation42. 
IFN-γ plays a critical role in the clearance of virus during Phase 1 of infection, and as a 
major effector protein produced by both CD4+ and CD8+ cells, we examined its role in 
the long-term control of SINV.  
To determine the source of IFN-γ throughout the course of SINV infection, mice 
were intracranially infected with SINV TE, and CLNs and brains were collected for flow 
cytometry. The three main known sources of IFN-γ, CD4+ T cells, CD8+ T cells, and NK 
cells, were examined for cytokine production during Phase 1 (5 and 7 DPI), Phase 2 (10 
and 14 DPI), and Phase 3 (90 DPI) of infection. In the CLNs, few cells produced IFN-γ at 
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any time point, with none of the cell populations examined emerging as a predominant 
source of IFN-γ (Figs 5-1A and 5-1C). In contrast, in the brain, NK cells were the 
predominant source of IFN-γ at 5 DPI, both as percentage of live cells and absolute 
numbers (Figs 5-1B and 5-1D). IFN-γ-producing cell numbers peaked in the brain at 7 
DPI, with CD8+ T cells overtaking NK cells as the predominant source of IFN-γ. By 14 
DPI, the number of CD4+ T cells producing IFN-γ was comparable to CD8+ T cells. In 
Phase 3 of infection, the number of T cells in the brains decreased considerably, with 
CD8+ and CD4+ T cells continuing to produce the majority of IFN-γ. From these data, 
NK cells produce the majority of the local IFN-γ early in the course of infection, but 
CD4+, and especially CD8+ T cells soon take over, becoming the predominant source of 
IFN-γ during Phases 2 and 3 of infection. 
 We next characterized the cells producing IFN-γ throughout infection. At all time 
points examined, less than half the CD4+ T cells, CD8+ T cells, and NK cells in the 
CLNs were producing IFN-γ (Fig 4-1E). In the brain, the percentage CD4+ and CD8+ T 
cells producing IFN-γ increased over the course of infection, going from approximately 
40 to 60% at 5 and 7 DPI to over 80% at 10, 14, and 90 DPI (Fig 4-1F). In contrast, the 
percentage of NK cells producing IFN-γ in the brain remained around 20 to 50%, similar 
to that of the NK cells in the CLNs. The MFIs for IFN-γ produced by CD4+ T cells, 
CD8+ T cells, and NK cells were assessed as a representation of how much IFN-γ 
individual cells were producing. In the CLNs, the MFI for IFN-γ remained low and 
unchanging among cell populations (Figs 4-1G and 4-1I). However in the brain, the MFIs 
for IFN-γ produced by CD4+ and CD8+ T cells increased over time, with the greatest 
increase occurring between 7 DPI and 10 DPI (Figs 4-1H and 4-1J). Similar to the CLNs, 
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the MFI for IFN-γ produced by NK cells in the brain was lower and remained relatively 
unchanged over time.  
  
Expression of cytokines associated with long-term T cell survival and proliferation 
are only transiently up-regulated during SINV infection 
 Long-term survival and proliferation of memory T cells are primarily facilitated 
by two cytokines: IL-7 and IL-15127. Expression of the mRNAs for these cytokines was 
examined by qRT-PCR in the brains of mice infected with SINV. Compared to 0 DPI, 
expression of both Il7 and Il15 sharply increased following infection, peaking at 7 DPI 
(Fig 5-2). Expression then abruptly decreased, returning to baseline levels by 28 DPI and 
remaining there through 180 DPI. These results indicate that at the mRNA level, IL-7 and 
IL-15 do not remain elevated to support maintenance of memory T cells in the brain 
during SINV infection. 
 
TEM cells are the predominant T cell population present long-term in the brain 
during SINV infection 
 We next sought to characterize the T cells populations present in the CLNs and 
brain during SINV infection. Using flow cytometry, T cells were defined as naïve T cells, 
short-term T effector cells (TEFF), effector memory T cells (TEM), or central memory T 
cells (TCM) at 7, 14, 28, and 90 DPI. Gating schemes used for characterization are shown 
in Fig 5-3A for CLNs and Fig 5-3B for brains.  
In the CLNs, naïve cells predominated in both the CD4+ and CD8+ T cell 
populations (Fig 5-3C), with far fewer cells showing a TEFF (Fig 5-3D) or TEM (Fig 5-3E) 
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phenotype. Less than 5% of the CD4+ T cells, but 10 to 15% of the CD8+ T cells in the 
CLNs were characterized as TCM cells (Fig 5-3F). The T cell population profile in the 
CLNs did not change over time during SINV infection. In contrast to the CLNs, very few 
CD4+ or CD8+ T cells were characterized as naïve cells (Fig 5-3G). Early in infection at 
7 DPI, TEFF cells were the predominant T cell population in the brain (Fig 5-3H); 
however as time went on, the percentage of CD4+ and CD8+ T cells characterized as 
TEFF cells decreased, and the percentage of cells showing a TEM phenotype increased, 
becoming the predominant T cell population at 90 DPI (Fig 5-3I). TCM cells were rarely 
found in the brain at any time during infection (Fig 5-3J). Therefore, during SINV 
infection, while naïve T cells predominate in the CLNs, in the brain the main T cell 
population transitions from TEFF cells early in infection to TEM cells during the period of 
long term maintenance and control of SINV reactivation. 
 
Brains from mice with impaired IFN-γ signaling have fewer CD8+ TRM cells  
 Tissue resident memory (TRM) cells are a recently characterized subset of memory 
T cells that do not circulate, but instead permanently remain at former sites of 
infection120. The presence of CD103+ TRM cells was assessed in CLNs and brains in WT 
B6, Ifngr1-/-, and Ifng-/- mice at 7, 14, and 28 DPI to determine what role, if any, IFN-γ 
played in their development, maintenance, and survival (Fig 5-4A). Very few CD4+ or 
CD8+ (Fig 5-4B) TRM cells were found in CLNs of SINV-infected mice at any time 
point. Slightly higher percentages of CD4+ T cells in the brain were characterized as TRM 
cells, though the numbers did not significantly change over time or differ among mouse 
strains (Fig 5-4C). Percentages of CD8+ T cells in the brain characterized as TRM cells, 
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however, did increase over time. WT B6 brains had significantly more CD8+ TRM cells 
than Ifngr1-/- brains at 28 DPI (p < 0.001, Tukey’s multiple comparisons test) and Ifng-/- 
brains at 14 and 28 DPI (p < 0.05 and p < 0.001 for 14 and 28 DPI, respectively, Tukey’s 
multiple comparisons test). The results show that IFN-γ signaling promotes the 
development of CD8+ TRM cells in the brain during SINV infection. 
 
T cells in the brain are proliferative during Phase 1, but not Phases 2 or 3, of SINV 
infection 
 To evaluate the proliferative potential of the T cells present in the CLNs and brain 
over the course of SINV infection, the intranuclear marker Ki67 was measured at 7, 14, 
28, and 90 DPI (Fig 5-5A). In the CLNs, less than 10% of the CD4+ or CD8+ T cells 
were positive for Ki67 at any of the time points (Fig 5-5B). In the brain, the fraction of T 
cells positive for Ki67 was approximately 50%, but it dropped to less than 10% at all 
other time points (Fig 5-5C). These findings show that during the period of active virus 
clearance in the brain, T cells are highly proliferative. However, during Phases 2 and 3, 
the fraction of T cells that are proliferating is minimal. 
 
Polyfunctionality of T cells in the brain increases over the course of SINV infection 
 During chronic virus infection, T cells tend to lose their ability to produce effector 
molecules, potentially making them less efficient at combatting pathogen reactivation146. 
To determine whether this happens over the course of SINV infection, CD4+ and CD8+ 
T cells were stimulated with PMA and ionomycin and evaluated for their ability to 
produce three major effector proteins, IL-2, IFN-γ, and TNF-α, at 7, 14, 28, and 90 DPI 
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(Fig 5-6A). Both CD4+ (Fig 5-6B) and CD8+ (Fig 5-6C) T cells increased in their 
polyfunctionality over the course of infection. While at 7 DPI, less than 10% of T cells 
were producing all three cytokines, by 90 DPI, the percentage increased to over 50%. 
 To further characterize the functionality of T cells in the brain during SINV 
infection, the MFIs of IL-2, IFN-γ, and TNF-α were quantified (Fig 5-7A). IL-2 
production by both CD4+ and CD8+ T cells increased over time, peaking at 90 DPI (Fig 
5-7B). For IFN-γ (Fig 5-7C) and TNF-α (Fig 5-7D), MFI values increased throughout 
Phases 1 and 2 of infection, peaking at 28 DPI, before declining slightly at 90 DPI. These 
findings show that not only do T cells increase in polyfunctionality over the course of 
infection, the amount of effector cytokines produced by T cells increases over time as 
well. 
 
Expression of T cell exhaustion markers decreases during SINV infection 
 Similar to the production of effector cytokines, T cells tend to increasingly 
express cell surface markers associated with exhaustion during chronic virus 
infections138,139. To evaluate T cell exhaustion during SINV infection, expression of both 
PD-1 and TIM-3 were measured on CD4+ and CD8+ T cells in CLNs and brains at 7, 14, 
28, and 90 DPI (Fig 5-8A). In CLNs, expression of both PD-1 and TIM-3 was minimal 
(Fig 5-8B), and far more CD4+ and CD8+ T cells expressed both markers in the brain 
(Fig 5-8C). Exhaustion marker expression peaked at 14 DPI in CD4+ T cells and at 7 DPI 
in CD8+ T cells and then decreased. These findings suggest that T cells present in the 
brain following clearance of infectious virus do not become exhausted and are fully 
capable of responding to possible virus reemergence. 
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DISCUSSION 
 
 IFN-γ is primarily produced by CD4+ T cells, CD8+ T cells, and NK cells95,96. 
During SINV infection, NK cells are the initial source of IFN-γ in the brain. Because NK 
cells are innate immune cells, they do not require activation and can respond to infection 
sooner than cells of the adaptive immune response, and IFN-γ specifically produced by 
NK cells is important for T cell recruitment to sites of infection332. At 7 DPI, when virus 
clearance is underway, CD8+ T cells become the predominant source of IFN-γ. As 
infection progresses into Phase 2, CD4+ T cells increase in number as CD8+ T cells 
decrease, and by 90 DPI, maintenance levels of IFN-γ are produced by both T cell 
subsets. CD8+ T cells appear to be the predominant source of the IFN-γ that facilitates 
virus clearance. During Phases 2 and 3, IFN-γ production during viral RNA clearance 
and control of reactivation is shared between CD4+ and CD8+ T cells. 
 The percentage of CD4+ T cells, CD8+ T cells, and NK cells producing IFN-γ in 
the CLNs remained low throughout the course of infection. IFN-γ production by NK cells 
in the brain was similar. However, while the percentage of CD4+ and CD8+ T cells in the 
brain producing IFN-γ remained around 50% during Phase 1 of infection, increased 
percentages of T cells secreting IFN-γ were found as time progressed, attaining greater 
than 80% by 90 DPI. A similar trend was seen in the amount of IFN-γ produced by 
individual T cells in the brain over time. These data suggest that CD4+ and CD8+ T cells 
gain their effector function at the site of infection rather than in the periphery and adapt to 
increase their effector capacity over course of infection. In contrast, NK cells, which are 
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part of the innate rather than adaptive immune response, produce consistent amounts of 
IFN-γ regardless of infection location or time. 
 Over the course of SINV infection, TEM cells replaced TEFF cells as the 
predominant CD4+ and CD8+ T cell populations in the brain. TEM cells can survive for 
several years while undergoing low-level cell turnover to replenish and maintain cell 
populations333. As measured by Ki67 expression, only T cells present in the brain during 
the height of virus infection were proliferating, with less than 10% of the T cells present 
in the brain during Phases 2 and 3 cycling. Similar Ki67+ T cell and B cell numbers have 
been seen during chronic coronavirus and SINV infection, respectively, in the CNS91,334.  
A hallmark of memory T cells is their ability to persist in the absence of 
continued antigen stimulation, and for many virus infections, T cells are retained in the 
CNS in the absence of detectable infectious virus86,335-337. In some cases, virus may 
periodically reactivate at low levels and support memory T cell maintenance338. 
Regardless, persistent SINV RNA does not necessarily need to periodically reactivate and 
produce viral antigen or infectious virus to maintain memory T cell populations in the 
brain. 
Traditionally, memory T cell survival is dependent on IL-7 and homeostatic cell 
turnover is mediated by IL-15127. Surprisingly, mRNA expression of both Il7 and Il15 in 
SINV-infected mouse brains returned to baseline by 28 DPI after peaking at 7 DPI. This 
suggests that at least at the level of mRNA expression, production of IL-7 and IL-15 does 
not increase to support long-term maintenance of memory T cells during SINV infection. 
Expression of IL-15 is mainly regulated post-transcriptionally, with IL-15 protein 
produced at low levels despite widespread Il15 mRNA expression127. During chronic 
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CNS infection with certain viruses, CD8+ T cells are able to undergo homeostatic 
proliferation in the absence of IL-15, indicating memory T cell homeostasis can be 
mediated in an IL-15-independent manner334,338. IL-7-independent mechanisms of TEM 
maintenance have not been reported, but TEM cells are characterized in part by their 
expression CD127, the IL-7 receptor, so perhaps constitutive low levels of IL-7 produced 
by stromal cells are sufficient to mediate TEM survival in the brain127. Alternatively, IL-7- 
and IL-15-dependent maintenance of circulating TEM cells may occur in secondary 
lymphoid tissues rather than the brain339. 
Over the course of infection, the percentage of CD8+ T cells expressing CD103, a 
marker for TRM cells in the brain, increased. As permanent residents of previous sites of 
infection, TRM cells are uniquely situated to provide an immediate and effective response 
to a pathogen. Priming of these cells is thought to occur in their tissue of residence, as 
opposed to secondary lymphoid tissues, allowing for a rapid response to local 
infection340. In our model, only CD8+ TRM cells appear to play a local role in virus 
control, and not CD4+ T cells. Though CD8+ TRM cells are much better described, CD4+ 
TRM cells play a role in control of other virus and parasitic infections330,341-344. TRM cells 
in the brain do not highly express CD127 nor appear to require IL-7 or IL-15 for 
survival117,345. This provides an alternate explanation on how control of virus reactivation 
could be achieved in the brain in the absence of upregulation of Il7 or Il15 expression. 
Previous studies have shown that in a mouse model for influenza, IFN-γ 
specifically produced by CD4+ T cells is required for generating CD8+ TRM cells in the 
lung329. Brains of mice defective in IFN-γ signaling possessed significantly fewer CD8+ 
TRM cells compared to wild-type mice with intact signaling, indicating IFN-γ promotes 
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the presence of TRM cells in the brain. Additionally, IFN-γ secreted by TRM cells helps to 
recruit CD8+ TEM and B cells to help combat pathogens by up-regulating expression of 
endothelial vascular cell adhesion molecule 1 (VCAM-1), so the TRM cells in the brains 
of Ifngr1-/- and Ifng-/- mice may not be as effective at combatting reactivating virus121.  
Little is known regarding T cell exhaustion in cases of acute virus infection where 
viral RNA persists following virus clearance. During chronic virus infections, memory T 
cells tend to lose their effector function capacity over time and show increased rates of 
apoptosis146. The extent of T cell exhaustion is directly proportional to the viral load and 
duration of virus persistence, suggesting that if persistent SINV RNA were replication 
competent and prone to reactivation, memory T cells present in the brain would show 
decreased polyfunctionality and increased inhibitory markers indicative of 
exhaustion146,346. Over the course of infection, the polyfunctionality of SINV-infected T 
cells in the brain in our mouse model actually increased. As T cells gain 
polyfunctionality, they exhibit a functional hierarchy for cytokine secretion, with IFN-γ 
tending to be secreted first, then TNF-α, and finally IL-2, and this hierarchy appears to 
apply to our model347. Furthermore, expression of inhibitory markers PD-1 and TIM-3 
decreased over the course of infection. These results indicate that rather than acquiring an 
exhaustive phenotype, during chronic SINV infection, memory T cells adapt and become 
more effective at responding to virus reactivation. This suggests that persistent SINV 
RNA remaining in the brain during Phase 3 of infection rarely reactivates or only does so 
at extremely low levels, and further studies are warranted to elucidate this.  
This study shows that memory T cells do exist in the brain following clearance of 
infectious virus during SINV infection. CD8+ TRM cells in particular are dependent on 
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IFN-γ signaling for proper production and function, providing a mechanism by which 
IFN-γ may control virus reactivation. Furthermore, over time memory T cells do not 
show signs of exhaustion but rather increase their polyfunctionality. Understanding the 
long-term maintenance of cellular immunity can assist in developing alphavirus 
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FIGURES 
Figure 5-1. Source of IFN-γ during SINV infection. Flow cytometry was used to 
evaluate what cells were producing IFN-γ in the CLNs (A, C, E, G, I) and brains (B, D, 
F, H, J) of WT B6 mice at 5, 7, 10, 14 and 90 DPI. CD4+ T cells (black circle and solid 
line), CD8+ T cells (gray square and solid line), and NK cells (white circle and black 
dashed line) producing IFN-γ were examined as both the percentage of live cells (A, B) 
and absolute cell counts (C, D). Also evaluated were the percentage of each cell type 
producing IFN-γ (E, F) and the MFI of IFN-γ for each cell type presented in graph form 
	   170	  
(G, H) and as histograms (I, J) (n = 3-7 pooled mice per time point from three 
independent experiments, except for data from 5 DPI CLNs, which were from two 
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Figure 5-2. Expression of mRNAs for cytokines involved in T cell survival during 
SINV infection. mRNA expression of Il7 (black circle and line) and Il15 (gray square 
and line) was examined by qRT-PCR in WT B6 mouse brains (n = 3-4 mice per time 
point; data presented as mean ± SEM; dashed line indicates gene expression of 0 DPI 
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Figure 5-3. Characterization of T cell populations in the CLNs and brain 
throughout the course of SINV infection. Using the above gating strategies for CLNs 
(A) and brains (B), flow cytometry was used to examine different T cell populations in 
WT B6 mice at 7 (black bars), 14 (light gray bars), 28 (dark gray bars), and 90 (white 
bars) DPI. The percentage of CD4+ and CD8+ T cells expressing markers characteristic 
of naïve T cells (C, G), TEFF cells (D, H), TEM cells (E, I), and TCM cells (F, J) were 
evaluated in CLNs (C-F) and brains (G-J) (n = 3-7 pooled mice per time point from three 
independent experiments; data presented as the mean ± SEM). 
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Figure 5-4. Effect of IFN-γ signaling on TRM cell populations. Flow cytometry was 
used to examine TRM cell populations by gating around CD103+ cells (A) at 7, 14, and 28 
DPI in the CLNs (B) and brains (C) of WT B6 (black bars), Ifngr1-/- (gray bars), and Ifng-
/- (white bars) mice, and results are presented as a percentage of CD4+ (left graphs) and 
CD8+ T cells (right graphs) (n = 2-7 pooled mice per strain per time point from three to 
four independent experiments; data presented as the mean ± SEM; *p < 0.05, ***p < 
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Figure 5-5. Proliferation of T cells in CLNs and brains throughout the course of 
SINV infection. Flow cytometry was used to evaluate T cell proliferation by gating 
around Ki67+ cells (A) in WT B6 mouse CLNs (B) and brains (C) at 7 (black bars), 14 
(light gray bars), 28 (dark gray bars), and 90 (white bars) DPI, with results presented as a 
percentage of CD4+ or CD8+ T cells (n = 3-10 pooled mice per time point from three 
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Figure 5-6. Polyfunctionality of T cells in the brain during SINV infection. (A) Flow 
cytometry was used to evaluate the production of IL-2, IFN-γ, and TNF-α by T cells in 
SINV-infected WT B6 mouse brains at 7, 14, 28, and 90 DPI after being stimulated with 
PMA and ionomycin. (B, C) Boolean gating was used to determine whether stimulated 
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CD4+ (B) and CD8+ (C) T cells were producing none of the cytokines (black), or one 
(light gray), two (dark gray), or all three (white) of the cytokines at each time point, with 
unstimulated cells from SINV-infected brains provided as a reference (n = 3-10 pooled 
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Figure 5-7. Effector function of T cells during SINV infection. (A) Histograms of IL-
2, IFN-γ, and TNF-α fluorescence of CD4+ and CD8+ T cells in WT B6 mouse brains 
that indicate how much of each cytokine individual cells were producing at 7 (black solid 
line), 14 (gray dashed line), 28 (black dashed line), and 90 (gray solid line) DPI. (B-D) 
The MFI was calculated for IL-2 (B), IFN-γ (C), and TNF-α (D) produced by CD4+ and 
CD8+ T cells at 7 (black bars), 14 (light gray bars), 28 (dark gray bars), and 90 (white 
bars) DPI (n = 3-10 pooled mice per time point from three independent experiments; data 
presented as the mean ± SEM). 
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Figure 5-8. T cell exhaustion during SINV infection. Flow cytometry was used to 
evaluate T cell exhaustion identifying cells expressing both PD-1 and TIM-3 (A) in WT 
B6 mouse CLNs (B) and brains (C) at 7 (black bars), 14 (light gray bars), 28 (dark gray 
bars), and 90 (white bars) DPI. Results were presented as a percentage of CD4+ and 
CD8+ T cells that are PD-1+TIM-3+ (n = 3-7 pooled mice per time point from three 
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The immune system presents a double-edged sword regarding virus infection of 
the CNS: an adequate immune response is necessary for control and clearance of the 
virus, yet cytokine production and cytotoxic activity of infiltrating immune cells can 
cause neuronal damage and death. Because neurons have limited regenerative capacity, 
loss of this valuable cell population results in neurological deficits. Mice experimentally 
infected with viruses including TMEV, influenza, and dengue virus or protozoal parasites 
including Toxoplasma gondii develop neurocognitive deficits such as impaired memory 
or increased anxiety167-169,348-351. In our studies, SINV infection resulted in development 
of disinhibition and hippocampus-dependent memory deficits, which correlated with 
inflammation and cell death in the brain.  
The immune response is well established to mediate most of the CNS pathology 
observed during fatal alphavirus encephalomyelitis41,54,56. In our mouse model of nonfatal 
alphavirus encephalomyelitis, treatment with a glutamine anatagonist, which inhibits 
immune cell proliferation, resulted in partial prevention of neurological sequelae. 
Histopathologic examination resulted in markedly decreased infiltration of inflammatory 
cells and cell death in the brain, indicating the immune response plays an important role 
in pathology associated with alphavirus encephalomyelitis. Mice infected with the 
nonfatal TE strain of SINV develop signs of encephalomyelitis characterized by hunched 
posture, abnormal gait, and paresis. Inhibiting the immune response by treating mice with 
the glutamine antagonist DON resulted in fewer mice developing clinical signs of 
encephalomyelitis by 7 DPI. The findings support the detrimental role inflammation can 
play during neurotropic virus infection. 
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We similarly examined clinical disease development during SINV infection in 
mice deficient in IFN-γ signaling. Numerous studies have been performed to examine the 
effect IFN-γ signaling has on virus-induced clinical disease using mice deficient in IFN-γ 
(Ifng-/-) or IFN-γ receptor (Ifngr1-/-). Increased mortality is seen in Ifngr1-/- or Ifng-/- mice 
during CNS infection with viruses such as JHMV, LCMV, and TMEV98,292,352,353. In 
experimental allergic encephalomyelitis (EAE) and in JHMV-induced autoimmune 
demyelinating encephalomyelitis, absence of IFN-γ signaling results in more severe 
demyelinating disease and increased lymphocyte infiltration354-356. When mice deficient 
in both IFN-α/β and IFN-γ receptor are infected with dengue virus, they are significantly 
more susceptible to developing lethal paralysis and systemic disease than mice deficient 
in IFN-α/β receptor alone357. Infection with other pathogens that do not necessarily target 
the CNS, such as JHMV, influenza virus, pseudorabies virus (PRV), monkeypox virus, 
Mycobacterium bovis, Listeria monocytogenes, and Leishmania major also results in 
more severe clinical disease and/or increased mortality in Ifngr1-/- and/or Ifng-/- mice358-
363. Furthermore, neutralization of gamma interferon production in influenza virus-
infected mice results in increased weight loss364. These studies all indicate that IFN-γ is 
protective against pathogen-induced clinical disease.  
In contrast, in our studies, Ifngr1-/- and Ifng-/- mice actually lost significantly less 
weight than WT B6 mice before recovering, indicating that IFN-γ actually exacerbates 
clinical disease during nonfatal alphavirus encephalomyelitis. The weight loss is likely 
directly due to decreased feed intake by WT B6 mice relative to Ifngr1-/- and Ifng-/- mice, 
but the reason why IFN-γ signaling leads to decreased food consumption remains 
unknown. Ifng-/- mice infected with the Sarafend strain of WNV are protected from 
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developing limbic seizures in contrast to WT B6 mice365. When these mice are treated 
with seizure-inducing NMDA or kainic acid, seizure responses are diminished or absent 
compared to WT B6 mice, indicating that IFN-γ plays an important role in regulating the 
excitatory seizure pathway. Glutamate is the major excitatory neurotransmitter that binds 
to NMDA and kainic acid receptors (in addition to AMPA receptors), and excitotoxicity 
induced by glutamate plays a major role in SINV-induced pathology49,65,366. In the CNS, 
IFN-γ receptor complexes with AMPA receptor subunit GluR1 on neurons, forming 
dendritic beads367. Through Jak/STAT signaling via the chimeric receptor, increased 
calcium influx stimulates nitric oxide production, inducing neuronal toxicity. In contrast, 
IFN-γ is reported to provide a protective effect against glutamate excitotoxicity in 
hippocampal neurons during dietary restriction368. The potential role IFN-γ-enhanced 
excitotoxicity plays in alphavirus infection warrants further investigation. 
As the quintessential proinflammatory cytokine, IFN-γ plays a multifactorial role 
in modulation of the immune response during infection. Different virus infections elicit 
diverse T cell responses via IFN-γ signaling. Increased mortality in Ifngr1-/- and Ifng-/- 
mice during EAE is attributed to IFN-γ-mediated suppression of the CD4+ T cell 
response, which facilitates EAE-induced pathology369. When mice are infected with a 
recombinant rabies virus encoding IFN-γ, fewer CD8+ T cells infiltrate the cortex and 
cerebellum370. Additionally, CD8+ T cells are increased in Ifng-/- mice infected with 
vaccinia virus371, supporting our finding of Ifngr1-/- and Ifng-/- mice having more CD8+ T 
cells in the brain at 7 DPI. The mechanism by which IFN-γ decreases cytotoxic 
lymphocyte generation is thought to be by limiting IL-2 production, creating a negative 
feedback loop358,372. In our studies, at least at the mRNA level, IL-2 production was not 
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decreased in WT B6 mouse brains relative to Ifngr1-/- and Ifng-/- mice during SINV 
infection. Alternatively, mouse mammary tumor virus (MMTV) infection of Ifngr1-/- 
mice results in no change in CD8+ T cell, CD4+ T cell, or B cell numbers in lymph 
nodes, nor any difference in virus titers373, and Ifng-/- mice show no difference in CD4 or 
CD8 T cells in the spinal cord following infection with TMEV98. 
Because neurons are a valuable yet finite and nonrenewable cell population, a 
noncytolytic mechanism for clearance is essential to maintain neurological integrity. 
Previous studies have shown that along with anti-SINV antibody, IFN-γ plays an 
important role in clearance of SINV from neurons and the CNS24,92,93. Work from other 
groups has shown that IFN-γ plays a vital role in the clearance of many different 
neurotropic virus and bacterial infections, including neurotropic MHV, borna disease 
virus, HSV, WNV, and Listeria monocytogenes374-378. As part of this thesis work, we 
found that IFN-γ affects each of the three major steps of SINV clearance and control (Fig 
6-1). First, IFN-γ facilitates infectious virus clearance through, at least in part, 
modulation of local production of anti-SINV antibody in the CNS. Second, viral RNA 
clearance is affected by IFN-γ, possibly through its influence on the T cell response in the 
CNS. And finally, IFN-γ promotes the development of CD8+ TRM cells in the brain 
throughout Phase 2 of infection, likely helping prevent reactivation of persistent virus. 
Antibody is necessary for successful clearance of several viruses, including 
respiratory syncytial virus, norovirus, hemagglutinating encephalomyelitis virus, MPyV, 
and rabies virus379-384. We found that compared to mice with intact IFN-γ signaling, 
Ifngr1-/- and Ifng-/- mice had reduced IgM and IgG production in the brain following 
SINV infection. This was despite comparable levels of IgM and IgG in the serum, which 
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has similarly been found in Ifngr1-/- and/or Ifng-/- mice during SINV and TMEV 
infection70,98. IgG2a and IgG2b in particular were decreased in mice with impaired IFN-γ 
signaling. During JEV infection, Ifng-/- mice have reduced production of IgG2a in 
response to vaccination, and the IgG2a/c, rather than IFN-γ, confers protection against 
virus infection385. Of the IgG subclasses, IgG2a is most effective at fixing complement 
and binding to FcγR receptor on macrophages386,387. Taken together, these findings 
suggest IFN-γ enhances anti-SINV antibody-mediated clearance of virus. 
In addition to decreased IgM and IgG production in the brain, Ifngr1-/- and Ifng-/- 
mice had reduced infiltration of B cells at 7 and 10 DPI compared to WT B6. This was 
despite comparable numbers of B cells in the CLNs. Previous studies have shown that 
SINV-specific ASCs infiltrate the brain during SINV infection and serve as the source of 
local anti-SINV antibody production91. Increases in mRNA expression of CXCL9 and 
CXCL10 has been associated with B cell recruitment to the brain during SINV infection, 
and increases in CXCL13 mRNA expression is associated with local formation of B cell 
follicles. All three of these chemokines are induced by IFN-γ and were reduced in mice 
with impaired IFN-γ signaling. Therefore, IFN-γ signaling promotes the expression of B 
cell migratory and maintenance chemokines in the brain during SINV infection. This in 
turn leads to increased infiltration of B cells producing anti-SINV antibodies. Through 
this mechanism, IFN-γ is able to facilitate clearance of infectious virus from the CNS 
(Fig 6-1). 
Considerably less is known about what factors facilitate viral RNA clearance. 
When IFN-γ is applied to measles virus-infected brain explant slices, clearance of viral 
RNA is achieved in the absence of primed leukocytes via the Jak/STAT pathway100. 
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Furthermore, when measles virus-primed leukocytes are applied to organotypic explants 
infected with WNV or MHV, viral RNA of each resident virus is completely eliminated, 
indicating IFN-γ-mediated viral RNA clearance is antigen-independent. Our in vitro 
findings that IFN-γ is sufficient for clearing SINV RNA from dAP-7 cells corroborate 
these results. However, when examining IFN-γ-mediated clearance of SINV RNA in 
vivo, we found the opposite effect, with initiation of viral RNA clearance actually 
accelerated in Ifngr1-/- and Ifng-/- mice. These findings indicate that influences outside of 
the neuron were affecting viral RNA clearance, leading us to examine the immune 
system, particular the T cell response. 
In addition to overall increases in CD8+ T cell numbers in the brain at 7 DPI, 
mice with impaired IFN-γ signaling had more CD8+ T cells producing granzyme B and 
more granzyme B being produced by individual CD8+ T cells compared to mice with 
intact IFN-γ signaling. Similarly, more perforin has been detected in brains of Ifngr1-/- 
and Ifng-/- mice infected with SINV NSV269, indicating during SINV infection, IFN-γ 
inhibits the granzyme-perforin exocytosis pathway by some mechanism. The 
noncytotoxic functions of granzyme B are becoming increasingly recognized, and this 
effector protein is no longer considered to exclusively induce cell death upon entry into a 
recipient cell296. Furthermore, several substrates recently identified for granzyme B bind 
RNA, including viral RNA, allowing for nucleic acid destruction in the absence of 
neuron death388. Therefore, we propose that granzyme B promotes clearance of viral 
RNA in a non-cytotoxic fashion (Fig 6-1). This mechanism provides an explanation for 
Ifngr1-/- and Ifng-/- mice showing accelerated viral RNA clearance from the CNS, despite 
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IFN-γ being sufficient to clear viral RNA in neurons. Further studies examining the role 
granzyme B plays in RNA virus clearance are warranted. 
Persistent viral RNA from positive-sense RNA viruses presents a potential 
problem, as the infectious nature of the RNA allows for possible virus reactivation and 
relapse of disease. When SCID mice are passively transferred hyperimmune serum or 
monoclonal antibody directed against SINV, they are able to clear both infectious virus 
and viral RNA24. However, when those antibodies are allowed to naturally decay, virus 
reactivates, indicating that replication-competent viral RNA persists43. Viral RNA and/or 
antigen persistence has been reported following both natural and experimental CNS 
infection with several flaviviruses and alphaviruses42,43,389-392. Virus persistence in acute 
CNS infections can lead to reactivation, causing neurological signs following apparent 
recovery, or induce an autoimmune MS-like response through mechanisms such as 
molecular mimicry or bystander activation393,394. Furthermore, latent viruses, such as 
HSV-1, can reactivate upon exposure to stressors that compromise T cell function395. 
Persistent virus is found in the arthralgic and arthritic alphaviruses such as CHIKV and 
Ross river virus and is thought to influence chronic arthralgia7,396-399.  
Prevention of virus reactivation is likely achieved through continued presence of 
immune cells at the previous site of infection91,400. Over the course of SINV infection, the 
primary T cell population in the brain changed from short-term effector T cells (TEFF) to 
memory T cells, and a small but robust population of CD8+ tissue resident memory T 
(TRM) cells formed in the brain. TRM cells are phenotypically and functionally distinct 
from circulating effector memory T (TEM) cells345. Upon antigen reactivation, TRM cells 
produce near-sterilizing immunity by rapidly inducing both the innate and adaptive 
	   187	  
immune response, including dendritic cell maturation, NK cell activation, and local 
antibody production121. CD8+ TRM cells present in the respiratory airway following 
infection with influenza or Sendai virus are able to produce IFN-γ faster than systemic 
TEM cells, leading to a rapid antigen-dependent decrease in virus replication upon 
reactivation331. While granzyme B production must be induced in TEM cells, TRM cells 
constitutively produce it, allowing them to deliver immediate effector activity to combat 
virus117. This presents another avenue by which granzyme B may be examined during 
SINV infection.  
The percentage of CD8+ T cells expressing CD103, a marker for TRM cells was 
decreased in Ifngr1-/- and Ifng-/- mice during Phase 2 of infection. IFN-γ produced by 
CD4+ T cells is necessary for generation of lung resident TRM cells following influenza 
virus infection329. As Ifngr1-/- and Ifng-/- mice cannot produce/respond to IFN-γ and have 
fewer CD4+ T cells in the brain at 10 DPI compared to WT B6 mice, this provides a 
possible mechanism for IFN-γ-mediated promotion of CD8+ TRM cell formation in the 
brain. The reduced CD8+ TRM cell population in mice with impaired IFN-γ signaling 
could lead in an impaired response to possible virus reactivation. Circulating TEM cells 
cannot access trigeminal ganglia latently infected with HSV-1, and so TRM cells are 
responsible for reactivation prevention through the secretion of IFN-γ and noncytotoxic 
lytic granules316,401-404. Indeed, during Phase 3 of infection, transient increases in viral 
RNA were seen in SINV-infected mice, particularly in Ifng-/- brains and spinal cords. 
Promotion of CD8+ TRM cell development in the brain following Phase 1 of infection 
provides another mechanism by which IFN-γ controls SINV infection. Therefore, not 
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only does IFN-γ facilitate clearance of infectious virus and viral RNA, but it also appears 
to contribute to virus reactivation control (Fig 6-1). 
During chronic virus infections, constant exposure to viral antigen leads to T cell 
exhaustion, exemplified by decreased effector function and increased expression of 
inhibitory markers146. Interestingly, as the course of SINV infection progressed, T cells 
actually increased in polyfunctionality and production of IFN-γ, TNF-α, and IL-2 effector 
cytokines and decreased expression of PD-1 and TIM-3 exhaustion markers. This 
suggests that resident T cells in the brain are not being constantly exposed to virus 
antigen in a way that induces exhaustion. Our current understanding of the replication 
competency of SINV RNA is extremely limited. However, during Phase 3 of infection, 
transient increases in RNA levels were occasionally seen, particularly in the spinal cords 
of Ifng-/- mice, suggesting that viral RNA is capable of replication leading to virus 
reactivation and requires diligent immune surveillance and control. Further studies 
examining the nature of viral RNA persistence represent an important avenue to explore 
in order to better understand immune control of SINV infection.  
While most parameters differing between mice with intact and impaired IFN-γ 
signaling during SINV infection were shared between Ifngr1-/- and Ifng-/- mice, some 
virus or immune characteristics only differed in one of the strains (Table 6-1). Most 
studies in the literature examining the in vivo effect of IFN-γ on virus infection utilize 
either Ifngr1-/- or Ifng-/- mice, rather than both strains. Previous work on the alphavirus 
encephalomyelitis mouse model using the neurovirulent NSV strain revealed differing 
inflammatory responses in Ifngr1-/- and Ifng-/- mice, including more severe inflammation 
and increased MHC Class II and Il17a expression in Ifngr1-/- mice269. Similarly disease 
	   189	  
severity is increased in Ifngr1-/-, but not Ifng-/-, mice infected with vaccinia virus and 
HSV-1289. However, in the previous study, no difference in virus replication was found 
between Ifngr1-/- and Ifng-/- mice, while in the current study, Ifng-/- showed increased 
infectious virus and viral RNA at 1 DPI, and both Ifngr1-/- and Ifng-/- mice showed 
delayed clearance of infectious virus from the spinal cord. These studies highlight that 
Ifngr1-/- and Ifng-/- mice may not necessarily produce the same immune response to virus 
infection and should therefore not be considered equivalent. 
Collectively, the studies presented in this thesis contribute to the understanding of 
the immunopathogenesis and immune control of alphavirus infection in the CNS. The 
immune response, particularly IFN-γ, plays a multi-faceted role in the clearance and 
control of SINV infection. However, as proven by inhibition of the T and B cell response 
by glutamine antagonism, the immune response is also responsible for the majority of the 
clinical disease and CNS pathologic changes induced during infection. Understanding the 
interplay between virus control and tissue damage induced by the immune response is 
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FIGURES 
 
Figure 6-1. Proposed effects of IFN-γ signaling-induced immunomodulation on 
SINV clearance and control in the CNS. During SINV infection, IFN-γ is primarily 
produced by NK cells and T cells. IFN-γ signaling upregulates mRNA expression of 
chemokines CXCL9 and CXCL10, which promote infiltration of B cells into the brain 
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and local production of SINV-specific antibody. This antibody then inhibits production 
and promotes clearance of infectious SINV. IFN-γ signaling also inhibits infiltration of 
CD8+ T cells into the brain and production of granzyme B by CD8+ T cells, which 
inhibits SINV RNA production in the brain. IFN-γ signaling affects long-term control of 
SINV and prevents virus reactivation by promoting the development of CD8+ TRM cells 
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TABLES 
Unique to Ifngr1-/- Mice Unique to Ifng-/- Mice 
  é Viral RNA in the brain at 1 DPI 
Faster recovery from clinical disease é Early expression of type I IFNs 
é Il17a expression é Ccl1 expression 
é IL-17a ê Il10 expression 
  ê Il2 expression 
  ê Il-4 
Shared by Ifngr1-/- and Ifng-/- Mice 
Accelerated development of clinical disease 
ê Weight loss 
Delayed infectious virus clearance in the spinal cord 
Faster initiation of viral RNA clearance in the brain and spinal cord 
ê Induction of Gbp2 and Irgm1 expression 
ê Expression of proinflammatory cytokines Tnf, Csf2, and Il6 
ê Expression of Cxcl9, Cxcl10, and Cxcl13 
ê Expression of PRR mRNAs 
ê CD4+ T cells 
é CD8+ T cells 
é Granzyme B 
ê B cells 
Less prolonged local production of IgM 
ê IgG2a and IgG2b 
ê CD8+ TRM cells  
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Table 6-1. Characteristics related to SINV infection in the CNS unique to each 
knockout mouse strain and shared by both Ifngr1-/- and Ifng-/- mice compared to 












































































A2m <±1.5 <±1.5 <±1.5 1.52 <±1.5 <±1.5 
A3galt2 <±1.5 -2.25 <±1.5 <±1.5 -2.35 <±1.5 
Abca1 <±1.5 -1.96 <±1.5 -1.58 <±1.5 <±1.5 
Abcb4 2.10 2.24 <±1.5 <±1.5 2.06 <±1.5 
Abo2 <±1.5 1.94 <±1.5 <±1.5 <±1.5 <±1.5 
Acat2 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.88 
Acot12 <±1.5 <±1.5 <±1.5 <±1.5 1.52 <±1.5 
Actb <±1.5 -1.73 <±1.5 <±1.5 -1.77 <±1.5 
Adamts1 <±1.5 -2.74 -1.61 <±1.5 -1.89 <±1.5 
Adamts5 <±1.5 -2.11 -1.57 <±1.5 <±1.5 <±1.5 
Adar <±1.5 <±1.5 <±1.5 1.66 <±1.5 <±1.5 
Adm -1.68 -3.18 <±1.5 -1.60 -1.98 <±1.5 
Adora1 <±1.5 1.93 <±1.5 <±1.5 <±1.5 <±1.5 
Adrb2 <±1.5 <±1.5 -1.78 <±1.5 <±1.5 <±1.5 
Aer61 <±1.5 <±1.5 <±1.5 <±1.5 -1.61 <±1.5 
Afap1 <±1.5 <±1.5 <±1.5 <±1.5 -1.63 <±1.5 
Ak2 <±1.5 <±1.5 <±1.5 1.56 -1.65 <±1.5 
Ak3l1 <±1.5 -1.80 <±1.5 <±1.5 -2.27 <±1.5 
Akap2 <±1.5 <±1.5 <±1.5 1.68 -1.55 <±1.5 
Akr1b8 -1.55 <±1.5 <±1.5 <±1.5 -1.67 <±1.5 
Amacr <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Amd1 <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Ampd1 1.55 1.72 <±1.5 <±1.5 <±1.5 <±1.5 
Angpt1 <±1.5 <±1.5 <±1.5 <±1.5 -1.67 <±1.5 
Angptl2 <±1.5 -1.86 <±1.5 <±1.5 -1.81 <±1.5 
Ankrd1 -1.56 -2.87 <±1.5 -3.33 <±1.5 <±1.5 
Anxa1 <±1.5 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Anxa11 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
Apaf1 <±1.5 <±1.5 <±1.5 <±1.5 -1.61 <±1.5 
Apol3 <±1.5 <±1.5 <±1.5 9.38 <±1.5 2.66 
Apol9a <±1.5 2.06 <±1.5 4.21 -2.04 <±1.5 
Apold1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.56 
Arg1 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 
 






























Arhgap24 <±1.5 -1.77 <±1.5 <±1.5 -1.64 <±1.5 
Arhgap29 <±1.5 <±1.5 <±1.5 1.51 -1.66 <±1.5 
Arhgdib <±1.5 <±1.5 <±1.5 <±1.5 -1.83 <±1.5 
Arl6ip5 <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Arrdc3 <±1.5 -2.57 <±1.5 <±1.5 -1.73 -1.61 
Asl <±1.5 <±1.5 <±1.5 1.63 <±1.5 <±1.5 
Asph <±1.5 <±1.5 <±1.5 <±1.5 -2.11 <±1.5 
Aste1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.56 
Atf3 2.40 3.41 <±1.5 2.76 <±1.5 <±1.5 
Atp2b1 <±1.5 <±1.5 <±1.5 <±1.5 -1.52 <±1.5 
Atp2b4 <±1.5 <±1.5 <±1.5 1.61 <±1.5 <±1.5 
Atp6v0e1 <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Atp6v1b2 <±1.5 <±1.5 <±1.5 1.74 -1.74 <±1.5 
Avpr1a <±1.5 -1.77 <±1.5 <±1.5 <±1.5 <±1.5 
B2m <±1.5 <±1.5 <±1.5 1.63 <±1.5 <±1.5 
B3galnt1 <±1.5 -1.69 <±1.5 <±1.5 -2.25 <±1.5 
Baiap2 <±1.5 1.61 <±1.5 <±1.5 <±1.5 <±1.5 
Bak1 <±1.5 <±1.5 <±1.5 1.86 -1.60 <±1.5 
Bche <±1.5 <±1.5 1.50 <±1.5 <±1.5 <±1.5 
Bdh1 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 
Bet1l <±1.5 <±1.5 <±1.5 <±1.5 -1.70 <±1.5 
Bglap <±1.5 <±1.5 <±1.5 <±1.5 1.71 1.69 
Birc2 <±1.5 <±1.5 <±1.5 1.66 <±1.5 <±1.5 
Bmp4 <±1.5 -2.77 <±1.5 <±1.5 -1.98 <±1.5 
Bmpr1a <±1.5 -1.85 <±1.5 <±1.5 -1.88 <±1.5 
Bmpr1b <±1.5 <±1.5 <±1.5 1.76 -1.52 <±1.5 
Btg1 <±1.5 <±1.5 <±1.5 <±1.5 -1.68 <±1.5 
Btg2 <±1.5 -2.28 <±1.5 <±1.5 -1.76 <±1.5 
Cacng3 <±1.5 <±1.5 <±1.5 <±1.5 1.59 <±1.5 
Casp1 <±1.5 <±1.5 <±1.5 1.89 <±1.5 <±1.5 
Casp12 <±1.5 <±1.5 <±1.5 1.98 <±1.5 <±1.5 
Casp2 <±1.5 -1.71 <±1.5 <±1.5 -1.57 <±1.5 
Casp3 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 
Cbr1 <±1.5 <±1.5 <±1.5 <±1.5 -2.17 <±1.5 
 






























Ccl2 <±1.5 <±1.5 <±1.5 1.87 -1.65 <±1.5 
Ccl5 2.22 2.94 <±1.5 <±1.5 2.28 <±1.5 
Ccl7 <±1.5 <±1.5 <±1.5 2.72 -2.35 <±1.5 
Ccr1 <±1.5 <±1.5 <±1.5 2.48 -1.74 <±1.5 
Cd14 <±1.5 <±1.5 <±1.5 <±1.5 -2.04 <±1.5 
Cd151 <±1.5 -1.68 <±1.5 <±1.5 -1.83 <±1.5 
Cd44 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 
Cd48 <±1.5 -1.76 <±1.5 <±1.5 -1.82 <±1.5 
Cd80 <±1.5 -1.91 -1.57 <±1.5 <±1.5 <±1.5 
Cd82 <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Cd97 <±1.5 <±1.5 1.54 <±1.5 <±1.5 <±1.5 
Cdc123 <±1.5 <±1.5 <±1.5 <±1.5 -1.52 <±1.5 
Cdc25a <±1.5 <±1.5 <±1.5 <±1.5 -1.58 <±1.5 
Cdc26 <±1.5 -1.72 <±1.5 <±1.5 -1.94 <±1.5 
Cdc42se1 <±1.5 -1.70 <±1.5 <±1.5 <±1.5 <±1.5 
Cdon <±1.5 -1.69 <±1.5 <±1.5 <±1.5 <±1.5 
Cflar <±1.5 <±1.5 <±1.5 1.65 -1.65 <±1.5 
Chac2 <±1.5 <±1.5 -1.63 <±1.5 <±1.5 <±1.5 
Chn1 <±1.5 <±1.5 <±1.5 <±1.5 1.50 <±1.5 
Cited1 1.64 <±1.5 <±1.5 <±1.5 <±1.5 -1.63 
Clcn5 <±1.5 -2.24 <±1.5 <±1.5 -1.73 <±1.5 
Cldnd1 <±1.5 -1.65 <±1.5 <±1.5 -1.61 <±1.5 
Clic2 <±1.5 1.58 <±1.5 2.37 -1.50 1.70 
Cndp2 <±1.5 <±1.5 <±1.5 1.83 -1.51 <±1.5 
Cnksr2 <±1.5 <±1.5 <±1.5 -1.74 1.70 <±1.5 
Cnksr3 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 <±1.5 
Cnot6 <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Col1a2 <±1.5 <±1.5 <±1.5 <±1.5 -1.59 <±1.5 
Col3a1 <±1.5 -1.81 <±1.5 <±1.5 <±1.5 <±1.5 
Crkrs <±1.5 <±1.5 <±1.5 <±1.5 -1.52 <±1.5 
Crygc <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.68 
Csf1 <±1.5 -1.66 <±1.5 <±1.5 -2.28 <±1.5 
Csnk1g1 <±1.5 <±1.5 <±1.5 <±1.5 -1.52 <±1.5 
Ctgf -1.92 -3.17 <±1.5 <±1.5 -2.54 <±1.5 
 






























Ctss <±1.5 1.68 <±1.5 <±1.5 1.82 <±1.5 
Cx3cl1 <±1.5 1.64 <±1.5 2.17 <±1.5 <±1.5 
Cx3cr1 <±1.5 <±1.5 -1.58 <±1.5 <±1.5 <±1.5 
Cxadr <±1.5 <±1.5 <±1.5 -2.10 <±1.5 <±1.5 
Cxcl1 <±1.5 -2.70 <±1.5 -2.26 <±1.5 -1.53 
Cxcl10 3.03 7.43 <±1.5 12.91 -1.74 2.23 
Cxcl11 <±1.5 7.01 <±1.5 10.77 <±1.5 2.51 
Cxcl12 -1.58 <±1.5 <±1.5 <±1.5 -1.53 <±1.5 
Cxcl9 <±1.5 12.55 <±1.5 39.34 -3.13 6.14 
Cxcr7 <±1.5 <±1.5 <±1.5 <±1.5 -2.32 <±1.5 
Cyb5d2 <±1.5 -1.77 <±1.5 <±1.5 <±1.5 <±1.5 
Cyp1b1 <±1.5 1.78 <±1.5 2.69 -1.51 <±1.5 
Cyr61 -2.08 -3.22 <±1.5 <±1.5 -2.90 <±1.5 
Dbnl <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Dcbld2 <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Degs1 <±1.5 <±1.5 <±1.5 <±1.5 -1.60 <±1.5 
Dhrs7b <±1.5 -1.81 <±1.5 <±1.5 -1.75 <±1.5 
Dnajb9 <±1.5 -1.66 <±1.5 <±1.5 <±1.5 <±1.5 
Dnase1l1 <±1.5 <±1.5 <±1.5 <±1.5 -1.76 <±1.5 
Dusp1 -2.21 -5.13 -1.79 <±1.5 -3.38 <±1.5 
Dusp6 <±1.5 -2.25 <±1.5 <±1.5 <±1.5 <±1.5 
Dyrk1a <±1.5 <±1.5 <±1.5 <±1.5 -1.59 <±1.5 
Ebna1bp2 <±1.5 1.59 <±1.5 <±1.5 <±1.5 <±1.5 
Edn1 <±1.5 -3.71 -2.91 <±1.5 -3.19 <±1.5 
Ednra <±1.5 <±1.5 <±1.5 <±1.5 -1.61 <±1.5 
Egr2 <±1.5 <±1.5 <±1.5 <±1.5 2.08 <±1.5 
Egr3 <±1.5 <±1.5 <±1.5 1.60 <±1.5 <±1.5 
Eif2ak3 <±1.5 -2.21 <±1.5 <±1.5 -2.04 <±1.5 
Eif4a2 <±1.5 -1.73 <±1.5 <±1.5 <±1.5 <±1.5 
Emp1 <±1.5 -1.76 <±1.5 <±1.5 -2.62 <±1.5 
Enc1 <±1.5 <±1.5 <±1.5 1.57 <±1.5 <±1.5 
Ensa <±1.5 -2.97 <±1.5 <±1.5 -2.56 -1.79 
Ero1l <±1.5 <±1.5 <±1.5 <±1.5 -1.67 <±1.5 
Expi <±1.5 1.80 <±1.5 2.43 <±1.5 <±1.5 
 






























Extl3 <±1.5 -1.81 <±1.5 <±1.5 -1.94 <±1.5 
F3 <±1.5 <±1.5 <±1.5 <±1.5 -2.12 <±1.5 
Fabp3 <±1.5 -1.71 <±1.5 <±1.5 -1.77 <±1.5 
Fam103a1 <±1.5 -1.70 <±1.5 <±1.5 -1.70 <±1.5 
Fam110c <±1.5 <±1.5 <±1.5 <±1.5 1.65 1.52 
Fam26e <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Fam33a <±1.5 -3.89 <±1.5 <±1.5 <±1.5 <±1.5 
Fam70a <±1.5 1.61 <±1.5 <±1.5 1.89 <±1.5 
Fam71f1 <±1.5 <±1.5 <±1.5 1.78 -1.51 <±1.5 
Fam82a2 <±1.5 <±1.5 <±1.5 1.65 <±1.5 <±1.5 
Fam96a <±1.5 -1.68 <±1.5 <±1.5 -1.79 <±1.5 
Fas <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Fat3 <±1.5 -1.88 <±1.5 <±1.5 <±1.5 <±1.5 
Fbn1 <±1.5 <±1.5 <±1.5 1.66 -2.06 <±1.5 
Fbxo30 <±1.5 1.52 <±1.5 <±1.5 <±1.5 <±1.5 
Fgf7 <±1.5 -4.82 <±1.5 -2.75 -1.94 <±1.5 
Fgf9 1.52 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 
Fhl4 <±1.5 <±1.5 <±1.5 <±1.5 1.65 <±1.5 
Figf <±1.5 -1.76 <±1.5 <±1.5 <±1.5 <±1.5 
Fntb <±1.5 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Fosl1 <±1.5 1.52 <±1.5 <±1.5 <±1.5 <±1.5 
Foxb1 <±1.5 1.61 <±1.5 <±1.5 1.70 <±1.5 
Foxq1 <±1.5 2.23 <±1.5 <±1.5 <±1.5 1.61 
Fst <±1.5 <±1.5 <±1.5 <±1.5 -1.58 <±1.5 
Fzd2 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.58 
Fzd9 <±1.5 <±1.5 1.77 <±1.5 <±1.5 <±1.5 
G3bp2 <±1.5 -1.74 <±1.5 <±1.5 -1.58 <±1.5 
Gadd45a <±1.5 <±1.5 <±1.5 -1.56 1.57 <±1.5 
Gadd45b 1.71 2.16 <±1.5 1.81 <±1.5 <±1.5 
Galnt7 <±1.5 -2.14 <±1.5 -1.54 <±1.5 <±1.5 
Gbp2 1.70 7.46 <±1.5 18.71 -2.51 4.18 
Gclm <±1.5 <±1.5 <±1.5 1.57 -1.78 <±1.5 
Gcnt2 <±1.5 -2.29 <±1.5 <±1.5 -2.05 <±1.5 
Gcom1 <±1.5 <±1.5 <±1.5 1.53 <±1.5 <±1.5 
 






























Gja1 <±1.5 -1.69 <±1.5 <±1.5 <±1.5 <±1.5 
Gja4 <±1.5 <±1.5 <±1.5 3.48 <±1.5 <±1.5 
Gja5 <±1.5 <±1.5 <±1.5 <±1.5 -1.88 <±1.5 
Glrx1 <±1.5 <±1.5 <±1.5 1.85 -2.09 <±1.5 
Glt8d1 <±1.5 <±1.5 <±1.5 <±1.5 -1.65 <±1.5 
Gmfb <±1.5 -1.73 <±1.5 <±1.5 -1.81 <±1.5 
Gna13 <±1.5 <±1.5 <±1.5 2.13 <±1.5 <±1.5 
Golph3l <±1.5 -1.72 -1.87 <±1.5 <±1.5 <±1.5 
Grb2 <±1.5 <±1.5 <±1.5 <±1.5 1.83 1.52 
Grip1 <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Grk5 <±1.5 -1.73 <±1.5 <±1.5 -1.57 <±1.5 
Gsta2 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.90 
Gstm1 <±1.5 -1.65 <±1.5 <±1.5 -1.78 <±1.5 
Gstm2 <±1.5 -1.66 <±1.5 <±1.5 -1.78 <±1.5 
Gstm4 <±1.5 <±1.5 <±1.5 <±1.5 -2.01 <±1.5 
Gstp1 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
Gtf2a1 1.59 1.74 <±1.5 <±1.5 <±1.5 <±1.5 
Guca2a <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.63 
Gzmb <±1.5 <±1.5 <±1.5 6.37 <±1.5 <±1.5 
H2-M10.6 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.58 
H2-T24 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.35 
Has2 <±1.5 <±1.5 2.22 <±1.5 -2.04 -1.84 
Hbegf <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.79 
Hbp1 <±1.5 -2.02 <±1.5 <±1.5 -1.59 <±1.5 
Hcn2 <±1.5 <±1.5 <±1.5 <±1.5 1.52 <±1.5 
Hdgfrp2 <±1.5 1.55 <±1.5 <±1.5 1.57 <±1.5 
Herpud1 <±1.5 -1.71 <±1.5 <±1.5 <±1.5 <±1.5 
Higd1a <±1.5 <±1.5 <±1.5 <±1.5 -1.66 <±1.5 
Hist1h1t <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 
Hivep2 <±1.5 <±1.5 1.71 2.21 -1.53 <±1.5 
Hk2 <±1.5 <±1.5 <±1.5 1.69 -2.17 <±1.5 
Hmgcr <±1.5 -1.89 <±1.5 <±1.5 -2.04 <±1.5 
Hmgcs1 <±1.5 -1.78 <±1.5 <±1.5 -2.21 -1.58 
Hmox1 -1.81 <±1.5 <±1.5 1.96 -3.10 <±1.5 
 






























Hnrnpa1 <±1.5 <±1.5 <±1.5 <±1.5 -1.65 <±1.5 
Hnrnpa3 -2.55 <±1.5 <±1.5 <±1.5 <±1.5 1.92 
Hnrnph2 -1.60 -1.89 <±1.5 <±1.5 -2.12 <±1.5 
Hoxa1 <±1.5 <±1.5 <±1.5 <±1.5 1.83 <±1.5 
Hpcal1 <±1.5 <±1.5 <±1.5 1.62 <±1.5 <±1.5 
Hrsp12 <±1.5 -1.72 <±1.5 <±1.5 <±1.5 <±1.5 
Hsd17b1 <±1.5 1.54 <±1.5 <±1.5 <±1.5 <±1.5 
Hspa13 <±1.5 -1.77 <±1.5 <±1.5 -1.78 <±1.5 
Hspa14 <±1.5 <±1.5 <±1.5 <±1.5 -1.53 <±1.5 
Hspa5 <±1.5 -2.00 <±1.5 <±1.5 -2.00 <±1.5 
Hspb1 <±1.5 <±1.5 <±1.5 <±1.5 -1.61 <±1.5 
Hspb8 <±1.5 <±1.5 <±1.5 1.94 <±1.5 <±1.5 
Htr2a <±1.5 -1.93 <±1.5 <±1.5 -1.64 -1.99 
Htr2b <±1.5 -2.34 <±1.5 <±1.5 <±1.5 <±1.5 
Id3 <±1.5 <±1.5 <±1.5 1.97 -2.96 <±1.5 
Ier3 -1.79 -2.22 <±1.5 <±1.5 -2.07 <±1.5 
Ifi47 <±1.5 21.82 <±1.5 66.98 -3.07 23.65 
Ifit1 2.41 4.11 <±1.5 3.64 <±1.5 <±1.5 
Ifit3 2.44 2.41 <±1.5 1.80 <±1.5 <±1.5 
Il18bp <±1.5 <±1.5 <±1.5 1.63 <±1.5 <±1.5 
Il1a <±1.5 <±1.5 <±1.5 2.81 <±1.5 <±1.5 
Il1r1 <±1.5 -2.08 <±1.5 <±1.5 -2.02 -1.56 
Il1rap <±1.5 <±1.5 <±1.5 1.81 -1.59 <±1.5 
Il33 <±1.5 -1.94 <±1.5 <±1.5 -1.89 <±1.5 
Il6 <±1.5 -4.49 -2.10 -2.05 -2.19 <±1.5 
Il7 <±1.5 1.77 <±1.5 <±1.5 <±1.5 1.53 
Il7 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.53 
Inhba <±1.5 -1.88 <±1.5 <±1.5 <±1.5 <±1.5 
Inpp1 <±1.5 <±1.5 <±1.5 <±1.5 -1.65 <±1.5 
Insig2 <±1.5 -1.70 <±1.5 <±1.5 -1.55 <±1.5 
Insl6 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.66 
Ip6k2 <±1.5 -2.03 <±1.5 <±1.5 -1.57 <±1.5 
Ireb2 <±1.5 -2.07 <±1.5 <±1.5 -2.16 <±1.5 
Irf1 <±1.5 3.36 <±1.5 8.91 -2.66 3.61 
 






























Irf9 <±1.5 <±1.5 <±1.5 2.37 -1.78 1.66 
Irgm <±1.5 6.55 <±1.5 23.71 -3.62 5.49 
Irs3 <±1.5 1.55 <±1.5 <±1.5 <±1.5 <±1.5 
Itga1 <±1.5 <±1.5 <±1.5 <±1.5 -1.73 <±1.5 
Jag1 <±1.5 -2.21 <±1.5 -1.56 <±1.5 <±1.5 
Kars <±1.5 <±1.5 <±1.5 1.50 <±1.5 <±1.5 
Kcne3 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.59 
Kcnj16 <±1.5 -2.15 <±1.5 <±1.5 <±1.5 -2.33 
Kcns2 <±1.5 2.02 <±1.5 <±1.5 <±1.5 <±1.5 
Kdm3a <±1.5 <±1.5 <±1.5 <±1.5 -1.78 <±1.5 
Klf6 <±1.5 -2.19 <±1.5 <±1.5 -2.63 <±1.5 
Klhdc3 <±1.5 -1.74 <±1.5 <±1.5 -1.60 <±1.5 
Klhl24 <±1.5 -1.83 <±1.5 -1.64 <±1.5 <±1.5 
Klrc3 <±1.5 2.96 <±1.5 <±1.5 <±1.5 <±1.5 
Kng1l1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.42 
Kprp <±1.5 -1.88 -1.62 <±1.5 <±1.5 <±1.5 
Laptm4b <±1.5 -1.96 <±1.5 <±1.5 -1.97 <±1.5 
Lbp <±1.5 <±1.5 <±1.5 <±1.5 -1.68 <±1.5 
Lgmn <±1.5 -1.68 <±1.5 <±1.5 -1.67 <±1.5 
Lgr4 <±1.5 -2.04 <±1.5 <±1.5 -2.05 <±1.5 
Lipogenin <±1.5 -1.86 <±1.5 <±1.5 <±1.5 <±1.5 
Lmo4 1.52 <±1.5 <±1.5 1.58 <±1.5 <±1.5 
Lnpep <±1.5 <±1.5 <±1.5 <±1.5 -1.66 <±1.5 
LOC100125371 <±1.5 -1.94 <±1.5 <±1.5 <±1.5 <±1.5 
LOC287167 <±1.5 <±1.5 <±1.5 <±1.5 2.25 <±1.5 
LOC288913 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.60 
LOC305691 <±1.5 <±1.5 <±1.5 <±1.5 1.99 <±1.5 
LOC362921 <±1.5 <±1.5 <±1.5 <±1.5 1.76 1.70 
LOC494539 <±1.5 <±1.5 1.55 <±1.5 <±1.5 <±1.5 
LOC619574 <±1.5 <±1.5 <±1.5 <±1.5 -1.73 <±1.5 
LOC690784 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.64 
Lpar3 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.73 
Lpcat3 <±1.5 <±1.5 <±1.5 <±1.5 -1.76 <±1.5 
Lphn2 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 <±1.5 
 






























Lum -2.01 -4.16 <±1.5 <±1.5 -3.88 <±1.5 
Ly49i3 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.77 
Ly6c <±1.5 <±1.5 -1.61 <±1.5 <±1.5 <±1.5 
Mafk <±1.5 1.80 <±1.5 <±1.5 <±1.5 <±1.5 
Map2k1ip1 <±1.5 <±1.5 <±1.5 <±1.5 -1.53 <±1.5 
Mapk14 <±1.5 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Mapk6 <±1.5 -2.19 <±1.5 <±1.5 -1.83 <±1.5 
Mat2a <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.25 
Mcfd2 <±1.5 -1.67 <±1.5 <±1.5 -1.94 <±1.5 
Metrn <±1.5 <±1.5 <±1.5 <±1.5 1.56 <±1.5 
Mfap3 <±1.5 -2.15 <±1.5 <±1.5 -2.11 -2.02 
MGC105649 <±1.5 5.80 1.56 17.16 -2.96 4.05 
MGC108823 <±1.5 10.79 1.63 44.23 -4.10 7.19 
MGC108974 <±1.5 <±1.5 1.84 <±1.5 <±1.5 -1.52 
Mid1 <±1.5 <±1.5 <±1.5 -1.60 <±1.5 <±1.5 
Minpp1 <±1.5 -1.74 <±1.5 <±1.5 -1.80 <±1.5 
Mitd1 <±1.5 1.89 <±1.5 3.72 -1.97 <±1.5 
Mllt11 <±1.5 <±1.5 <±1.5 -2.00 1.65 <±1.5 
Mmadhc <±1.5 -1.66 <±1.5 <±1.5 <±1.5 <±1.5 
Mmgt2 <±1.5 -1.72 <±1.5 <±1.5 <±1.5 <±1.5 
Mmp14 <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Mras <±1.5 1.56 <±1.5 2.27 <±1.5 <±1.5 
mrpl11 <±1.5 <±1.5 <±1.5 <±1.5 -1.79 <±1.5 
Mterf -1.54 -1.90 <±1.5 <±1.5 -2.23 <±1.5 
Mx2 1.94 2.38 <±1.5 1.64 <±1.5 <±1.5 
Myd88 <±1.5 <±1.5 <±1.5 1.50 <±1.5 <±1.5 
Myst2 <±1.5 <±1.5 <±1.5 <±1.5 -1.59 <±1.5 
N4bp2l2 <±1.5 <±1.5 <±1.5 <±1.5 -1.78 <±1.5 
N5 <±1.5 -1.87 <±1.5 <±1.5 <±1.5 <±1.5 
Naaa <±1.5 <±1.5 <±1.5 <±1.5 1.64 <±1.5 
Nampt <±1.5 1.75 <±1.5 3.95 -2.26 <±1.5 
Nampt <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 
Ndst1 <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Nedd9 <±1.5 <±1.5 <±1.5 <±1.5 -2.12 <±1.5 
 






























Nid67 <±1.5 <±1.5 <±1.5 1.75 <±1.5 <±1.5 
Nip7 <±1.5 <±1.5 <±1.5 <±1.5 -1.58 <±1.5 
Nme7 <±1.5 -1.64 <±1.5 <±1.5 -1.63 <±1.5 
Nos2 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.57 
Npbwr1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.16 
Npepo <±1.5 -1.67 <±1.5 <±1.5 <±1.5 <±1.5 
Npm2 <±1.5 1.53 <±1.5 <±1.5 <±1.5 <±1.5 
Nppb <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.06 
Nppc <±1.5 1.70 <±1.5 <±1.5 <±1.5 <±1.5 
Nr4a1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.83 
Nras <±1.5 <±1.5 <±1.5 <±1.5 -1.80 <±1.5 
Nrg1 <±1.5 1.61 1.55 <±1.5 <±1.5 <±1.5 
Nrp1 <±1.5 <±1.5 <±1.5 <±1.5 -1.65 <±1.5 
Nub1 <±1.5 <±1.5 <±1.5 1.53 <±1.5 <±1.5 
Nupr1 <±1.5 -1.76 <±1.5 <±1.5 -1.76 <±1.5 
Oas1b <±1.5 3.00 <±1.5 3.98 <±1.5 1.75 
Oas1i <±1.5 2.21 <±1.5 3.70 -1.68 1.66 
Oasl <±1.5 2.05 1.76 <±1.5 1.89 <±1.5 
Oasl2 1.70 3.67 <±1.5 6.79 -1.85 1.60 
Olr1 <±1.5 2.39 2.16 6.14 -2.57 <±1.5 
Olr101 <±1.5 <±1.5 <±1.5 <±1.5 1.92 <±1.5 
Olr1014 <±1.5 1.76 <±1.5 <±1.5 1.59 <±1.5 
Olr1029 <±1.5 <±1.5 -1.71 <±1.5 <±1.5 <±1.5 
Olr1065 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.53 
Olr1077 <±1.5 <±1.5 -2.36 <±1.5 <±1.5 2.18 
Olr110 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.92 
Olr1108 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.68 
Olr1111 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.61 
Olr1122 <±1.5 <±1.5 -2.16 <±1.5 <±1.5 <±1.5 
Olr113 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.58 
Olr1130 <±1.5 <±1.5 <±1.5 <±1.5 1.68 <±1.5 
Olr114 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.63 
Olr1147 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.66 
Olr1148 <±1.5 <±1.5 -1.78 <±1.5 <±1.5 <±1.5 
 






























Olr1151 <±1.5 <±1.5 <±1.5 <±1.5 1.57 <±1.5 
Olr119 <±1.5 <±1.5 <±1.5 <±1.5 1.66 <±1.5 
Olr1196 <±1.5 1.68 <±1.5 <±1.5 <±1.5 <±1.5 
Olr1200 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.57 
Olr1202 <±1.5 <±1.5 -2.35 <±1.5 <±1.5 2.63 
Olr1219 <±1.5 <±1.5 -1.86 <±1.5 <±1.5 <±1.5 
Olr1235 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.53 
Olr128 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.55 
Olr1285 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.86 
Olr1308 <±1.5 <±1.5 2.26 <±1.5 <±1.5 <±1.5 
Olr1313 -2.19 <±1.5 <±1.5 <±1.5 <±1.5 1.55 
Olr1316 <±1.5 1.90 <±1.5 <±1.5 1.79 <±1.5 
Olr132 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.69 
Olr135 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.87 
Olr1351 <±1.5 1.82 <±1.5 <±1.5 <±1.5 1.63 
Olr1386 <±1.5 <±1.5 -1.64 <±1.5 <±1.5 <±1.5 
Olr1388 <±1.5 <±1.5 -1.62 <±1.5 <±1.5 <±1.5 
Olr1406 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.65 
Olr1442 <±1.5 <±1.5 1.51 <±1.5 <±1.5 <±1.5 
Olr1448 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.64 
Olr145 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.68 
Olr1450 <±1.5 <±1.5 -2.21 <±1.5 <±1.5 2.79 
Olr1485 <±1.5 <±1.5 -1.86 <±1.5 <±1.5 1.80 
Olr1498 <±1.5 <±1.5 <±1.5 <±1.5 2.20 1.65 
Olr150 <±1.5 <±1.5 -1.70 <±1.5 <±1.5 <±1.5 
Olr1529 <±1.5 <±1.5 <±1.5 <±1.5 1.79 1.92 
Olr1533 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -3.04 
Olr1536 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.81 
Olr157 <±1.5 <±1.5 <±1.5 <±1.5 1.64 <±1.5 
Olr1605 <±1.5 3.02 <±1.5 <±1.5 4.23 <±1.5 
Olr1607 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.74 
Olr161 <±1.5 -2.35 <±1.5 -2.52 -1.64 <±1.5 
Olr1625 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.77 
Olr1639 <±1.5 <±1.5 <±1.5 <±1.5 1.79 <±1.5 
 






























Olr1643 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.08 
Olr1683 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -5.46 
Olr1684 <±1.5 <±1.5 -2.17 <±1.5 <±1.5 <±1.5 
Olr1690 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.52 
Olr1705 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.68 
Olr1736 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.78 
Olr175 <±1.5 <±1.5 -1.97 <±1.5 <±1.5 2.19 
Olr198 <±1.5 <±1.5 <±1.5 <±1.5 1.74 <±1.5 
Olr219 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.19 
Olr221 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.83 
Olr242 <±1.5 <±1.5 <±1.5 <±1.5 2.19 <±1.5 
Olr302 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.71 
Olr311 <±1.5 <±1.5 <±1.5 <±1.5 2.07 2.25 
Olr318 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.70 
Olr329 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.71 
Olr343 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.83 
Olr352 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.63 
Olr358 <±1.5 1.55 <±1.5 <±1.5 <±1.5 <±1.5 
Olr374 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.14 
Olr376 <±1.5 <±1.5 -1.72 <±1.5 <±1.5 1.72 
Olr380 <±1.5 <±1.5 -1.74 <±1.5 <±1.5 2.53 
Olr387 <±1.5 <±1.5 2.57 <±1.5 <±1.5 -2.56 
Olr404 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.62 
Olr413 <±1.5 <±1.5 -1.73 <±1.5 <±1.5 <±1.5 
Olr422 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.90 
Olr427 <±1.5 <±1.5 <±1.5 <±1.5 2.11 <±1.5 
Olr47 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.66 
Olr514 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.68 
Olr527 <±1.5 <±1.5 -2.32 <±1.5 <±1.5 <±1.5 
Olr53 <±1.5 <±1.5 -1.99 <±1.5 <±1.5 <±1.5 
Olr530 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.03 
Olr537 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.05 
Olr545 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.69 
Olr602 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.41 
 






























Olr607 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.54 
Olr677 <±1.5 <±1.5 <±1.5 <±1.5 1.66 <±1.5 
Olr678 <±1.5 <±1.5 -1.64 <±1.5 <±1.5 1.74 
Olr705 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.51 
Olr710 <±1.5 <±1.5 <±1.5 <±1.5 2.39 <±1.5 
Olr737 <±1.5 <±1.5 -1.81 <±1.5 <±1.5 <±1.5 
Olr748 <±1.5 <±1.5 -1.75 <±1.5 <±1.5 <±1.5 
Olr756 <±1.5 <±1.5 -1.74 <±1.5 <±1.5 <±1.5 
Olr796 <±1.5 <±1.5 -2.33 <±1.5 <±1.5 <±1.5 
Olr801 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.71 
Olr823 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.93 
Olr828 <±1.5 <±1.5 -1.66 <±1.5 <±1.5 <±1.5 
Olr838 <±1.5 <±1.5 <±1.5 <±1.5 3.75 <±1.5 
Olr857 <±1.5 <±1.5 2.07 <±1.5 <±1.5 -1.62 
Olr862 <±1.5 <±1.5 -2.19 <±1.5 <±1.5 <±1.5 
Olr920 <±1.5 <±1.5 1.81 <±1.5 <±1.5 1.74 
Omd <±1.5 -2.10 <±1.5 <±1.5 -2.24 <±1.5 
Osmr <±1.5 <±1.5 <±1.5 1.71 -1.62 <±1.5 
Parp3 <±1.5 <±1.5 <±1.5 1.61 <±1.5 <±1.5 
Pcdhb15 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 
Pcdhb19 <±1.5 -1.69 <±1.5 <±1.5 <±1.5 <±1.5 
Pdcd10 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
Pde4b <±1.5 -1.76 <±1.5 -1.62 <±1.5 <±1.5 
Pdgfa <±1.5 <±1.5 <±1.5 <±1.5 -1.61 <±1.5 
Pdgfc <±1.5 -1.80 <±1.5 <±1.5 -1.56 <±1.5 
Pdha2 <±1.5 <±1.5 <±1.5 <±1.5 1.73 <±1.5 
Pelo <±1.5 <±1.5 <±1.5 <±1.5 -1.73 <±1.5 
Pfkp <±1.5 <±1.5 <±1.5 2.06 -1.65 <±1.5 
Phf11 <±1.5 1.84 <±1.5 1.87 <±1.5 <±1.5 
Phlda1 <±1.5 1.60 1.75 <±1.5 <±1.5 <±1.5 
Pik3r1 <±1.5 <±1.5 <±1.5 <±1.5 -2.06 <±1.5 
Pitx2 <±1.5 <±1.5 <±1.5 <±1.5 1.55 <±1.5 
Pkm2 <±1.5 <±1.5 <±1.5 <±1.5 -1.76 <±1.5 
Plag1 <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
 






























Plk2 <±1.5 -2.50 <±1.5 <±1.5 -2.21 <±1.5 
Plod2 <±1.5 <±1.5 <±1.5 <±1.5 -1.58 <±1.5 
Plp1 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
Pmch <±1.5 <±1.5 <±1.5 <±1.5 1.60 <±1.5 
Pnrc1 <±1.5 -2.53 <±1.5 <±1.5 -2.40 <±1.5 
Pnrc2 <±1.5 -1.68 <±1.5 <±1.5 -1.69 <±1.5 
Polr1c <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Porf1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.52 
Ppap2b <±1.5 <±1.5 <±1.5 <±1.5 -1.56 <±1.5 
Ppargc1a <±1.5 <±1.5 <±1.5 -1.69 <±1.5 <±1.5 
Ppm2c <±1.5 <±1.5 <±1.5 1.75 -1.80 <±1.5 
Ppp1cc <±1.5 <±1.5 <±1.5 <±1.5 -1.75 <±1.5 
Ppp1r10 <±1.5 <±1.5 <±1.5 <±1.5 -1.77 <±1.5 
Ppp1r3c <±1.5 -3.09 <±1.5 <±1.5 -2.30 <±1.5 
Ppyr1 <±1.5 2.35 <±1.5 <±1.5 <±1.5 <±1.5 
Prdm4 <±1.5 <±1.5 <±1.5 <±1.5 -1.73 <±1.5 
Prkar2a <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Prl <±1.5 <±1.5 <±1.5 <±1.5 1.58 <±1.5 
Prps1 <±1.5 <±1.5 -1.59 <±1.5 <±1.5 <±1.5 
Prss1 <±1.5 <±1.5 -1.69 <±1.5 <±1.5 <±1.5 
Prssl1 <±1.5 1.59 <±1.5 <±1.5 1.63 1.56 
Psma2 <±1.5 <±1.5 <±1.5 <±1.5 -1.60 <±1.5 
Psmb8 <±1.5 <±1.5 <±1.5 2.11 <±1.5 1.58 
Psmb9 <±1.5 2.07 <±1.5 2.87 <±1.5 1.54 
Psph 1.54 1.84 <±1.5 <±1.5 1.68 <±1.5 
Ptafr <±1.5 1.58 <±1.5 <±1.5 <±1.5 <±1.5 
Ptbp1 <±1.5 -1.70 <±1.5 <±1.5 -1.82 <±1.5 
Ptgfr -1.55 -3.13 <±1.5 <±1.5 -2.56 -1.60 
Ptgs2 <±1.5 -1.80 <±1.5 <±1.5 <±1.5 -1.72 
Ptpn12 <±1.5 1.67 <±1.5 <±1.5 <±1.5 <±1.5 
Ptpn9 <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Pxk <±1.5 <±1.5 <±1.5 1.66 <±1.5 <±1.5 
Pxmp2 <±1.5 <±1.5 <±1.5 <±1.5 1.59 <±1.5 
Pyroxd1 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
 






























Qrfp <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.67 
Rab27a <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.89 
Rab30 <±1.5 <±1.5 <±1.5 -1.59 <±1.5 <±1.5 
Rab3a <±1.5 <±1.5 <±1.5 -1.57 <±1.5 <±1.5 
Rabggtb <±1.5 <±1.5 <±1.5 <±1.5 -1.79 <±1.5 
rCG_59505 <±1.5 -1.69 <±1.5 <±1.5 <±1.5 <±1.5 
Rcvrn <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.95 
Rdh10 <±1.5 <±1.5 <±1.5 3.11 -2.10 <±1.5 
Rdh11 -1.55 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 
Rg9mtd1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.89 
RGD1304579 <±1.5 <±1.5 <±1.5 1.76 -1.60 <±1.5 
RGD1304827 <±1.5 -1.75 <±1.5 <±1.5 <±1.5 <±1.5 
RGD1305225 <±1.5 <±1.5 <±1.5 <±1.5 1.64 <±1.5 
RGD1307799 <±1.5 <±1.5 <±1.5 <±1.5 -1.60 <±1.5 
RGD1308059 <±1.5 -2.03 <±1.5 <±1.5 <±1.5 <±1.5 
RGD1309228 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.52 
RGD1309326 <±1.5 <±1.5 1.57 <±1.5 <±1.5 <±1.5 
RGD620382 <±1.5 <±1.5 <±1.5 <±1.5 1.58 <±1.5 
RGD69425 <±1.5 1.82 <±1.5 <±1.5 1.75 <±1.5 
Rho <±1.5 1.51 <±1.5 <±1.5 <±1.5 <±1.5 
Ripk3 <±1.5 <±1.5 <±1.5 1.64 -1.56 <±1.5 
Rnase4 <±1.5 -2.29 <±1.5 <±1.5 -2.12 <±1.5 
Rnd1 <±1.5 1.69 <±1.5 <±1.5 <±1.5 <±1.5 
Rnd3 <±1.5 -1.72 <±1.5 <±1.5 <±1.5 <±1.5 
Rpl13a <±1.5 <±1.5 <±1.5 1.96 -1.83 <±1.5 
Rpl28 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.03 
Rsad2 2.06 2.72 <±1.5 2.23 <±1.5 <±1.5 
Rsrc1 <±1.5 1.58 <±1.5 <±1.5 <±1.5 <±1.5 
Rxfp3 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.19 
S100a8 3.26 3.37 <±1.5 <±1.5 3.81 <±1.5 
Sblf <±1.5 -2.13 <±1.5 -1.50 <±1.5 <±1.5 
Sc4mol <±1.5 -1.81 <±1.5 <±1.5 -1.72 <±1.5 
Scd <±1.5 -1.77 <±1.5 <±1.5 -1.52 <±1.5 
Scgn <±1.5 1.51 <±1.5 <±1.5 <±1.5 <±1.5 
 






























Scn3b <±1.5 <±1.5 <±1.5 1.57 <±1.5 <±1.5 
Sdc4 <±1.5 <±1.5 <±1.5 1.82 <±1.5 <±1.5 
Sdpr <±1.5 <±1.5 -1.75 <±1.5 <±1.5 <±1.5 
Sectm1b <±1.5 4.66 <±1.5 17.13 <±1.5 4.95 
Sel1l <±1.5 -1.81 <±1.5 <±1.5 -1.73 <±1.5 
Selplg <±1.5 <±1.5 1.85 <±1.5 <±1.5 <±1.5 
Serpinb3 <±1.5 <±1.5 1.59 <±1.5 <±1.5 <±1.5 
Serpinc1 <±1.5 <±1.5 <±1.5 <±1.5 1.50 <±1.5 
Serpine1 <±1.5 <±1.5 <±1.5 <±1.5 -2.18 <±1.5 
Serpinh1 <±1.5 -1.80 <±1.5 <±1.5 -1.70 <±1.5 
Sgms2 <±1.5 <±1.5 <±1.5 <±1.5 -1.51 <±1.5 
Shmt2 <±1.5 1.51 <±1.5 <±1.5 <±1.5 <±1.5 
Slc16a13 <±1.5 -1.77 <±1.5 <±1.5 -1.63 <±1.5 
Slc16a3 <±1.5 <±1.5 <±1.5 <±1.5 -2.08 <±1.5 
Slc16a7 <±1.5 -2.11 <±1.5 <±1.5 <±1.5 -1.59 
Slc20a1 <±1.5 <±1.5 1.78 1.63 <±1.5 <±1.5 
Slc23a2 <±1.5 <±1.5 <±1.5 <±1.5 -1.67 <±1.5 
Slc29a2 <±1.5 <±1.5 <±1.5 <±1.5 -1.50 <±1.5 
Slc2a1 <±1.5 <±1.5 <±1.5 <±1.5 -2.02 <±1.5 
Slc38a2 <±1.5 -3.00 <±1.5 <±1.5 -2.01 <±1.5 
Slc38a6 <±1.5 -1.75 <±1.5 <±1.5 <±1.5 <±1.5 
Slc3a2 <±1.5 1.82 <±1.5 <±1.5 1.81 <±1.5 
Slc6a6 <±1.5 -2.21 <±1.5 <±1.5 -2.72 <±1.5 
Slc7a13 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.54 
Slc7a5 <±1.5 1.63 <±1.5 <±1.5 <±1.5 <±1.5 
Slfn3 <±1.5 2.10 <±1.5 4.37 -2.08 1.58 
Slfn8 <±1.5 <±1.5 <±1.5 1.52 <±1.5 <±1.5 
Sncg <±1.5 <±1.5 <±1.5 <±1.5 -1.52 <±1.5 
Socs3 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.73 
Sod2 <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Sp100 <±1.5 1.72 <±1.5 2.56 <±1.5 <±1.5 
Sp140 <±1.5 2.02 <±1.5 2.92 <±1.5 <±1.5 
Spag11b <±1.5 <±1.5 -2.10 <±1.5 <±1.5 <±1.5 
Spetex-2G <±1.5 <±1.5 <±1.5 <±1.5 8.19 <±1.5 
 






























Sqle <±1.5 -1.87 <±1.5 <±1.5 -2.57 <±1.5 
St3gal4 <±1.5 <±1.5 <±1.5 <±1.5 -2.02 <±1.5 
Stat1 <±1.5 1.58 <±1.5 3.34 -2.12 1.67 
Stat2 <±1.5 2.47 <±1.5 3.68 <±1.5 1.55 
Stat3 <±1.5 <±1.5 <±1.5 1.66 <±1.5 <±1.5 
Sult1c2 <±1.5 <±1.5 -2.08 <±1.5 <±1.5 <±1.5 
Syne1 <±1.5 <±1.5 <±1.5 -1.59 <±1.5 <±1.5 
Synpo <±1.5 <±1.5 <±1.5 <±1.5 -2.00 <±1.5 
Taar8c <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.64 
Tada1l <±1.5 -1.76 <±1.5 <±1.5 -1.74 <±1.5 
Tap1 <±1.5 2.49 <±1.5 4.80 -1.93 1.88 
Tap2 <±1.5 <±1.5 <±1.5 1.83 <±1.5 <±1.5 
Tas2r119 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.78 
Tbc1d14 <±1.5 <±1.5 <±1.5 <±1.5 -1.66 <±1.5 
Tbp <±1.5 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Tdg <±1.5 <±1.5 <±1.5 <±1.5 -1.55 <±1.5 
Terf2ip <±1.5 -1.77 <±1.5 <±1.5 -2.33 <±1.5 
Tf <±1.5 <±1.5 <±1.5 <±1.5 1.52 <±1.5 
Tfpt <±1.5 1.86 <±1.5 <±1.5 1.55 <±1.5 
Tgm2 <±1.5 1.54 <±1.5 2.33 -1.51 <±1.5 
Timp1 <±1.5 <±1.5 <±1.5 <±1.5 -2.83 <±1.5 
Tlr4 <±1.5 -1.99 -1.89 <±1.5 <±1.5 <±1.5 
Tm9sf2 <±1.5 <±1.5 <±1.5 <±1.5 -1.64 <±1.5 
Tmem140 <±1.5 <±1.5 -1.69 <±1.5 <±1.5 1.50 
Tmem218 <±1.5 -1.74 <±1.5 <±1.5 <±1.5 <±1.5 
Tmem50b <±1.5 <±1.5 <±1.5 <±1.5 -1.53 <±1.5 
Tmem77 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.03 
Tnfaip1 <±1.5 <±1.5 <±1.5 <±1.5 -1.67 <±1.5 
Tnfrsf11b <±1.5 -1.68 <±1.5 <±1.5 <±1.5 <±1.5 
Tnfrsf1a <±1.5 <±1.5 <±1.5 <±1.5 -2.00 <±1.5 
Tnfsf10 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.94 
Tnfsf15 <±1.5 -2.43 -1.75 -1.71 <±1.5 <±1.5 
Tnfsf4 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.56 
Tnrc6b <±1.5 -1.76 <±1.5 <±1.5 <±1.5 <±1.5 
 






























Tomm70a <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 
Tp53inp1 <±1.5 -1.72 -1.59 <±1.5 -1.79 <±1.5 
Trafd1 <±1.5 <±1.5 <±1.5 1.55 <±1.5 <±1.5 
Trib3 <±1.5 <±1.5 <±1.5 <±1.5 1.52 <±1.5 
Trim25 <±1.5 <±1.5 <±1.5 <±1.5 -1.65 <±1.5 
Tsc22d1 <±1.5 <±1.5 <±1.5 1.72 -1.62 <±1.5 
Tsku <±1.5 <±1.5 <±1.5 <±1.5 -2.67 -1.82 
Tssk2 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 2.18 
Tubb3 <±1.5 1.61 <±1.5 5.25 -3.26 1.58 
Txndc8 2.16 3.05 <±1.5 <±1.5 3.89 <±1.5 
Txnip <±1.5 <±1.5 <±1.5 1.78 -2.35 <±1.5 
Txnrd1 <±1.5 <±1.5 <±1.5 1.57 <±1.5 <±1.5 
Ubac1 <±1.5 -1.79 -1.61 <±1.5 -1.69 <±1.5 
Ufc1 -1.50 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Ufm1 <±1.5 <±1.5 <±1.5 <±1.5 -1.81 <±1.5 
Ugcg <±1.5 -1.91 <±1.5 <±1.5 -1.82 <±1.5 
Ugdh <±1.5 1.90 <±1.5 2.76 <±1.5 <±1.5 
Unc5c <±1.5 -1.70 <±1.5 <±1.5 -1.52 <±1.5 
Uqcrh <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Uts2 <±1.5 <±1.5 <±1.5 <±1.5 1.58 <±1.5 
V1rc20 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.80 
V1rc6 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.64 
V1rd24 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.68 
V1re4 <±1.5 <±1.5 <±1.5 <±1.5 -1.70 -1.63 
V1re7 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.24 
V1rf6 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -2.02 
V1rg13 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 1.73 
V1rg16 <±1.5 -1.92 <±1.5 <±1.5 <±1.5 <±1.5 
V1rm3 <±1.5 <±1.5 -2.02 <±1.5 <±1.5 <±1.5 
Vamp5 <±1.5 <±1.5 <±1.5 <±1.5 -1.56 <±1.5 
Vcan <±1.5 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 
Vegfc <±1.5 -1.70 <±1.5 <±1.5 <±1.5 <±1.5 
Vezt <±1.5 <±1.5 <±1.5 <±1.5 -1.54 <±1.5 
Vgll4 <±1.5 -2.22 <±1.5 <±1.5 -1.80 <±1.5 
 






























Vmac <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.55 
Vof16 <±1.5 -2.77 <±1.5 <±1.5 -2.89 <±1.5 
Vom2r32 <±1.5 1.88 <±1.5 <±1.5 1.87 1.79 
Vsnl1 <±1.5 <±1.5 <±1.5 <±1.5 <±1.5 -1.58 
Wars <±1.5 1.73 <±1.5 2.65 -1.54 <±1.5 
Wdr70 <±1.5 1.53 <±1.5 <±1.5 <±1.5 <±1.5 
Wisp1 <±1.5 <±1.5 <±1.5 <±1.5 -1.70 <±1.5 
Xdh <±1.5 <±1.5 <±1.5 2.27 -1.82 <±1.5 
Zc3hav1 <±1.5 1.74 <±1.5 2.29 <±1.5 <±1.5 
Zfp238 <±1.5 <±1.5 <±1.5 <±1.5 -1.70 <±1.5 
Zfp386 <±1.5 -1.91 <±1.5 <±1.5 -1.83 <±1.5 
Znf292 <±1.5 -1.75 <±1.5 <±1.5 -1.64 <±1.5 
Znf294 -1.85 -2.87 <±1.5 <±1.5 -1.68 <±1.5 
Znf483 <±1.5 <±1.5 <±1.5 -1.62 <±1.5 <±1.5 
 
Table A-1. Gene list from microarray analysis of SINV-infected, IFN-γ-treated 
dCSM14.1 cells. Selected genes from a rat exon library showing at least ±1.5 fold-
change in gene expression between experiment groups for at least one of the above 
comparisons. Fold-change expression less than ±1.5 is designated with <±1.5. Fold-
change expression ≥ 2.0 is designated by red numbers, and fold-change expression ≥ -2.0 
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APPENDIX B 
  Brain Spinal Cord 
Gene WT B6 vs Ifngr1-/- 
WT B6 vs 
Ifng-/- 
WT B6 vs 
Ifngr1-/- 
WT B6 vs 
Ifng-/- 
Apcs 1.08 1.08 1.14 1.39 
C3 -2.13 -3.11 -1.17 -1.49 
C5ar1 -1.98 -2.46 -2.07 -1.71 
Casp1 -3.38 -2.79 -3.04 -2.37 
Ccl12 -2.17 -1.46 -2.00 -1.05 
Ccl5 -1.70 -1.70 -1.56 -1.10 
Ccr4 1.12 -1.50 1.40 1.71 
Ccr5 -2.11 -1.99 -2.29 -1.47 
Ccr6 1.22 -1.28 -1.69 1.07 
Ccr8 -1.95 -3.50 -2.47 -1.60 
Cd14 -1.13 -1.16 1.29 1.69 
Cd4 1.00 -1.54 -1.62 -1.09 
Cd40 -4.79 -6.77 -5.58 -3.91 
Cd40lg -1.47 -1.53 -1.43 1.26 
Cd80 -1.53 -1.71 -1.29 -1.15 
Cd86 -2.75 -2.85 -2.43 -1.86 
Cd8a -1.23 -1.29 -1.09 1.65 
Crp -1.58 -1.58 2.30 -1.54 
Csf2 -5.70 -5.70 -2.39 -4.29 
Cxcl10 -8.01 -6.87 -5.09 -1.92 
Cxcr3 1.09 1.02 -1.13 1.48 
Ddx58 -1.92 -1.74 -1.71 -1.15 
Fasl -1.33 1.16 -1.66 1.11 
Foxp3 -1.29 1.06 1.31 1.67 
Gata3 1.30 1.12 1.12 1.38 
H2-Q10 -1.29 1.05 1.04 1.65 
H2-T23 -4.24 -4.90 -3.62 -2.56 
Icam1 -2.82 -3.48 -2.60 -1.95 
Ifna2 -1.13 2.07 -1.79 1.05 
Ifnar1 -1.19 -1.73 -1.15 -1.08 
Ifnb1 -5.31 -2.87 -1.93 -1.15 
Ifng -1.88 -8.58 -2.00 -4.01 
Ifngr1 -5.75 -1.56 -6.04 -1.04 
Il10 -1.82 -1.36 -1.71 1.12 
Il13 -1.45 -1.37 1.54 1.44 
Il17a 1.08 1.08 1.14 1.39 
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 Brain Spinal Cord 
Gene WT B6 vs Ifngr1-/- 
WT B6 vs 
Ifng-/- 
WT B6 vs 
Ifngr1-/- 
WT B6 vs 
Ifng-/- 
Il18 -1.14 1.12 -1.19 -1.03 
Il1a -1.11 1.04 1.16 1.43 
Il1b -2.08 -3.01 -1.66 -1.17 
Il1r1 -1.02 1.01 -1.13 -1.06 
Il2 -2.90 -6.67 -1.11 -3.54 
Il23a 1.77 1.55 2.43 2.26 
Il4 1.56 1.32 2.85 2.01 
Il5 -3.08 -1.25 -2.46 -1.55 
Il6 -5.45 -5.19 -1.88 1.16 
Irak1 -1.02 -1.11 -1.06 1.05 
Irf3 -1.01 1.04 -1.02 1.21 
Irf7 -3.06 -3.51 -2.14 -1.51 
Itgam 1.04 -1.04 -1.22 -1.13 
Jak2 -1.23 -1.24 -1.47 -1.22 
Ly96 -1.42 -1.51 -1.62 -1.22 
Lyz2 -1.69 -2.57 -1.97 -1.94 
Mapk1 1.16 1.17 1.08 1.17 
Mapk8 1.14 1.36 1.23 1.27 
Mbl2 1.14 4.22 -3.15 -2.23 
Mpo -1.41 -1.65 -1.11 1.84 
Mx1 -3.49 -2.92 -2.39 1.03 
Myd88 -2.88 -4.35 -1.44 -1.03 
Nfkb1 -1.26 -1.38 -1.14 1.03 
Nfkbia -1.51 -1.61 -1.60 -1.24 
Nlrp3 -2.47 -2.10 -1.93 -1.71 
Nod1 -3.21 -3.29 -2.62 -1.94 
Nod2 -3.08 -3.25 -2.68 -2.74 
Rag1 -1.85 -1.21 1.45 2.52 
Rorc 1.12 1.02 1.87 1.41 
Slc11a1 -2.95 -3.80 -2.50 -2.21 
Stat1 -2.89 -2.61 -2.31 -1.65 
Stat3 -1.76 -2.12 -1.34 -1.32 
Stat4 -1.37 -1.32 -1.24 1.23 
Stat6 -1.85 -2.50 -1.68 -1.56 
Tbx21 -1.47 -1.83 -1.32 1.03 
Ticam1 -1.42 -2.01 -1.16 -1.40 
Tlr1 -1.53 -1.32 -1.64 -1.19 
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 Brain Spinal Cord 
Gene WT B6 vs Ifngr1-/- 
WT B6 vs 
Ifng-/- 
WT B6 vs 
Ifngr1-/- 
WT B6 vs 
Ifng-/- 
Tlr2 -1.83 -2.01 -1.73 -1.35 
Tlr3 -1.87 -1.33 -2.14 -1.40 
Tlr4 -2.15 -2.30 -2.18 -1.83 
Tlr5 -1.42 -1.75 1.24 1.36 
Tlr6 -2.52 -1.75 -2.32 -1.51 
Tlr7 -1.75 -1.38 -1.67 -1.34 
Tlr8 -3.69 -3.20 -2.68 -2.44 
Tlr9 -4.61 -8.30 -4.18 -3.10 
Tnf -4.34 -5.50 -4.01 -3.28 
Traf6 -1.14 -1.37 -1.21 -1.05 
Tyk2 1.01 -1.17 -1.27 -1.25 
 
Table B-1. Gene list from microarray analysis using Mouse Innate & Adaptive 
Immune Responses RT² Profiler PCR Array on WT B6, Ifngr1-/-, and Ifng-/- mouse 
brains and spinal cords at 7 DPI. Fold-change expression ≥ 2.0 is designated by red 
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Doctoral Thesis Research, Johns Hopkins University School of Medicine and Bloomberg 
School of Public Health, Department of Molecular Microbiology and Immunology, 
Baltimore, MD 
 Laboratory of Diane Griffin, MD, PhD    2011-2016 
§ Examined the immunopathogenesis and clearance of Sindbis virus in 
the central nervous system during nonfatal alphavirus 
encephalomyelitis 
§ Determined mice develop persistent neurological sequelae following 
alphavirus infection 
§ Determined glutamine antagonist treatment mitigates development of 
clinical disease and central nervous system pathology but delays virus 
clearance 
§ Identified the role interferon gamma plays in viral RNA clearance and 
the mechanisms by which it facilitates virus clearance 
§ Identified memory T cells present in the brain following clearance of 
infectious alphavirus 
 
Veterinary Student Research Externship, University of Missouri, Department of 
Veterinary Pathobiology, Columbia, MO 
 Laboratory of Matthew H. Myles, DVM, PhD   2009 
§ Developed a recombinant hemagglutinin-neuraminidase protein of 
Sendai virus for use in a diagnostic test 
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Veterinary Student Research Fellowship, Texas A&M University College of Veterinary 
Medicine and Health Science Center, Department of Microbial and Molecular 
Pathogenesis, College Station, TX 
Laboratory of James E. Samuel, PhD     2007-2010 
§ Compared clinical and cytokine profiles between Coxiella burnetii 
isolates during persistent and reactivated Q fever in mice 
§ Developed a mouse model for intratracheal Coxiella burnetii infection 
 
Undergraduate Student Research, Texas A&M University, Department of Biochemistry 
and Biophysics, College Station, TX 
 Laboratory of Susan Colette Daubner, PhD    2003-2006 
§ Examined the mechanism of 14-3-3 protein activity on tyrosine 
hydroxylase 
 
Summer Undergraduate Medical Research Fellowship, University of Texas Southwestern 
Medical Center, Department of Neurology, Dallas, TX 
 Laboratory of Ramon Diaz-Arrastia, MD, PhD   2005 
§ Examined genetic biomarkers in traumatic brain injury outcome 
 
 
AWARDS, SCHOLARSHIPS, AND FELLOWSHIPS 
 
American Society for Virology Student Travel Award   2015 
§ Scholarship awarded to support travel to the 2015 American Society for 
Virology 34th Annual Meeting at Western University in London, Ontario  
 
NIH T32 Training Grant for Veterinarians in Biomedical Research, 2011-2014 
Johns Hopkins University School of Medicine 
§ NIH T32 OD011089, PI MC Zink 
§ Postdoctoral fellowship in laboratory animal medicine 
 
Burroughs Wellcome Fund Career Award for Medical Scientists   2014 
Institutional Nomination, Johns Hopkins University       
§ Selected as one of five applicants by the Johns Hopkins University Internal 
Review Committee for nomination to submit an application to the Burroughs 
Wellcome Fund Career Award for Medical Scientists.  
 
National Institute of Neurological Disorders and Stroke Travel Award 2013 
§ NINDS 1R13NS084525, PI DE Griffin 
§ Scholarship awarded to a postdoctoral fellow to support travel to the 2013 
Infections of the Nervous System: Pathogenesis to Worldwide Impact Gordon 
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John C. Clarke Award, Texas A&M College of Veterinary Medicine 2010 
§ Annually presented to the top five academically-ranked students of the 
graduating Texas A&M College of Veterinary Medicine DVM class 
 
Mike Keeling Memorial Veterinary Scholarship, Texas A&M College  2010 
of Veterinary Medicine      
§ Presented to a veterinary student with academic achievement and an interest 
in laboratory animal or special species medicine 
 
Texas A&M College of Veterinary Medicine Academic and Excellence  2010 
Award 
§ Awarded to the top three academically-ranked students in the fourth year 
DVM class 
 
Red Finley and Glory and Mojo Neshiem Memorial Scholarship, Texas  2010 
A&M College of Veterinary Medicine 
§ Presented to a veterinary student who has displayed excellent empathy and 
compassion to both owner and pet as well as aptitude and ability in either 
small animal medicine or oncology 
 
Phi Zeta Induction, Eta Chapter, Texas A&M College of Veterinary 2009 
Medicine 
§ Election into the Honor Society of Veterinary Medicine during third year of 
curriculum as part of the scholastic top 10% of the College of Veterinary 
Medicine Class of 2010 
 
Danny Davis Memorial Scholarship, Texas A&M College of Veterinary 2008 
Medicine  
§ Awarded to veterinary students who have best demonstrated exemplary 
dedication, perseverance, and loyalty to the study of veterinary medicine 
 
Charles River Laboratories Student Veterinarian Travel Award  2008 
§ Travel scholarship awarded to a veterinary student displaying interest and 
aptitude in the field of laboratory animal medicine 
 
Texas A&M College of Veterinary Medicine Class of 1975 Endowed 2006-2007 
Scholarship  
§ Scholarship to study at Texas A&M University College of Veterinary 
Medicine 
 
NIH T35 Veterinary Medical Student Research Training Grant, Texas  2007 
A&M Agrilife   
§ NIH T35 RR019530, PI LG Adams 
§ Summer veterinary student research fellowship 
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Phi Beta Kappa Induction, Kappa Chapter, Texas A&M University  2006 
§ Academic honor society with membership granted to the top 10% of college 
graduates of the university 
 
Texas A&M College of Agriculture and Life Sciences Senior Merit 2006 
Award 
§ Presented to a graduating senior in recognition of an outstanding record of 
academic achievement and distinguished leadership 
 
Nestor R. Bottino Award for Undergraduate Research, Texas A&M  2006 
University 
§ Departmental award from the Texas A&M Department of Biochemistry & 
Biophysics presented to a graduating senior who has shown aptitude and 
excellence in research during their undergraduate career 
 
Phi Kappa Phi Induction, Chapter 53, Texas A&M University  2006  
§ Academic honor society that extends membership to the top 10% of the 
university class 
  
Texas A&M Chapter of Gamma Sigma Delta Outstanding Junior Award  2005  
§ Award of merit from the Honor Society of Agriculture presented to a junior in 
the College of Agriculture for academic achievement 
 
McFadden Scholarship, Texas A&M University    2003-2006 
§ College scholarship for study at Texas A&M University awarded to high 
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TEACHING & ACADEMIC SERVICE 
 
2014-present Course Mentor, Regulations That Govern Animal Research course, 
Johns Hopkins School of Medicine 
 
2012-present Lecture Presenter, LAM/Path Integrated Problem Solving course, 
Johns Hopkins School of Medicine 
 
2010-present Veterinary Postdoctoral Training Program Admissions Committee 
Member, Johns Hopkins School of Medicine, Department of 
Molecular and Comparative Pathobiology 
 
2015 On-Site Seminar Coordinator, The Laboratory Animal 
Professional's Guide to the Science Behind Common Alternatives 
to Animal Models, 2015 National Meeting of the American 
Association of Laboratory Animal Science  
 
2015 Laboratory Assistant, Clinical Examination and Clinical Pathology 
& Specimen Collection Labs, Mouse Pathobiology and 
Phenotyping Shortcourse 2015 
 
2015 Remote Site Facilitator for Continuing Education Seminar, District 
of Columbia Academy of Veterinary Medicine 
 
2014-2015 ACLAM Boards Eligibility Project Research Co-Mentor for 
Cassandra Moats, Clinical Resident in Laboratory Animal 
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2013-2015 Laboratory Mentor, Lab of Diane Griffin, Johns Hopkins 
Bloomberg School of Public Health, Department of Molecular 
Microbiology and Immunology 
§ Alicia Braxton, veterinary student research externship, 2015 
§ Elizabeth Troisi, PhD research rotation, 2015 
§ Julia Zhao, MHS thesis project, 2014-2015 
 
2013-2014 Senior Trainee in Laboratory Animal Medicine, Johns Hopkins 
School of Medicine Department of Molecular and Comparative 
Pathobiology 
 
2013-2014 Teaching Assistant, Fundamental Virology course, Johns Hopkins 
Bloomberg School of Public Health 
 
2013-2014 Laboratory Animal Medicine Regulations Club Coordinator, Johns 
Hopkins School of Medicine Department of Molecular and 
Comparative Pathobiology 
 
2010-2014 Veterinary Trainee in Laboratory Animal Medicine, Institutional 
Animal Care and Use Committee, Johns Hopkins University 
§ Animal Use Protocol Veterinary Reviewer, 2010-2014 
§ Lecturer and Laboratory Instructor for Rodent Surgery and 
Class lab, 2010-2011 
 
2012 Cellular and Molecular Medicine Program Pollard Scholar, 
Principles of Immunology I course, Johns Hopkins Bloomberg 
School of Public Health 
 
2012 Lecture Presenter, The Use of Animals in Biomedical Research, 
Introduction to Research Ethics II course, Johns Hopkins School of 
Medicine 
 
2010-2011 Teaching Assistant, Third Year Medical Student Surgery Lab, 
Minimally Invasive Surgical Training Center, Johns Hopkins 
School of Medicine 
 
2010 Laboratory Assistant, Clinical Examination and Clinical Pathology 
& Specimen Collection Labs, Mouse Pathobiology and 
Phenotyping Shortcourse 2010 
 
2010 Laboratory Assistant, Mouse Necropsy Lab, Summer Internship 
Program, Johns Hopkins School of Medicine 
 
2007-2009 Research Committee Student Chair, Texas Veterinary Medical 
Association 
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2007-2009 Texas A&M College of Veterinary Medicine Open House 
§ Small Animal Hospital Chair, 2008, 2009 
§ Endoscopy Room Chair, 2008 
§ Anatomy Room Co-Chair, 2007 
 
2008 Laboratory Instructor, Mouse Intubation Lab, Department of 






District of Columbia Academy of Veterinary Medicine   2015-present 
American College of Laboratory Animal Medicine, Diplomate  2014-present 
American Society for Virology      2014-present  
American Association for Advancement in Science    2012-present 
American Association of Laboratory Animal Science   2010-present  
American Society of Laboratory Animal Practitioners   2007-present  
Society for Neuroscience       2014-2015  
International Society for Neurovirology     2013-2014 
American Veterinary Medical Association     2006-2013 
Texas Veterinary Medical Association     2010-2011 
Texas A&M Student Chapter of American Society of Laboratory  2007-2010  
Animal Practitioners 
§ President, 2008-2009 
§ Vice President, 2007-2008 
§ Co-founder, 2007 
Texas A&M Student Chapter of American College of Veterinary   2006-2010  
Pathologists 
§ President, 2008-2009 
Texas A&M Biochemistry and Genetics Society    2003-2006 
§ Treasurer, 2004-2006 
	  
	  
	  
	  
 
